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ABSTRACT 
 
Biologically active compounds are usually polyfunctional molecules bearing one or more 
stereocenters. Enzyme catalyzed transformations are well suitable for their preparation 
since they act in a very mild and selective manner. 
 
The study of three selected biocatalyzed transformations has been the aim of my PhD 
researches. 
 
The first project, regards the development of an advantageous and mild method to 
selectively transform the 24-hydroxyl function of ascomycin, a 23-membered 
macrolactam, bearing two secondary alcoholic moieties bounded at position 24 and 32 of 
its macrocycle. This selective protection is required to transform ascomycin into 
pimecrolimus, its 32-epi chlorine analogue, an immunomodulator useful for the treatment 
of inflammatory skin diseases. The advantage offered by enzymes, showed to be not only 
their ability to regioselective discriminate between the two secondary hydroxyl groups, but 
also, their chemoselectivity, i.e. the capacity to leave intact the other functional groups 
present in the structure of ascomycin. Among enzymes to screen for the desired 
transformation we selected lipases, taking into account their well know regioselectivity in 
the acylation of secondary alcohols and their efficiency to transform lipofilic compounds. 
The second topic regards the clopidogrel, a thienopyridine compound that inhibits platelet 
aggregation by selectively binding to adenylate cyclase-coupled ADP receptors. It is 
indicated for the reduction of atherosclerotic events. Its structure contains a stereocenter: 
since only the S(+) isomer is biologically active, the compound must be prepared in the 
enantiomerically pure form. Although it is known and used by several years, usually this 
target is achieved by means of time consuming and expensive fractional crystallization of  
the unnatural aminoacid easily recognizable in its structure, 2-chloro-phenylglycine. The 
aim of my work was to find an enzymatic approach to achieve the suitable resolution with 
a low cost and a good optical purity overcoming the disadvantages of fractional 
crystallization. Different kinds of hydrolases were screened on several amides and esters 
derivatives of 2-chloro-phenylglycine or of a more advanced intermediate of the 
preparation. 
2 
 
The third project, realized in Canada at Université Laval, deals with the resolution of the 
enantiomers of erhytro-p-nitrophenylserine, a non proteogenic aminoacid bearing the 
opposite stereochemistry of the antibiotic chloramphenicol, the D(-)-threo-2-di-
chloroacetamido-p-nitrophenylserinol. The obtained optically pure aminoacids, by means 
of penicillin acylase, after their reduction to aminoalcohols were then N-acylated with the 
proper chiral L-methioninesulfone. The diastereoisomeric amides were tested as inhibitors 
for amidotransferase, an enzyme absent in humans and present in some archea, organella 
and bacterials, and then an ideal target for new antibacterial compounds. 
 
The analytical methods employed to verify the outcomes of reactions are 1H and 13C, 
COSY and HSQC NMR and mass spectroscopy; the selectivity and the conversion of the 
enzymatic resolution were checked by means of reverse phase and chiral HPLC. The 
configuration of the final compounds was also proved by specific optical rotatory values.  
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1. Introduction 
1.1 The discovery of a new science. 
The enzymes (from greek, ἐν ζύμῳ [en zýmō], inside the yeast) are very specialized 
proteins that catalyze the reactions of the cellular metabolism. 
The knowledge of enzymatic reactions is well before the XX century, despite the fact that 
the chemical processes catalyzed by agents of biological origin were understood only 
vaguely. Reactions such as fermentation of sugar solutions, the acidification and 
processing of milk into cheese, the putrefaction of urine were certainly observed by chance 
as accidental occurrences, but the use of grafts from previous fermentations as catalysts is 
probably very old . The concept of 'fermentation' is found in the Bible: “A little yeast 
leavens the whole lump” (1st Letter at Corinthians, 5, 6). In addition to wine, whose 
production depends only by enzymes naturally present in the skin of grapes, even beer (or 
similar fermented beverage derived from barley) has been described by many classic 
authors, including Xenophon, Herodotus, Pliny and Tacitus. The Latin word fermentum, 
used by Virgil for example, refers to anything that causes a reboot and then also with beer 
or yeast itself.  
Anyway, the basic concept of enzymology, i.e. catalysis of chemical reactions by agents of 
biological origin, began to consolidate in only seconds XIX century. 
 
The idea of catalysis was formulated for the first time by the Swedish chemist J. J. 
Berzelius, such as "a force different from the forces that we know so far". In the third 
edition of his chemistry text published in 1837, he wrote: "This is a force likely to be more 
widespread than was previously thought and whose there is still hidden nature[...]. The 
catalytic ability seems to be that some bodies, only by virtue of their presence, not their 
similarities, can awaken dormant similarities at that temperature, and as a result, elements 
of a complex body settle down to a new order" (Berzelius, Lehrbuch der Chemie, vol. VI, 
18373 Dresden-Leipzig, pp. 19-25). These chemical interpretations arrived at the right 
time, because several cases of biological catalysis were described in the previous 50 years. 
In 1783 L. Spallanzani, an Italian physiologist, showed that the flesh was melted by the 
gastric juice of crows, in 1830 R. Robiquet and A.-F. Boutron-Charard discovered the 
hydrolysis of amygdalin by bitter almonds, and in the same year A.-P. Dubrunfaut showed 
that an extract of malt starch turned into sugar. In an article, that for many it is the birth of 
enzymology, A. Payen and J. Persoz (in 1833) described the precipitation with alcohol, 
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from malt extract, of a substance that could be stored in the dry state while maintaining the 
ability to hydrolyze starch and which they called 'diastasis'. The sinigrinase and pepsin 
were described shortly thereafter. 1, 2 
The half century following was characterized by the dispute over the possibility that some 
of these biological catalysis depended, to some extent, on the presence of living organisms. 
The great work of L. Pasteur proved (on the basis of earlier contributions by T. Schwann 
and C. Cagniard de Latour) that yeast was a living thing and that many fermentations, both 
aerobic and anaerobic, were caused by living organisms. Despite their importance for 
overall development of biology, these results encouraged a trend 'vitalistic' in the study of 
fermentation. Pasteur made a distinction between 'soluble or unorganized ferments', such 
as diastase and pepsin, and 'organized ferments', such as yeast, as L. Traube suggested the 
hypothesis that the “organized ferment” properties belonged to the soluble enzymes 
present in them. On the other hand, Liebig and other chemists ridiculed the idea that all 
chemical reactions depend in some way by the presence of life: in a satirical article 
published anonymously by Liebig in 1839, they did mock the idea that the yeast cells had " 
a sucker facial for eat sugar, alcohol jet coming out anus, while carbon dioxide bubbling 
out enormous genitals " (Das Geheimnis der enträtselte geistigen Gärung in" Liebig's 
Annalen der Chemie, 1839, XXIX, pp. 100-104). The demonstration, given by E. Buchner 
(1897), that a juice-free extract from yeast cells could still ferment sugar, revealed that 
Pasteur and Liebig were both right, each from its own point of view. Yeast is made up of 
real organisms, but the chemical processes of fermentation are caused by a system of non-
living catalysts produced in yeast cells. The term 'enzyme' was suggested by W. Kühne in 
1878 to indicate the presence of this catalyst 'in yeast but he intended to apply also to more 
complex organisms which, he said, "are not so fundamentally different from single-celled 
organisms like many would have us believe." The word 'enzyme' replaced soon (except in 
German) the more ambiguous 'ferment'. 3 
 
After resolution of the dispute between Pasteur and Liebig, the XX century opened with 
the scene ready for the exceptional development of enzymology.  
Following the demonstration of existence of enzymes independently of a living cell, the 
research focused on the chemical nature of enzymes themselves. Numerous evidences 
showed the close association between protein and enzyme activity, but an influential part 
of the scientific community of the early twentieth century (including the Nobel Laureate 
Richard Willstätter) argued that proteins were not only the transport of enzymes. The 
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scientist said that the enzymes were composed of one part colloidal protein called 
apoenzyme or apofermentum, and an active group called coenzyme or cofermentum. The 
cofermentum determines the specificity of the enzyme. In 1926, however, James Sumner 
showed how the enzyme urease was a protein itself crystallized and in 1937 he showed the 
same for catalase. However, were the work of Northrop and Stanley on the digestive 
enzymes pepsin, chymotrypsin and trypsin to definitively confirm the hypothesis of 
Sumner. The three researchers were awarded the Nobel Prize in 1946 . 4 
 
The discovery that the enzymes were crystallizable gave way to a tense race to define the 
three-dimensional structures of enzymes through techniques such as X-ray crystallography. 
The first macromolecule to be defined with this technique was lysozyme, the enzyme that 
digests the bacterial cell wall and contents in tears, saliva and in the album. The 
crystallization of lysozyme was carried out by the group coordinated by David Chilton 
Phillips in 1965 and this marked the beginning of structural biology. 5 
 
 
The XX century was characterized by the development of purified enzyme preparations to 
employ as catalysts in organic synthesis. 
 
1.2 Enzymes as catalysts  
 
Enzymes are proteins that acts as catalysts in the reactions of the living. Generally they are 
globular proteins but not all the catalysts are proteins: some RNA, called ribozymes, are 
also endowed with catalytic activity. Anyway the difference between the enzymes and the 
other catalysts is their specificity of substrate due to the presence, in their tridimensional 
structure of the active site, the portion of the  macromolecule directly involved in the 
catalysis. In order to analyze the basic principles of the enzymes action, is essential to 
know the evolution of a reaction from a thermodynamic point of view. In 1935, Eyring 
proposed that for a reaction to proceed the reactants molecules must overcome a free 
energy barrier: once the reactants have reached this state of highest free energy, the so 
called transition state, they proceed into products at a fixed rate. 
The free energy contains both enthalpic and entropic terms. In general, the lower is the 
activation energy, the faster the overall reaction will proceed.  
The transition-state teory is summaryzed into the Eyring equation (eq 1) 
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K = (kT/h) exp (-∆G/RT)       (1) 
 
In which K, k, h and R are the rate, Boltzmann, Planck and gas constants, respectively, ∆G 
and T represent the activation energy  and the temperature for the reaction.  
Since ∆G is correlated to ∆H and ∆S, the enthalpy and entropy of activation, by equation 2, 
equation 1 can be rearranged to equation 3: 
 
∆G = ∆H - T∆S                     (2) 
 
K = (kT/h) exp (-∆H/RT) exp (∆S/R)       (3) 
 
One role of enzymes can be considered to be the reduction in the free energy of activation 
by stabilizing the rate limiting transition state and this reduction in ∆G results in an 
acceleration in reaction rate. Enzymes accomplish this reduction by either reducing the 
entalpy of activation (∆H), setting up more favorable interaction between substrates (an 
entropy effect, ∆S), or by modifying interactions with solvent, or all of these. 
 
Many reactions of enzymes follow a pattern of kinetic behavior known as Michaelis-
Menten kinetics.  
They ideally subdivided the multistage reaction process of enzymatic catalysis in two 
phases: in the first one, the substrate (S) initially is bound noncovalently to the enzyme at a 
specific pocket called active site. This  complex (ES), called Michaelis complex, provide 
the proper alignment of reactants and catalytic groups in the active site that is the place 
where the chemical step take place. 
Because each molecule of enzyme has only a limited number of active sites, usually one, 
the number of substrate molecules that can be processed per unit of time is limited. 
In the second step the reaction happens and the product (P) is released by the active site of 
the enzyme, who can be recovered unchanged at the end of the reaction (E). 
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After an enzyme (E) is mixed with a large excess of substrate (S) and before equilibrium is 
reached, the reactive intermediates have different concentrations than they do at 
equilibrium. This short time interval is called the pre-steady state. Once the concentrations 
of the intermediates have reached equilibrium, the system is considered to be in the steady 
state. This steady state is the period in which the concentration of the reactive 
intermediates change slowly and this conditions are called as steady state conditions.  
Steady state rates are a good approximation of conditions used in synthesis and steady state 
rates are measured because these data are easy to collect (as compared to the most pre-
steady state rates) and generate the most reliable and relevant enzymatic constants. 
 
As showed in the eq. 4  and represented in the figure 1.1, the inizial rate v0, for low 
concentration of substrate S, is directly proportional to the concentration of enzyme and 
substrate (S). As the concentration of the substrate increases, a point will be reached where 
further increase in the substrate concentration does not further increase v. 
 
Figure 1.1. Relationship between the initial rate and substrate concentration in the Michaelis-Menthen 
kinetics.  
 
ݒ݋ = ୩ୡୟ୲ [୉]଴ [ୗ]
୏୫ା[ୗ]                      (eq. 4) 
 
Kcat [E]0 = vmax                            (eq. 5) 
 
v = (kcat/Km)[E]0[S]                (eq. 6) 
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In this equation km  represents the concentration of substrate at which  v = vmax/2 and kcat is 
the apparent first-order enzyme rate constant for the conversion of the enzyme-substrate 
complex to product, also called the turnover number. 
At high concentration of substrate, equation 4 simplifies to eq. 5. Correspondingly, at low 
concentration of substrate, equation 4 simplifies to equation 6. 
 
By applying the Michaelis-Menten kinetics, the measured reaction rates or velocities (v) 
can be transformed into rate constants that describe the enzymatic mode of action. 
Useful costants, such as kcat, km, kcat/km, can be easily determined. Very important to 
compare the efficiency and selectivity of two enzymes is the value of  kcat/km, that, for the 
above system is equal to k1k2/(k-1+k2).6  
 
1.3 Nomenclature of enzymes 
 
From zymase characterized by Buchner, all enzymes were named using the suffix-ase. 
Commonly, the name of the enzyme is composed by the fusion of the substrate with the 
suffix. For example, lactase is able to split the lactose molecule, DNA polymerase is 
involved in the formation of polymers of DNA.  
The need of clear rules for defining the name of enzymes, led the International Union of 
Biochemistry and Molecular Biology to meet in the Enzyme Commission, established in 
1955. They proposed a classification of enzymes based on EC numbers: to each enzyme is 
assigned a code composed of four numbers and a systematic name according to the reaction 
catalyzed. 
On the basis of the forst EC number, all enzymes are classified into six different classes. 
 
 -EC 1 oxidoreductase: catalyze redox reactions; 
 -EC 2 - Transferase: catalyze the transfer of a functional group; 
 -EC3 hydrolase: catalyze the hydrolysis of various types of chemical bonds; 
- EC 4 - lyase: catalyze the breakage of covalent bonds through hydrolysis ; 
 -EC 5 - Isomerases: catalyze isomerization within a molecule, catalyze the intramolecular  
reorganization; 
- EC 6 - Ligase: catalyze the bond between two molecules through a covalent bond.7 
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1.4 Chirality and selectivity  
 
The main reason of the wide application of enzymatic catalysis in organic synthesis is the 
emphasis upon their selectivity. The synthesis of optically active materials is an argument 
of great actuality. The well understanding of biological process and the general recognition 
that chirality plays a crucial role in nature and in biological properties fostered a 
tremendous efforts in enantioselective synthesis. Opposite enantiomers interact differently 
within an organisms and can display various activities, such as different flavor and smell or 
different pharmacological actions. Probably the most famous evidence of this latter 
behaviour was the theratogenic effect showed by the racemic drug thalidomide. Around 
1960, its racemic administration to pregnant women caused severe birth defects in 
approximately 10.00 children. After this sadly famous event, the Food and Drug 
Administration requires that adequate information be provided to establish the 
effectiveness and safety of new drug: the choice of a racemic synthesis over the 
development of an enantiopure drug must be justified and, anyway, investigation on the 
bioavailability and pharmacological effects for both the single enantiomer and the racemic 
mixture are required (Figure 1.2). 
 
 
 
Figure 1.2. Examples of the effects of chirality in nature.  
 
In chemical reactions selectivity take many forms: at the simplest level, the chemist is 
concerned with the ensuring that, as far as possible, only the desiderate functional group is 
transformed, leaving unreact the unwanted (chemoselectivity) (Figure 1.3). At the next 
level of control, the chemist wishes to determine at which of two or more positions of 
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similar reactivity, a reaction will occur (regioselectivity) (Figure 1.3). Perhaps the most 
subtle control required by the organic chemist is the stereoselectivity and, in particular, the 
formation of only one optical isomer (enantioselectivity) (Figure 1.4). Enzymes, do to the 
presence of the active site in quaternary structure of a protein, are able to show all these 
kinds of selectivity. 
 
Figure  1.3 . Acylation of sugar and natural glycosides by protease subtilisin occurs at the indicate sites: 
example of  regio- and chemoselectivity of subtilisin. 
 
 
Figure 1. 4. Lipase PS-enantioselective hydrolysis of β-amino ester. 
 
The reason of enzymes selectivity must be correlate to their substrate specificity. 
Obedience to Michaelis-Menten kinetics yields interesting conclusions about the 
specificity of enzyme-catalysed reactions. In vitro “non-specific” substrates are sometimes 
described as “poor” because they show a low value of kcat or a high value of km. However, 
in vivo specificity results from a competition by the substrates for the active site of the 
enzyme. If two substrates, A and B, compete for the same enzyme different conclusion 
could be reached about their relative specificity if rate of reaction or the kms of the 
individual substrates are compared instead of their relative values of kcat/km. If the enzyme 
catalyses the reaction of both A and B, the relevant equations may be obtained by the usual 
procedures (eq.11) 
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(ܧܣ) =  (ா௢)(஺)௄ᇲ௠
௞௠ ௞ᇲ௠ା௞௠ (஺)ା ௄ᇲ௠(஺)                                                                       (eq.8) 
 (ܧܤ) =  (ா௢)(஻)௄ᇱ௠
௞௠ ௞ᇲ௠ା௞௠ (஻)ା ௄ᇲ௠(஻)                                                                       (eq.9) 
 
ௗ(௉)
ௗ(௉ᇲ) =  ௄௖௔௧(஺)ൣ௄ᇲ௠ା(஻)ା ௄ᇲ௠(஺)/௄௠൧௞ᇲ௖௔௧(஻)[௄௠ା(஺)ା ௄௠(஻)/௄ᇱ௠]                                                               (eq.10) 
 
௩
௩ᇱ
=  ಼೎ೌ೟಼೘  (஺)ೖᇲ೎ೌ೟
಼ᇲ೘
(஻)                                                                                                    (eq.11) 
 
Whether the enzyme is working below or above saturation for both substrates, the relative 
rate of the two reactions is given by the last equation (eq.11). Specificity between 
competing substrates is therefore given simply by relative values of Kcat/Km and not by the 
individual values of Kcat or Km. Specificity can apparently be reflected in poor binding 
(high Ks) and/or slow catalytic steps (low Kcat) but specificity between competing 
substrates is controlled only by their relative value of Kcat/Km. 
According to transition-state theory the second-order rate constant kcat/km is directly related 
to the free-energy difference (∆G⃰) between the enzyme-substrate transition state (ES⃰) and 
the free unbound substrate and enzyme. 
 
 
௄௖௔௧
௄௠
=  ௞்
௛
exp(−∆ܩ ∗/ܴܶ)                                                             (eq.12) 
 
It follows that the maximum relative rate of the enzyme-catalyzed reaction of two substrate 
S1 and S2, of the same chemical reactivity, is given by the difference in the free of binding 
the non- reacting parts of the substrates to the enzyme in the transition state minus the 
difference between their free energies in the ground state. The latter difference may be 
insignificant in some cases but in others, e.g. replacing a hydrophobic by an hydrophilic 
group, it may make the major contribution. Ground state difference could be reflected in 
the solubility of the two substrates.8 
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Figure 1. 5. Energy diagram for an enzyme –catalyzed reaction. E = enzyme; A and B = substrates; P and Q 
= products; [EA] and [EB]9 = enzyme-substrates complexes:∆∆G≠ = difference in free energy; ≠ denotes a 
transition state. 
 
In the specific case in which A and B are two enantiomers of a racemic mixture, whose 
relative configurations are (R) and (S), the selectivity of the enzyme is always expressed as 
E, enantioselectivity, also called enantiomeric ratio, because is the ratio of specificity 
constant for the two enantiomers.(eq.12) 
For an irreversible enzymatic reaction, E value can be related to the extent of conversion c, 
(eq.15), and to the enantiomeric excess, ee, (eq.13), a value that describes the enantiomeric 
purity of any compound.  
 
ܧ = (ేౙ౗౪ేౣ )౎(ేౙ౗౪
ేౣ
)౩                                                                                       (eq.12) 
 % ݁݁ோ = ୖିୗୖାୗ     X 100         For R ˃ S                                               (eq.13) 
 
ܧ = ୪୬[ଵିୡ൫ଵାୣୣ౦൯]
୪୬[ଵିୡ൫ଵାୣୣ౦൯] = ୪୬[ଵିୡ(ଵାୣୣ౩)]୪୬[ଵିୡ(ଵାୣୣ౩)]                                                   (eq.14) 
 
ܿ = ୣୣ౩
ୣୣ౩ା ୣୣ౦                                                                                      (eq.15)     
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1.5 Water versus organic solvents  
 
From the first asymmetric synthesis, realized by Emil Fisher when he applied the 
cyanohydrin reaction to L-arabinose, the tremendous potential of enzyme has been widely 
discovered and improved to be more functional for they employ in organic chemistry. The 
most important discovery in the field of the technological utility of enzyme was probably 
the concept of the employment of enzyme in an organic medium. As long as the use of 
enzyme is restricted to their natural, aqueous reaction media, their application in the field 
of organic chemistry is necessarily limited by a series of consideration. Most such 
compounds are insoluble in water and water, often give rise to unwanted side reaction; 
moreover, the thermodynamic equilibria of many processes are unfavorable in water and 
product recovery is sometimes difficult from this medium. All these considerations 
suggested to add varying portion of water-miscible co-solvents  to achieve and enhanced 
concentration of the substrate in the reaction medium, work that was pioneered by Jones 
and coworker in the late 1970s 1980s.10 Soon it became clear that the presence of the 
organic medium was not detrimental, but, on the contrary, it can improve the enzymatic 
activity and, surprisingly, influence the stereoselectivity of the enzyme. The rational of 
these experimental results, was that, for the enzymatic activity, it is not important that the 
reaction happens in aqueous medium but the water bounded to the protein. Approximately, 
for some enzyme the maximal enzyme activity is verified when 1000 molecules of water, a 
monolayer, is bounded to its surface. A more rigorous way to correlate enzyme activity 
with the water present in the reaction medium was proposed by Halling and Goderis, who 
expressed the water in the medium no longer in terms of content but in terms of 
thermodynamic water activity (aw):  
aw = χwγw   
χw = molar fraction of water. 
γw = water activity coefficient; it increases as a fraction of solvent hydrophobicity. It 
follows that a given value of aw will be obtained at a lower water concentration in a 
hydrophobic than in a hydrophilic medium. This essential water acts as a lubrificant 
providing the enzyme molecule with the flexibility necessary for the catalysis. That’s for 
water ability to form hydrogen bonds with the functional group of the enzyme which 
before were bound one to each other “unlocking” the structure.11 
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Further studies in this field, conducted by Klibanov, revealed that the stability of enzymes 
was superior in pure organic solvents where they lack the pliability and the conformational 
flexibility to denature and maintain their native conformations.  
 
1.6 The choice of solvent and medium engeneering 
 
Substrate selectivity is manifested in the ability of an enzyme to discriminate between two 
distinct, albeit structurally similar functional groups. 
Besides the advantages on the stability of the enzyme, the organic medium was also 
advantageous in terms of selectivity. The term “medium engineering”, that is the 
possibility to affect enzyme selectivity simply by changing the solvent in which the 
reaction is carried out, was coined by Klibanov, who indicated it as an alternative or an 
integration to protein engeneering.12 
Concerning the most critical characteristic of the enzyme, their selectivity, there are many 
documented cases of switching of enzyme selectivity in dependence of the solvent. Kinetic 
studies carried out mostly with hydrolases have shown that enzymes in organic solvent 
follow conventional models, for example, Chatterije and Russel, demonstred the identity of 
mechanism of subtilisin catalyzed ester-hydrolysis and transesterification in organic 
solvents. Considering the kinetic parameters in organic solvents, the values may be very 
different from solvent to solvent and for water; similarly, substrate specificity may change 
dramatically. A clear example of this is offered by subtilisin, that in dichloromethane 
prefers, as substrate, N-acetyl-L-serine ethyl-ester, while in tert-butylamine it prefers N-
acetyl-L-phenylalanine ethyl ester (Table 1.1). 
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Table 1.1. Substrate specificity (S, (Kcat/Km)Ser/(Kcat/Km)Phe) in the transesterification of N-Ac-L-Ser-OEt 
(Ser) 5 and N-Ac-L-Phe-OEt (Phe) 6 with 1-propanol, catalyzed by subtilisin Carlsberg in various anhydrous 
organic solvents. 
 
All these effects can be at least partly explained by the different solvation of the substrates 
as the reaction medium change, often based on differences in their hydrophobicity. For 
instance, the main driving force of enzyme-substrate binding for many proteases, such as 
α-chymotripsin and subtilisin, is the hydrophobic interaction between the side chain of the 
amino acids substrate and the active site of the enzyme. Consequently, in water, an 
hydrophobic substrates is more reactive than an hydrophilic one simply because this 
driving force is greater. This situation should change markedly, however, when an organic 
solvent (in which by definition there are no hydrophobic interaction) is used instead of 
water. 
In 1986, Zaks and Klibanov reported that the substrate specificity of α-chymotripsin in 
octane was reversed compared to that in water.13 Since hydrophobic interaction contributes 
significantly to substrate binding to chymotripsin in water, it was suggested that the 
reversal of substrate specificity in organic solvent was due to the lack of hydrophobic 
interactions in non-aqueous media. 
By a practical application, the possibility to influence the selectivity of a particular enzyme 
by the medium of reaction regards especially the enantiomeric and prochiral 
stereoselectivity. One of the most famous example of this, is the asymmetric hydrolysis of 
dihydropyridine diesters reported by Hirose et al. and represented in the Figure 1.6.14 He 
reported that in the Pseudomonoas lipase- catalyzed desymmetrization of prochiral 
dihydropyridine dicarboxylates the (S)-monoesters as high as 99% ee were obtained in 
water-satured di-isopropyl ether, whereas the (R)-isomers were formed preferentially (88-
91% ee) in water saturated cyclohexane. Since the log P values of the solvent were similar, 
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it seemed unlikely that the inversion of enantioselectivity was brought about by a 
difference in the portioning of the substrate between the enzyme and the media. The 
authors attributed the change in enantioselectivity to direct interaction between the solvent 
and the enzyme. 
 
Figure 1.6. Asymmetric hydrolysis of dihydropyridine diesters depending on the solvents. 
 
Concerning the effect of solvents on enantioselectivity, that represented an important 
aspect of my work, as an old example of kinetic resolution of racemic mixtures, mention 
must be made on the report of Kise an Tomiuchi on the significant effect of acetonitrile on 
the enantioselectivity of different proteases toward the kinetic resolution of (L)-DOPA that 
was obtained with 99% of enantiomeric excess in the presence of 90% of acetonitrile 
(Figure 1.7)15. 
 
 
Figure 1.7. Kinetic resolution of  L-Dopa by chymotripsin. 
 
Three different hypotheses were formulated to try to rationalize the effects of the solvent 
on enzymatic enantioselectivity. The first suggests that the solvent, depending on its 
polarity, could modify the biocatalyst conformation and, thus, influence the selectivity by 
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altering the molecular recognition process between substrates and enzyme.16 The second 
theory tries to explain the solvent effects on enantioselectivity by means of the contribution 
of substrate solvation to the energetic development of the reaction.17 An example of the 
contribute of this substrate solvation was also claimed in the case of subtilisin-catalyzed 
resolution of secondary alcohols.18 In a third model it has been proposed that solvent 
molecules could bind within the active site and, depending on their structure, interfere with 
the association or transformation of one enantiomer more than the other one and the van 
der Waals volume was suggested as one of the parameters that govern solvents effects on 
enzyme selectivity. In these works was demonstrated that the tertiary structure of enzymes 
was the same once the proteins had been dissolved in water or suspended in organic 
solvent. It was found that, both in organic solvents and in mixtures of organic solvents and 
water, molecules of different solvents were found to be located in different region of the 
active site. An example of this is offered again by subtilisin, whose active site was found to 
be penetrate by organic solvents with the displacement of some molecules of water.19 
1.7 Environmentally friendly solvents: ionic liquids. 
Ionic liquids can be defined as salts that do not crystallize at room temperature and their 
recently intensive investigation is correlated to their property to be environmental respect 
that include them in the green solvents. They are composed of a 1,3 dialkylimidazolium or 
N-alkylpyridinium cation; and a noncoordinating anion; they have no vapor pressure and, 
in principle, can be reused more efficiently than conventional solvents (Figure 1.8). 
 
Figure 1.8. Chemical structure of the 1,3 dialkilimidazolium ionic liquids. 
 
 Their polarity is in the range of lower alcohol or formamide and their miscibility with 
water varies widely and unpredictably and is not strictly correlated with their polarity.20 
Even though the miscibility of ionic liquids and organic solvents is not yet well 
documented, generally they mix with lower alcohols and ketones, dichloromethane, and 
THF, whereas they do not mix with alkanes and ethers. 21 Many application of this solvents 
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in biocatalysis were reported in the last year, principally because their high polarity 
increase the solubility of polar substrates and extend the range of application of  
biocatalysis. Moreover, both increased enzyme stability and activity have been reported as 
compared to conventional organic solvents media for the lipase from C. antarctica and α-
chymotripsyn. It has been proved that ionic liquids are able to positive influence enzymes 
enantioselectivity when employed both in mixture with water or in plain organic solvents. 
As described in chapter 3, ionic liquids-tert-butanol cosolvent systems markledy boosted 
the activity, stability and enantioselectivity of C.antarctica lipase B22 and, similarly, 
cosolvents system consisting of ionic liquids and chloroform or tert-butanol increased the 
selectivity of the same enzyme in the resolution of racemic mandelate.23 
1.8 Modes of using enzyme in organic media: immobilization on supports. 
The introduction of organic medium for enzymatic reactions, has raised the question about 
the solubility of biocatalysts. In fact, in most solvents, enzymes and other proteases are 
insoluble and form a solid phase in the bulk organic phase: therefore heterogeneous 
catalytic system are commonly used for enzymes catalysis in organic media. The most 
common way to use solid enzyme in organic media is to suspend the solid enzyme directly 
in the solvent. The solid enzyme could derived by a process of lyophilization of the 
solution of the enzyme. This process is very critical and might inactivate the enzyme that is 
probably caused, at least partly, by a reversible conformational change in the enzyme. To 
avoid this and thereby increase the activity of lyophilized enzymes in dry organic solvents, 
the liophylization can be carried out in the presence of lyoprotectants such as sorbitol.24 
The second important aspect is the pH of the solution to lyophilize. Protonation and 
deprotonation of enzymes influence their catalytic activities and, the same enzyme, 
depending on the kind of reaction that need to catalyze, requires different condition of “pH 
control”, as we faced for the enzyme penicillin acylase, (see chapter 3). For this reason, is 
important to adjust the pH value of the enzyme solution prior to lyophilization because of 
the enzyme keeps its ionization state from the aqueous solution in which it was present 
before the removal of water. This property has been called “pH memory” of enzymes in 
organic media and was theorized by Zaks and Klibanov in 1985. The wanted pH control of 
the system could be obtain by adding buffers in the solution of the enzyme before the 
lyophilization or buffering substances such as trisoctylamine and triphenyl acetic acid that, 
being soluble in organic solvent, can be added directly to the medium of reaction.25 The 
majority of the enzymes used for the experimental work correlate to this thesis belongs to 
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this class of powder-lyophilized. They are often inexpensive, if compared with other 
preparation, easy commercially available and suitable for many applications; however, the 
enzyme particles sometimes tend to aggregate and attach to the walls of the reactor, 
decreasing the catalytic surface. 
Instead of lyophilized enzyme podwer, enzyme crystals can be used as catalysts in organic 
media. In order to increase the stability, crosslinking with glutaraldehyde has been carried 
out, for example, with the enzyme thermolisine: this enzyme preparation is more stable 
towards thermic inactivation and exogeneous proteolysis.  
Enzymes immobilized on  solid supports are one of the more recent innovation in the mode 
of use of enzymes, provides great advantageous in their employment in organic medium 
and are used to a large extend also for preparative purposes. They allow to overcome the 
problem of diffusion cited above and, furthermore, often they show considerably higher 
catalytic activity than enzyme powder. Many could be the reasons of this: the enzyme, 
spread to a wide area, which makes a larger proportion of the active sites available for 
catalytic function and facilitates mass transfer of substrate and products. Another possible 
reason is that the support can protect the enzyme from possible inactivation during drying 
or lyophilization and that the support provides a favorable micro-environment for the 
enzyme during catalysis increasing the catalytic activity.26  
Several materials of quite different types and with different properties have been 
successfully used for different applications of enzymes in organic media and the choice of 
the kind of material represents a critical aspect. In the choosing of a support, both their 
morphological and chemical characteristic are of importance. In particular, for practical 
application, the most important morphological characteristics are particle size, pore size 
and specific surface area and compressibility. By a chemical point of view is important to 
value the amount of water, products and substrate partition and the direct effects of the 
support on the enzyme. The methods of immobilization are also very important in the final 
performance of the enzyme and range from the simple mix of a solution of the enzyme and 
the support and the subsequent dryness at reduced pressure or the linkage of the enzyme at 
the support. 
Talking about the kind of supports, there is Celite, a kind of diatomaceous earth very 
common that can be use to support the enzyme immediately before use. It results to be a 
good support for chymotripsin and lipases. Among the inorganic supports there are also 
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allumina and silica gel. Synthetic polymers have been showed to be suitable material for 
the enzyme: among these the most common are hydrophobic supports, such as polystyrene, 
very useful for Candida lipase that show an increase in the esterification activity with the 
hydrophobicity of the modifying reagent. For the use in aqueous media are frequently used 
agarose gel and other polysaccharide. 
By a practical point of view, the use of supported enzyme simplify the work up of the 
reaction: the enzyme can be easily and completely removed by a simple filtration avoiding 
tedious formation of emulsion.  
1.9 Applications of biocatalysts 
 The described peculiar properties of enzymes, expecially their high selectivity and their 
ability to work under mild conditions, appear to be particularly suitable for supporting the 
synthesis and the modification of natural products. The raising importance that enzymatic 
transformation is assuming in synthesis is mainly due to the economical vantage of 
biocatalytic method when compared with the classical organic procedures, due to the low 
cost of biocatalysts and mostly, the absence of collateral side reaction that avoid tedious 
and time consuming purification and, by a preparative point of view, simplify the protocol 
of impurity profile. In the course of the second half of the XX secol, the literature provides 
us a wide and detaild range of examples that prove the predominant role that biocatalisys 
covers in the field of organic chemistry.  
In 1995, Nicolaou et al. reported the chemoenzymatic synthesis of (-) Taxol, an approved 
drug for the treatment of cancer, originally isolated from Taxus brevifolia. By means of the 
recombinant lipase showed in the Figure 1.9, throw double step of subsequently acylation 
of the primary alcohol by the acyldonor isoprophenyl-acetate, the key intermediate was 
obtained with an excell enantiopurity.27 
This example is very interesting because underlines that the selected enzyme, is able to 
discriminate both the functional groups that underwent acylation, leaving inalterated the 
secondary alcohol (chemoselectivity) and the stereoisomer (enantioselectivity). 
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Figure 1.9. Asymmetric preparation of the (-) Taxol. 
 
In the same period Chênevert et al. reported the preparation of baclofen, an analogue of 
GABA (γ-aminobutirryc acid), active as selective agonist for the GABAB receptor. 
Racemic baclofen is somministered for its antispastic activity but its two enantiomers show 
different pharmacological and toxicological properties: the (-) enantiomer is more active 
but also more toxic than the (+). For this reason the preparation of the enantiopure (-) R-
baclofen was object of study. As underlined in the Figure 1.10, the desiderate 
stereochemistry was introduce in the prochiral di-ester throw the enantiotopic hydrolysis of 
the ester moiety achieved by α-chymotrypsin.28 
 
 Figure 1.10. α-chymotrypsin enantiotopic ester hydrolysis in the route to (R) baclofen . 
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Always with the auxilium of a lipase, from Candida antarctica was accomplished, in our 
laboratory, the preparation of oxandrolone, a synthetic anabolic hormon, administered in 
severe burns and to improve the quality of life of patients with HIV infection. (Figure 
1.11). The vantage of the biotransformation is the regioselective removal of the ester group 
bound at the less hindered position three, very difficoult to perceive by a classical ester 
hydrolysis in basic condition. 29  
 
Figure 1.11. Regioselective Candida antarctica lipase B ester-hydrolysis in the preparation of  oxandrolone . 
 
In our laboratory the potentialities of biocatalysis were also employed to accomplish the 
preparation of several natural compounds, i.e. frontaline, a pheromone, mevalonolactone 
and a new potential antiandrogen (Figure 1.12 a-b-c).30-32 
 
Figure 1.12. Regioselective Candida antarctica lipase B ester-hydrolysis in the preparation of  oxandrolone . 
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1.10 Enzymes useful for biocatalysis 
Reviewing the books and publications dealing with biotransformation, we can see that the 
hydrolases are the most prominent enzymes in both academic and industrial applications.33 
 
Figure 1.13. Enzymes type used in biotransformations. 
 
This wide class comprehends amidases, proteases, esterases, lipases, nitrilases, 
phosphatases and epoxide hydrolases. Of particular interest are amidases, proteases, 
esterases and lipases because they catalyze the hydrolysis and the formation of esters and 
amides, functional groups ubiquitous in intermediate and building blocks of biological 
interest. Their widespread utilize is mainly do, as underline above, to their wide substrate 
specificity, their stability and their commercially availability, together with their low cost 
and their indipendence from cofactors. Many application of this hydrolytic enzymes can be 
found in the peptide synthesis, modification of sugar as well as desymmetryzation of meso 
and prochiral compounds. To this class belong many enzymes that I used for my 
experiments, the great part of which are serine hydrolases, term related to their active site 
and to their consequent mechanism of action. 
- LIPASES 
Many different kind of lipases will be cited in the course of the thesis, mainly with a 
microbial origin. In the Figure 1.14, is shown the structure of the active site of one of the 
most famous and effective lipases, lipase from Candida antarctica, CAL B, not only 
because offers a good example to exemplify the mechanism of action of serine proteases, 
but because it is the enzyme that allowed us to obtain the best results for the realization of 
the first project of this thesis. 
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Figure 1.14. Active site of CAL B34 and reaction mechanisms of lipase-catalysis. 
 
The hydroxy group of serine, the imidazole ring of histidine and an acid amino acid 
residue, aspartate or glutamate, (the so called catalytic triade) at the active site of serine 
hydrolases are mainly responsible for the catalytic process itself. The reactions catalysed 
by serine hydrolases proceed through a tetrahedral acyl-enzyme intermediate where the 
acyl group of the substrate (RCOOR’) is covalent bound to the serine hydroxy-group 
present in the active site. In the natural process, water act as nucleophile, (Nu-H); the 
nucleophilic compound (Nu-H) can be water and, in this case, the ester hydrolysis is 
observed, but many other reaction can be carried out by a simply change of nucleophile 
(Figure 1.15)35. 
 
Figure 1.15. Different catalyzed reactions depending on the nature of the nucleophile. 
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 The biological function of lipases, as expressed in their denomination (triacylglycerol 
acylhydrolases), is the hydrolysis and the transesterification of triglycerids. Therefore, their 
first application is the formation or hydrolysis of an ester moiety. For esterification 
(acylation) of alcoholic groups, a reaction of equilibrium, active compounds were 
employed as acyl donor.  Trichloroethyl or trifluoroethyl esters, anhydrides, oxime esters 
are some of these but the best methods employ vinyl acylates. In this case, in fact, the 
formed enol tautomerizes to acetaldehyde making the reaction irreversible (Figure 1.16).36- 
37 
 
 
 
Figure 1.16. Irreversible esterification. 
 
This process have found wide applications, at the beginning, in the resolution of 
compounds bearing a secondary alcohol, for which, according with the Kaslauskas’ rule, 
the L-enantiomer is the favorite to be accepted in the active site of enzyme (Figure 1.17).  
 
Figure 1.17. Kazlauskas’ rule for the resolution of secondary alcohols by lipases. 
 
 
Figure 1.18. Cyclic anhydride as acyl donor in the chemoenzymatic synthesis of (-) Paroxetine 
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Later, also primary alcohols bearing a stereocenter at position 2 were successfully resolved 
(Figure 1.18). Also in this case, Kazlauskas, analyzing the great number of examples 
reported in literature, can suggest a rule about the lipases enantiopreference. 
Beside lipase B, the yeast Candida antarctica produces also lipase A. The use of CAL A 
was neglected by the second isoenzyme CAL B, and a possible explanation is that a 
relative high CAL A loading seems to be needed in comparison with the B isoform.38 
Anyway this is an enzyme that shows unique peculiarities, high thermo-stability, (major 
than 90°C), specificity in the hydrolysis of triglycerides, its particular recognition of the 
trans-trans fatty acids and, moreover, its preference in the recognition of hindered 
secondary alcohols. Not only alcohol can be resolved by means of lipases but also aliphatic 
and aromatic amines.39 Amino alcohols and amino acids can be discriminated through 
enantioselective N-acylation.40 
 
- ESTERASE 
As example of this family I propose Pig liver esterase, a serine type esterase that catalyzes 
the stereoselective hydrolysis of a wide variety of esters. The commercially available 
enzyme contains several isoenzymes; they behave, however, similarly in term of 
stereoselectivity. Of several models developed for interpreting and predicting the 
specificity of pig liver esterase, the cubic-space active site model reported by Jones seems 
mostly broadly useful, and has been applied to a number of prochiral, cyclic and acyclic 
meso esters (Figure 1.19).41 
 
Figure 1. 19. Active-site model for PLE. HL = large hydrophobic pocket; Hs = small hydrophobic pocket; PF 
= polar front; PB = polar back. 
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- PROTEASES 
Proteases are essential constituents of all form of life on earth, including prokaryotes, 
fungi, plants and animals. These enzymes have become widely used in the detergent 
industry, since their introduction in 1914, as detergent additives. They are classified into 
various groups, dependent on whether they are active into acid, basic or neutral condition 
and on the characteristic of the active site group of the enzyme, i.e. metallo-, aspartic-, 
cysteine-, sulphidryl- or serine-type. Microorganisms elaborate a large array of proteases, 
which are intracellular/and or extracellular. Intracellular proteases are important for 
various cellular and metabolic processes, such as sporulation and differentiation, protein 
turnover, maturation of enzymes and hormones and maintenance of the cellular protein 
pool. Extracellular proteases are important for the hydrolysis of proteins in cell free 
environments and enable the cell to adsorb and utilize hydrolytic products. At the same 
time, these extracellular proteases have been commercially exploited to assist protein 
degradation in various industrial processes and as biocatalyzators for asymmetric 
synthesis.42  
We reported here a short description of some alkaline serine-type proteases, the most 
commercially exploited, deeply studied in experiments explained later.  
α-Chymotrypsin, consisting of three linear peptide chains, was firstly recognized by its 
ability to cause the clotting of milk.43 Its natural role is the hydrolysis of amide bonds of 
proteins of aromatic amino acids such as Phe, Tyr and Trp. It also catalyzes the hydrolysis 
of various esters. An active-site model of the enzyme was proposed by Cohen to explain 
the enantioselectivity. The model contains four pockets: each correspond to one of the four 
group with different size attached to the α-carbon of a substrate. More recently, was 
reported the molecular modeling of the enzyme-substrate interactions in the calculation of 
enantioselectivity.44 The enzyme was employed for the hydrolysis of several N-protected 
amino acid methyl ester to give the corrisponding L-enantiomer of the acid and the enzyme 
mantains this activity also for α-substituted amino acids (α-methyl and alkenyl). 
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Figure 1.20.  Active site of chymotripsin.  
Other important proteases belong to the class of subtilisin. These are generally 
extracellular enzyme in order to assolve their function of scavenging nutrients. They all 
origin from Bacillus species and the most utilyzed in the field of biocatalysis are the 
subtilisin NOVO or BPN’, produced by the Bacillus amyloliquefaciens, subtilisin 
Carlsberg, produced by Bacillus licheniformis and so called by the name of the laboratory 
where was discovered in 1947. There is also the subtilisin produced by Bacillus subtilis 
whose activity is close to that of  subtilisin Carlsberg. The protease activity of subtilisin is 
similar to that of chymotrypsin but with a broader substrate specificity.45 Their active site 
is a triad made up of serine, histidine and aspartate and consequently, their mechanism of 
catalysis is similar to that described for lipases. Beside its natural peptidase activity, other 
important applications of this enzyme are the resolution of chiral amine by enantioselective 
acylation. The selectivity of this enzyme is not limited to amides but is also high effective 
in the resolution of N-protected aminoacid esters by their L-enantioselective hydrolysis: 
these features make this enzyme a catalyst of first choice when racemic amino acids have 
to be resolved.  
 
Figure 1.21. Different regioselectivity of  lipases and  proteases in then acylation of the alkaloid 
castanospermine . 
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Notheworthy is the employ of subtilisin to prepare specific esters of natural glycosides 
(Figure 1.3). Concerning its ability to acylate secondary alcohols, as clearly reported in the 
figure , the protease shows different selectivity than the lipase (Figure 1.21). The 
explanation can be found in the models proposed for their rispective active site, that 
accommodate the two substituent (L and S), bounded to the secondary alcohol, in a 
specular manner (Figure 1.22). 46 
 
Figure 1.22. Differences of the active site of lipase and subtilisin. 
 
Other important features that we could test directly are its high stability and its versatility 
to adapt to different kinds of medium, that, anyway, could be improved by immobilization, 
or cross linked crystallization, as reported in the third chapter. 
Other proteases tested in our screening, i.e. papain and chymopapain, and protease from 
Aspergyllus oryzae, and from Streptomyces griseus were chosen for their well documented 
use in the stereoselective hydrolysis of esters of N-protected amino acids.  
- AMIDASES 
Finally penicillin acylase, the enzyme that allow us to achieve the best results for the 
researches carried out in Canada, belongs to the class of amidases. It is a serine hydrolase 
and consequently  its mechanism of action is very similar of that described for the 
proteases. By a structural point of view  is, on the contrary,  completely different since it 
belongs to the class of the N-terminal nucleophile hydrolases, which have not the catalytic 
triad but an N-terminal serine that is activated by bridging water molecule. (Figure 1.23) 
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Figure 1.23. Schematic representation of the active site of penicillin acylase. 
Penicillin acylase has a somewhat complex substrate specificity. The acyl binding (ρ1) 
sub-site is highly specific for phenylacetic acid and for this reason penicillin acylase is 
mainly used in the manufacturing of the β-lactam building block 6-aminopenicillanic acid 
from penicillin G  (Figure 1. 24.) 
 
Figure 1.24.  Penicillin acylase in the preparation of semisynthetic penicillines. 
The ρ2 sub-site mainly interacts with the reactant through hydrophobic and steric forces. 
The ρ3 sub-site, in contrast, specifically binds negatively charged groups, which explains 
the high specificity of penicillin acylase for L-amino acid residues, but it also recognize 
ester groups. The commonly used penicillin acylase from E. Coli is commercially available 
in various carried-bound formulations. Crossed link enzyme maintains its activity even in 
pure organic solvents but, compared with lipases or subtilisin, is less stable and lose its 
catalytic activity upon dehydratation. 9 
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2. IMMUNOMODULATOR PIMECROLIMUS 
2.1 Introduction 
Patients with chronic inflammatory skin diseases suffer from a markedly impaired quality 
of life. 
In dermatological practice is increasing the demand for an alternative to topical 
corticosteroids, that for fifty years represented the gold standard topical therapy against 
inflammation. In fact, the use of topical corticosteroids is notoriously limited by side 
effects local and systemic (ie, skin atrophy, striae and telangiectases relaxing, diabetes 
mellitus, osteoporosis and inhibition of the hypothalamic-pituitary-adrenal axis). 
Therefore, in recent decades, the efforts in the search for new dermatological drugs have 
been directed to discover topical therapeutic alternatives with immunomodulating 
properties, but devoid of known side effects of corticosteroids. 
Particular emphasis was therefore given to a new class of macrolide lactones molecules 
with effect immunomodulatory which act selectively inhibiting the expression of genes for 
interleukin 2 (IL2) in T lymphocytes: tacrolimus and pimecrolimus (Figure 2.1) are the two 
macrolides prototypes of this new class of topical immunomodulators.1 
 
 
 
Figure 2.1. The two immunosuppressive macrolactam tacrolimus and pimecrolimus. 
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2.2 Previous compounds  
Because topical applications of drugs frequently reduces the unwanted effects of systemic 
administration, these are generally preferred for the treatment of dermatological 
inflammatory skin diseases. In the course of the years, many topical formulations of 
classical systemic antiinflammatory drugs were developed. To date, topical corticosteroids 
have been the mainstay of drug therapy for atopic dermatitis, because of their broad 
immunosuppressant and anti-inflammatory effects. The first report of the topical use of 
hydrocortisone (Figure 2.2, compound a) were made in 1952. Since then, there have been 
numerous modifications of the corticosteroid molecule, such as halogenation, 
hydroxylation and modification of side chains, allowing the increase of its pharmacological 
effect.(Figure 2.2)2  
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Figure 2.2. a. Hydrocortisone, b. Betametasone, c. Clobetasole, d. Triamcinolone acetonide. 
At present, topical corticosteroids are classified into groups according to their potency. The 
European classification system has four levels numbered I to IV (from very potent, as 
clobetasol, to mild, as hydrocortisone), in descending order of potency.3 The increase in 
steroids potency was accompanied by the occurrence of more frequent and severe side 
effects, both locally, as skin atrophy, glaucoma and some cases of allergic contact 
dermatitis and also systematically, due by the suppression of the hypothalamic-pituitary-
adrenal axis. These steroids-induced side effects can become a major concern in patients 
receiving therapies for long periods of time, as in the case of atopic dermatitis. These 
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concerns are even more important in children, both because growth suppression can be a 
sequela of systemic corticosteroids excess and because a greater body surface area-to-
weight ratio makes the potential for systemic absorption a greater concern. In addition, 
application to certain anatomic areas, such as the face, especially the eyelids and groin, has 
a particular potential for adverse events. For all these reasons, alternative treatments for 
atopic dermatitis (AD) are greatly needed. 
Another compound that has been an important role in antiinflammatory therapy certainly is 
cyclosporine (Figure 2.3) that belongs to the family of cyclic polypeptides. 
 
Figure 2.3. The cyclic polypeptide cyclosporine A. 
CyA was isolated from the fungus Tolyplocadium inflatum and since its introduction in 
early 1980s has revolutionized immunosoppressive therapy in transplantation medicine. It 
inhibits T-cells activation and was employed for the treatment of atopic dermatitis, 
psoriasis, pyoderma gangrenosum only by sistemic somministration; in fact the drug is not 
active topically probably for its large molecular size, 1202 Da, and low liphofily which 
impede its ability to penetrate skin. Its oral administration associated with the risks of 
serious systemic effects, particularly renal toxicity, doesn’t encourage its systemic use.1 
Tacrolimus (FK506) (Figure 2.1) is a neologism composed of letters found in the following 
words: Tsukuba-macrolide-immunosoppressive. It is consider the first of a new class of 
topical calcineurine inhibitors. In fact t. was isolated in 1984 from the bacterium, 
Streptomyces tsukubaensis, a species discovered in Tsukuba, Japan. Although t. shows 
similar biological properties to CyA, there is no structural relationship: tacrolimus is a 
macrolide, the chemical term that refers to presence of a lactone in the cyclic carbone 
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backbone of the structure, with an atomic weight of 822 Da. Despite this high molecular 
weight, t., contrary to cyclosporine, is very hydrophobe, insoluble in water and may be 
easily dissolved in methanol, chloroform, acetone or ethanol. Since t. is unstable in 
aqueous solution, it has been marketed in dermatology for patient with moderate to severe 
AD, since early 2001, by Fujisawa Healthcare Inc as an ointment under the trade name 
Protopic. Tacrolimus has been used also intravenously and orally for the prevention of 
organ rejection after allogeneic kidney or liver and in bone marrow transplantation.4 
Unlike tacrolimus and CyA, pimecrolimus (Figure 2.1) was developed specifically to treat 
inflammatory skin conditions. P. is an ascomycine derivative with a molecular weight of 
810 Da. Ascomycin (Figure 2.7), the parent compound, was originally isolated in the early 
1960s from the fermentation product of Streptomyces hygroscopicus var ascomyceticus 
and showed only antifungal activity. Preclinical studies in animal models have found that 
although p. exhibits high anti-inflammatory activity in skin, it has only a low potential for 
systemic immunosuppression. In fact, in animal studies, p. demonstrated cutaneous local 
anti-inflammatory properties equivalent or slightly superior to those of cyclosporine A and 
tacrolimus in model of allergic contact dermatitis while, in the transplanted kidney model, 
was three times less potent than CyA and fifteen times less potent that tacrolimus at 
preventing organ rejection. 
 
Figure 2.4. Lipophilicity distribution of tacrolimus and pimecrolimus. Blue indicates hydrophilic regions; 
Brown lipophilic regions. 
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Since is proved that the two macrolactams pimecrolimus and tacrolimus share a similar 
mechanism of action (described later), a possible explanation for the above-describes 
differences in their pharmacologic properties lies in their structures. Actually, although the 
two compounds are both macrolactams, pimecrolimus exhibits a higher overall 
lipophilicity, compared with tacrolimus and this property makes pimecrolimus more 
selective for skin and endowed with a large therapeutic index for safely and effectively 
treating cutaneous inflammatory diseases. 5 
2.3 Mechanism of action and pharmacokinetic of pimecrolimus 
The mechanism of action of pimecrolimus (ASM 981), that it shares with tacrolimus (FK 
506) is the blockage of T-cell activation. Ascomycin macrolactams are immunophilin 
ligands that bind to a specific cytosolic receptor. Pimecrolimus, like tacrolimus and 
rapamycin binds to immunophilin macrophilin-12 also known as FK506 binding protein 
and FKBP-12. X-ray crystal structure and NMR analysis showed that the left hand part of 
the macrolactam, containing the tricarbonylic portion, is responsible for the binding with 
this macrophilin and for this reason is called “binding domain”. Then, the right part of the 
macrocicle, together with elements of the immunophilin, interacts with the protein 
phosphatase calcineurin, which plays a key role in the Ca2+ dependent activation of 
lymphocytes, and thus represents the “effector domain”(Figure2.5). 6 
 
Figure 2.5. Functional domains in the structure of macrolactams’ family.  
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Calcineurine is a ubiquitous Ca2+/calmodulin-dependent protein phosphatase necessary for 
survival by regulating the responses to stresses such as high salt and by controlling cell 
division in many eukaryotic microorganisms. In mammals, calcineurine is required for 
many functions in a variety of tissues: learning and memory, renal function and, of course, 
the immune response. The selective sensitivity of immune function to this drug is thought 
to reflect the low level of expression of calcineurin in lymphocytes relatives to cells in 
other tissues (eg. neurons) in which calcineurin is more abundant and was originally 
characterized. By an evolutionistic point of view, for bacterial organisms that secrete an 
agent which would inhibit a neighbor’s calcineurine would gain an important competitive 
growth advantage. When a T-lymphocyte is activated by binding peptide antigen in the 
presence of a major histocompatibility protein, intracellular calcium is released and 
calcineurine is activated to dephosphorylate certain target protein. One critical target of 
calcineurine is a transcription factor called  NF-AT (nuclear factor of activated T-cells). 
Upon this dephosphorylation, the cytoplasmic subunit of NF-AT traslocates to the nucleus 
and there it can binds its nuclear counterpart to form an active transcription factor, required 
for the production of a whole family of cytokines central to initiating an immunoresponse. 
 
Figure 2.6. Mechanisms of action of macrolactams immunomodulators. CyA, Cyclosporine; mTOR, 
mammalian target of rapamycines⃰; NF-AT, nuclear factor of activated T-cell; RBP, rapamycin binding 
protein. ⃰Among the family of macrolactam immunosupressor, there is also sirolimus, also known with the 
name of rapamycin, a 31 member macrocyclic polyketide first isolated from Streptomyces hygroscopicus as 
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antifungal agent and later shown to be a immunosuppressive and antiproliferative agent. The biological 
activities of r. are dependent on the binding to FKBP12 and the subsequent formation of a tertiary complex 
with mTor (mammalian target-of-rapamycin). The compound is currently approved for use in renal 
transplantation and shows promise as a coating for coronary stents to prevent restenosis following 
angioplastic but is not suitable for topical application.7 
By inhibiting the action of calcineurin, the pimecrolimus-macrophilin complex prevents 
the dephosphorylation of cytoplasmatic component of the nuclear factors of activated T 
cells (NF-AT). NF-AT regulates the mRNA transcription of a number of inflammatory 
cytokines; therefore, pimecrolimus blocks this transcription, especially Th1 ( IL-2, IFN-γ) 
and Th-2 (IL-4, IL-10) type cytokines (Figure 2.6). Other cytokines, including IL-5, IL-10 
and TNF-α, are decreased in production by pimecrolimus in a dose-dependent manner. It 
doesn’t appear to cause systemic immunodeficiency. Pimecrolimus also targets mast cells 
which play an important role to anti-inflammatory activities. Pimecrolimus inhibits not 
only the transcription and synthesis of cytokines from mast cells, induced by antigen/IgE, 
but also the released of preformed mediators serotonin and β-hexosaminidase by the 
inhibition of Fcϵ-RI (hight affinity IgE-receptor)-mediated degranulation and secretion. 
Moreover, studies of the gene expression of blood cells in patients treated with oral 
pimecrolimus, showed that pimecrolimus caused a strong down-regulation of the 
expression of mRNA for genes associated with the macrolactam target pathway and 
inflammation. However, no changes were found in the mRNA for genes which generally 
reflect drug related side effect like those associated with apoptosis, stress and enzymatic 
induction. 4, 8 
From a pharmacokinetics point of view, the systemic adsorption of pimecrolimus showed 
to be negligible. In adult patients being treated for AD, with an involvement between 13% 
and 62% of Body Surface Area, for periods up to a year, a maximum pimecrolimus 
concentration of 1.4 ng/ml was observed among those subjects with detectable blood levels 
and in the majority of samples in adult (91% of the subjects), blood concentration of 
pimecrolimus were below 0.5 ng/ml. 
Laboratory in vitro plasma protein binding studies using equilibrium gel filtration have 
shown that 99.5% of pimecrolimus in plasma is bound to proteins over the p. concentration 
range of 2-100 ng/ml tested. The major fraction of p. in plasma appears to be bound to 
various lipoproteins. As with other topical calcineurine inhibitors, it is not know whether p. 
is absorbed into cutaneous lymphatic vessels or regional lymph nodes. 
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The metabolism of pimecrolimus has been studied in human subjects by using the 
radiolabeled drug. After a single oral dose in healthy subjects, unalterated pimecrolimus 
was the major drug-derived component found in blood. Numerous minor metabolites of 
moderate polarity, which appeared to be products of o-demethylations and oxygenation of 
the parent compound, were identified. Drug-related radioactivity was excreted principally 
in feces (78.4%) and only a small fraction (2.5%) was recovered in urine.5 
2.4 Clinical applications 
Pimecrolimus was developed for the treatment of inflammatory skin diseases. Several 
studies have evaluated its effectiveness. The systemic immunosoppressive potential of 
pimecrolimus is low and pharmacokinetic studies have shown very low blood level of 
pimecrolimus after topical application, with no accumulation after repeated application. 
The cream Elidel, containing pimecrolimus in the concentration of 1% was approved by 
the FDA in December of 2001 for the treatment of atopic dermatitis. It is indicated as 
second-line therapy for the short term and non continuous chronic treatment of mild to 
moderate AD in non-immunocompromised adults and children 2 years of age and older, 
who have failed to respond adequately to other topical prescription treatment or when 
those treatment are not advisable. They are indicated for a short-term or intermittent 
treatment.9 
Atopic dermatitis, or eczema, is a common skin disease that is often associated with other 
atopic disorders, such as allergic rhinitis and asthma. The clinical manifestation of atopic 
dermatitis vary with age; three stages can often be identified. In infancy, the first 
eczematous lesion usually emerges on the cheeks and the scalp. Scratching, which 
frequently starts a few week later, causes crusted erosions. During childhood, lesions 
involve flexures, the nape, and the dorsal aspect of the limbs. In adolescents and adulthood, 
lichenified plaques affect the flexures, head and neck. In each stage, itching that continues 
throughout the day and worsens at night causes sleep loss and substantially impair patient’s 
quality of life. 
The hallmark of atopic dermatitis are a chronic, relapsing form of skin inflammation, a 
disturbance of epidermal-barrier function that culminates in dry skin, and IgE-mediated 
sensitization to food and environmental allergens. The histological features of acute 
eczematous patches and plaques are epidermal intracellular edema (spongisis) and 
prominent perivascular infiltrate of lymphocytes, monocytes macrophages, dendrites cells, 
41 
 
and few eosinofils in the dermis. In subacute and chronic lichenified and excoriated 
plaques, the epidermis is thickened and its upper layer is ipertrophied. 
Two hypotheses concerning the mechanisms of atopic dermatitis have been proposed. One 
holds that the primary defect resides in an immunologic disturbance that causes Ig-E 
mediated sensitization, which epithelial-barrier dysfunction regarded as a consequence of 
the local inflammation. The other proposes that an intrinsic defect in the epithelial cells 
leads to the barrier dysfunction; the immunologic aspects are considered to be an 
epiphenomenon. Several candidates genes have been identified in atopic dermatitis, 
notably on chromosome 5q31-33. All of them encode cytokines involved in the regulation 
of IgE synthesis: interleukine-4, interleukine-5, interleukine-12, interleukine-13 and 
granulocyte-macrophage colony stimulating factor (GM-CSF). These and other cytochines 
are produced by two main types of T lymphocytes. Type 2 helper T cells (Th2) produce 
interleukine-4 as well as interleukine-5 and interleukine-13, two cytokines that up-regulate 
the production of IgE and stimulates production of IgG antibodies. Type 1 helper T cells 
(Th1) produce mainly interleukin-12 and interferon-γ, which suppresses production of IgE 
and stimulates production of IgG antibodies.  
Epidemiologic studies indicates that the worldwide incidence of AD has increased in 
recent years, especially in industrialized countries; in the United States, AD has become a 
common condition in children with a prevalence of anywhere from 7%  to 17%. 
The initial mechanisms that induce skin inflammation in patients with AD are unknown. 
They could entail neuropeptide-induced, irritation-induced, or pruritus-induced scratching, 
which releases pro-inflammatory cytokines from keratinocytes, or they could be T-cell-
mediated but IgE-independent reactions to allergens present in the disturbed epidermal 
barrier or in food (so-called food-sensitive atopic dermatitis). Allergen-specific IgE is not a 
prerequisite, however, because the atopy patch test can show that aeroallergens applied 
under occluded skin induce a positive reaction in the absence of allergen-specific IgE. 
By resuming, barrier dysfunction and chronic inflammation are characteristic of atopic 
dermatitis; therefore, a long-term clinical management should emphasize prevention and 
reduction of bacterial colonization by means of local application of lotions containing 
antiseptic such as triclosan and chlorexidine and, most important, the control of 
inflammation by the regular use of topical corticosteroids or topical calcineurine inhibitors. 
10 
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Although at present, pimecrolimus has been approved only for the treatment of AD, in the 
course of the last 10 years, have also been beneficial in numerous other dermatological 
diseases. Among the several dermatitis, best evidence of its effectiveness are achieved for 
seborrhoieic dermatitis, a common problem in parkinson’s disease and perianal dermatitis, 
in which pimecrolimus acts faster and with a longer effect, if compared with the topical 
corticosteroids: within 1 week of treatment, a complete clinical remission could be 
obtained. There are promising results from small series and case reports on oral and genital 
lichen planus and anogenital lichen sclerosus. Other possible indications include allergic 
and irritant contact dermatitis, cutaneous lupus erythematosus, rosacea and vitiligo. 11, 12 
The well known effect of inactivation of T-limphocytes proliferation, may also be related 
to cancer development. On March 2005, the FDA issued an advisory to healthcare 
providers urging caution in prescribing topical t. and p., particularly for use in children, 
because of a possible increased risk of cancer. This advisory was made on the 
recommendations stemming from the FDA Pediatric Advisor Meeting on February 15, 
2005. The concern was based on information from animal studies, a small number of case 
reports, and the pharmacology of the drugs. The small number of cases reported to the 
FDA med watch program were lymphomas, melanoma and squamous cell carcinoma. On 
January 2006, a labeling change was approved for both agents. The new labeling included 
a boxed warning about the possible risk of cancer: it issued that human studies to correlate 
the risk of cancers with the use of p. and t. it may take many years and it clarifies that these 
drugs are second-line treatments for AD, that should be used only for patient who have 
failed treatment with other therapies and that they are not indicated for use in children 
younger than 2 years old. 
Nowdays, there is no causal proof that TCI, pimecrolimus and tacrolimus, cause limphoma 
or nonmelanoma skin cancer. Treatment with systemic calcineurine inhibitors as a part of 
an immunosuppressive regimen increases the risk of sun-induced non-melanoma skin 
cancer and melanoma.  
The most frequent adverse effect observed with topical pimecrolimus in most studies was 
skin burning. However, this was a transient phenomenon with no further consequences in 
contrast to skin atrophy and the hypotalamic-pituitary- adrenal axis suppression that the 
exaggerated use of corticosteroids  may cause. 13, 14 
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2.5 Aim of the work 
As clearly described above, Pimecrolimus is a recent compound of very high value, widely 
used for systemic antiplatelet therapy and very promising for the treatment of several 
dermatological diseases. For this reason, its preparation has elicited great interest among 
medicinal chemistry. 
 
 
 
 
 
 
 
 
Figure 2.7. Structure similarity between ascomycin and pimecrolimus. 
Pimecrolimus is a semisynthetic product that could be prepared starting from a product of 
fermentation, ascomycin: in fact, as underlines in Figure 2.7, the two macrolactams differ 
only for the substituent present at position 32, an oxydryl or a chlorine of inverted 
configuration respectively for 1 and 2. The presence of two equivalent secondary hydroxy 
groups at position 24 and 32 makes difficult the directly introduction of the chlorine on the 
nucleus of ascomicin. Therefore, till now, the preparation of pimecrolimus was 
accomplished by the previous protection of the 24-alcohol, usually carried out by silylation 
of both the 2 hydroxy group, followed by a partially selective deprotection at position 32, 
with fluoridric acid at low temperature.15  
The disadvantages of this protocol of reaction are the large amount of silylating agent 
required for the reaction of protection (3- 4 eq) and the need to purify by chromatography 
every intermediate for both the protection and the deprotection step. Moreover the 
complexity of the compound, bearing many different functional groups, makes every 
chemical reaction susceptible of the formation of byproducts: it has been shown that 
ascomycin, upon treatment with nucleophiles or strong bases, undergoes a wide variety of 
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rearrangement-, cyclization-, clevage-, and epimerization reactions.16 In fact this is a very 
complex molecule, containing a pipecolate residue linked by an amide and an allylic ester 
moiety (C26-29) to a polyketide backbone. Most notably, the macrolactam features the 
unusual pattern of three adjacent carbonyl groups within the binding domain (C8-C10, 
tricarbonyl portion, α, β diketoamide moiety, whereby one carbonyl group (C 10) is 
involved in emiketal formation with the secondary hydroxyl group at C 14 to form the 
tetrahydropyrane unit (C 10- 14). Although the structure at the binding domain of 
ascomycin shown by formula in Figure 2.8 A is the main isomeric form adopted in organic 
solution, the close proximity of the tricarbonyl portion to the hydroxyl group at C-14 could 
potentially lead to the formation of numerous alternative isomers (Figure 2.8 B-T-E-F).  
Moreover, each potential equilibria product may exibit a mixture of rotamers with respect 
to the geometry of the amide bond. 6, 17 
 
Figure 2.8: Rearrangements at the tri-carbonylic portion of the binding domain of ascomycin. 
For these reasons mainly, could be interesting and useful to employ biocatalysis to prepare, 
through a selective transformation, the 24-protected key intermediate to perceive the 
conversion of ascomycin into pimecrolimus. 
More in detail, the main objective of the work, will be the regioselective protection of the 
hydroxy group bounded to the carbon 24, by acylation, realized by a suitable enzyme in 
presence of an acyl donor. Then, the so obtained 24-protected intermediate should be 
transformed into the correspondent 32-epi-chloro and finally converted in the final 
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compound 2 by the same enzyme catalyzed regioselective hydrolysis of the 24-protected 
group (Scheme 2.1). 
 
Scheme 2.1. General enzymatic pathway. 
As enzymes, we choose to study lipases as potential catalysts, first of all because they are 
the most suitable and used enzymes for the reaction of transesterification, the reaction 
required for the protection of the hydroxyl function, more over because this class of 
hydrolases accept substates poorly soluble in water, as for the macrolactams, being their 
catalytic activity in organic solvents very well documented. 
2.6 Results and discussion 
In order to indagate the selectivity of lipases, at first we treated ascomycin with several of 
them among the most common and available, in irreversible transesterification conditions 
using vinyl acetate as acyl donor in an organic solvents.18, 19 This preliminary screening 
allowed us to conclude that ascomycin was not substrate for Pseudomonas fluorescens 
(PFL), porcine pancreas (PPL) and Candida cylindracea (CCL) lipases, whereas Candida 
antarctica lipase (CAL B, Novozym, 435), as revealed by NMR analysis,  regioselectively 
afforded the 32-monoacetate, as unique product, with a percent conversion depending on 
the chosen solvent (Table 1). 
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Scheme 2.2. Regioselective Candida antartica lipase B-catalyzed transformations of ascomycin 1 to its 32-
monoacetate 3. 
Lipase Solvent Time (h) Conversion (%)a 
PFL Chloroform 100 0 
PPL Toluene 94 0 
CCL Toluene 92 0 
CAL B Acetonitrile 53 30 
CAL B tertButylmethylether 53 10 
CAL B Toluene 80 100 
a from TLC and 1H-NMR  
Table 2.1. Lipases-catalyzed transesterification of  1 to 3 with vinyl acetate.  
Evidences about enzymatic reactions outcomes were preliminary obtained by means of a 
1H-NMR analyses comparison with the literature data of ascomycin 120 and 24,32-di-O-
formyl-ascomycin .6 In fact 1H-NMR data of acetates 3-5 are not reported. Ascomycin 1 
presents two signals, at 3.40 and 3.92 ppm, assigned to H-32 and H-24, respectively. 
Whereas the former is overlapped to the OCH3 signals the latter (i.e. H-24 signal) and the 
H-32 signal  (at 4.71 ppm) of 24,32-diformate , are more predictive for our purposes. The 
presence of a signal at 4.70 ppm, beside the signal at 3.92 ppm, allowed to conclude that 
the 32-monoacetate 3 was the unique product of CAL B-catalyzed transesterification 
(Scheme 2.2). 1H-NMR analyses showed also that the catalytic action of the enzyme was 
directed on both the two rotamers of 3. 
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This result was surprising, not only considering the big size of the compound, that is 
however accepted as substrate but more over because the lipase showed further 
chemoselectivity leaving inalterated the cyclic lactone present in the structure of the 
compound, that, if opened, should be difficult to cyclize again in the same position. The 
result is in agreement with the reported selective lipase-catalyzed 32-acylation of 
tacrolimus and sirolimus (42-position) type macrolides 21, 22 and is probably imputable at 
the high hindrance that surrounds the 24 hydroxy group that makes this position not 
accessible at the active site of the enzyme. Even if the regioselectivity of CAL B was 
opposite than the desiderate, we decided, however, to take advantage of the discovered 
regiopreference of the enzyme working on the substrate 24, 32-diacetate 4 in hydrolytic 
conditions. Following this second protocol, reported in the Scheme 2.3, we adapted the 
substrate to the selectivity of the enzyme in order to obtain the desiderate 24- protected 
ascomycin 5. 
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Scheme 2.3. Regioselective Candida antartica lipase B-catalyzed transformations of 22, 32 diacetyl 
ascomycin 4 to its 24-monoacetate 5. 
Solvent Acyl acceptor Time (h) Conversion (%)a 
Toluene H2O 80 0 
Toluene Methanol 48 0 
Toluene Ethanol 100 0 
Toluene n-Butanol 120 30 
tertButylmethylether n-Octanol 100 100 
Table 2.2. CALB-catalyzed hydrolysis or alcoholysis of 4 to 5 a from TLC and 1H-NMR 
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Again NMR analysis allowed us to assign the structure of 24-monoacetate 5 to the product 
obtained from alcoholysis: the H-32 signal at 4.71 ppm was absent, indicating that the 
hydroxy group was not engaged in an ester bond; in addition, also the resonance due to the 
H-24 of 24-alcohol, at 3.92 ppm was absent whereas the region between 5.0 and 5.4 ppm, 
where usually is present the H-24 of esterified ascomycin (5.22 ppm for diformate), was 
modified.  
As summarized in the Scheme 2.4, the diacetate 4 was easily prepared from ascomycin by 
treatment with acetic anhydride and dimethylaminopyridine (DMAP) in pyridine23 and 
then selectively deacetylated at position 32, by means of CAL B-catalyzed alcoholysis, 
with tertbutyl methyl ethr (TBME) as the solvent and n-octanol as the acyl acceptor.  
Preparation of pimecrolimus was then accomplished starting from compound 5 that was 
treated with polymer bound triphenylphosphine in carbon tetrachloride to afford 32-
chloroderivative 6 (40%); removal of 24-acetate was performed in acidic conditions (3N 
HCl, 40% yields) to avoid the lactone hydrolysis in presence of bases, 24, 25 affording 
pimecrolimus 2 in only 14% overall yield (Scheme 2.4). 
 
Scheme 2.4. First chemoenzymatic approach using O-Ac as 24-protecting group. 
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Since the presence of 24-acetate seemed to be crucial for the lowering of  the yields of two 
final steps, we planned to switch the acetyl group into a silyl one, more easy to idrolyze; so 
we prepared, through the regioselective enzymatic approach, 24-silyl derivative 8, i.e. the 
key intermediate of traditional syntheses of pimecrolimus 2 (Scheme 2.5). 
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Scheme 2.5. Final chemoenzymatic approach to obtain pimecrolimus 2 using a silyl ether as 24-protecting 
group.  
Starting from the previously enzymatically obtained 32-monoacetate 3, by silylation with 
TBDMSOTf (5 equiv), in presence of  2,6-lutidine, 24-O-TBDMS, 32-O-acetyl derivative 
7 was obtained; removal of  32-acetyl group was achieved by means of  a CAL B-
catalyzed alcoholysis,19 affording intermediate 8 in good yields (80%). In these mild 
conditions, typical of enzyme-catalyzed transformations, problems related to acidic or 
basic treatments of ascomycin family compounds were avoided. In the biocatalyzed 
alcoholysis step it is possible to recycle the same enzyme sample used in the previous 32-
acylation step, without significant loss of activity; in fact, if fresh CAL B is used, instead 
of the recycled enzyme, a comparable time is required to achieve the same conversion 
percent of 7 to 8 (about quantitative). Again, in order to introduce the chlorine at position 
32, polymer bound triphenyl phosphine26 was used, leading to 9. We observed that when, 
after a 60-70% transformation, the polymer is removed and replaced with fresh reagent a 
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nearly complete conversion is achieved and the 32-chloro derivative 9 can be used in the 
next step without any further purification. The same transformation was successfully 
(73%) realized also with dichlorotriphenylphosphorane not applicable, on the contrary, in 
the case of 24-monoacetate 7 for the formation of a complex mixture.27 PTSA in 
dichloromethane/methanol (1/1) at 25-30 °C, among the tested conditions (hydrochloric 
acid in methanol, PTSA in tetrahydrofuran/water) gave best results for 24-hydroxy group 
deprotection;28 pimecrolimus29 2 was recovered in 46% yields, after separation, by column 
chromatography, from a less polar compound (30-35%), identified as 23-
dehydropimecrolimus.30 The presence of this compound is common to other reported 
deprotection methods, as e.g. hydrofluoric acid in acetonitrile,15 in variable elevated 
amounts.  
Overall yields  (29%) of pimecrolimus 2  from ascomycin 1, were comparable to those 
observed when intermediate 8 is prepared through the reported bissilylation-
monodesilylation process.15 
 
 
 
 
 
 
 
 
 
 
 
 
 
51 
 
2.7 1H NMR analysis of compounds 3, 4 and 5.  
 
To ascertain the structure of acetates 3 and 4 a more accurate NMR study carried on by 
Prof. Diego Colombo. 1H-NMR analysis were performed at 500 MHz with a Bruker FT-
NMR AVANCETM DRX500 spectrometer using a 5 mm z-PFG (pulsed field gradient) 
broadband reverse probe, and 13C-NMR spectra were collected at 125.76 MHz at 323K.  
Through 1D and 2D COSY, HSQC and HMBC experiments, it was possible to 
unambiguously establish the acetyl positions in these compounds. The experiments were 
carried out in Pyd5 at 323K. Using these experimental conditions the spectra showed a 
good spread of the proton resonances and, especially, of all the methyl groups. Two sets of 
signals are identified, since the macrolactam system exists as a mixture of two rotamers in 
a 60/40 ratio, as in the case of ascomycin 1.20 The study started with 24,32-diacetate 4 and 
was focused on the signals of ascomycin moiety carrying the acetyl groups. As an entry 
point for the study of 4, the well resolved characteristic C-25 linked methyl doublet at 1.12 
and 1.11 ppm (major and minor rotamer) was selected. Starting from that signal, H-25 
(2.18 and 2.42 ppm, major and minor rotamer), H-24 (5.50 and 5.65 ppm, major and minor 
rotamer) and H-26 (5.47 and 5.52 ppm, major and minor rotamer) were assigned by 
COSY.  
 
Figure 2.10 Numbered structure of macrolactams belonging to ascomycin. 
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 32-Monoacetate 3 
 
Attribution 1H (ppm) Integration 
CH3-25 
1.20 and 1.18  (major and minor 
rotamers) 
3H 
H-25 
2.10 and 2.24 (major and minor 
rotamers) 
1H 
H-24 
4.47 and 4.55 (major and minor 
rotamers) 
1H 
H-26 
5.78 and 5.81 (major and minor 
rotamers) 
1H 
H-28 
5.43 and 5.42 (major and minor 
rotamers) 
1H 
H-29 2.40 (major and minor rotamers) 1H 
H-30a 1.18 (major and minor rotamers) 1H 
H-30b 2.15 (major and minor rotamers) 1H 
H-31 3.33 (major and minor rotamers) 1H 
H-32 4.94 (major and minor rotamers) 1H 
OCH3-31 3.36-3.35 (major and minor rotamers) 3H 
O=C-CH3-32 2.03-2.02  (major and minor rotamers) 3H 
 
 
 
SpinWorks 2.5:   .
PPM   9.2     8.8     8.4     8.0     7.6     7.2     6.8     6.4     6.0     5.6     5.2     4.8     4.4     4.0     3.6     3.2     2.8     2.4     2.0     1.6     1.2    0.8    0.4   
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 24, 32 Diacetate 4. 
 
Attribution 1H (ppm) Integration 
CH3-25 
1.12 and 1.11  (major and minor 
rotamers) 
3H 
H-25 
2.18 and 2.42 (major and minor 
rotamers) 
1H 
H-24 
5.50 and 5.65 (major and minor 
rotamers) 
1H 
H-26 
5.47 and 5.52 (major and minor 
rotamers) 
1H 
O=C-CH3-24 
2.05 and 2.07 (major and minor 
rotamers) 
3H 
H-28 
5.40 and 5.51 (major and minor 
rotamers) 
1H 
H-29 2.42 (major and minor rotamers) 1H 
H-30a 1.20 (major and minor rotamers) 1H 
H-30b 2.15 (major and minor rotamers) 1H 
H-31 3.34 (major and minor rotamers) 1H 
H-32 4.97 (major and minor rotamers) 1H 
OCH3-31 3.36-3.35 (major and minor rotamers) 3H 
O=C-CH3-32 2.02  (major and minor rotamers) 3H 
 
SpinWorks 2.5:  
PPM   9.2     8.8     8.4     8.0     7.6     7.2     6.8     6.4     6.0     5.6     5.2     4.8     4.4     4.0     3.6     3.2     2.8     2.4     2.0     1.6     1.2    0.8    0.4   
file: E:\asco diacet\15\fid   expt: <zg> freq. of 0 ppm: 500.129994 MHz
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 24-Monoacetate 5 
 
Attribution 1H (ppm) Integration 
CH3-25 
1.13 and 1.11  (major and minor 
rotamers) 
3H 
H-25 
2.19 and 2.42 (major and minor 
rotamers) 
1H 
H-24 
5.50 and 5.65 (major and minor 
rotamers) 
1H 
O=C-CH3-24 
2.05 and 2.07 (major and minor 
rotamers) 
3H 
H-26 
5.48 and 5.52 (major and minor 
rotamers) 
1H 
H-28 
5.44 and 5.45 (major and minor 
rotamers) 
1H 
H-29 2.44 (major and minor rotamers) 1H 
H-30a 1.18 (major and minor rotamers) 1H 
H-30b 2.15 (major and minor rotamers) 1H 
H-31 3.21 (major and minor rotamers) 1H 
H-32 3.68 (major and minor rotamers) 1H 
OCH3-31 3.46-3.44 (major and minor rotamers) 3H 
 
 
PPM   9.2     8.8     8.4     8.0     7.6     7.2     6.8     6.4     6.0     5.6     5.2     4.8     4.4     4.0     3.6     3.2     2.8     2.4     2.0     1.6     1.2    0.8    0.4   
file: E:\asco 24 acet\2\fid   expt: <zg> freq. of 0 ppm: 500.129994 MHz
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3. THE ANTITHROMBOTIC CLOPIDOGREL. 
 
3.1 Introduction  
Despite many recent advancements in the treatment of coronary hearth disease, it continues to be 
an important source of patients morbidity and mortality as well as a significant source of  
healthcare-related expenditures. Clopidogrel 1, Figure 3.1, an antiplatelet thienopyridine, has 
become an integral part of the management of acute coronary syndromes (ACS) and, consequently, 
has become one of the world’s best selling drugs. Numerous trial have demonstrated the clinical 
efficacy of clopidogrel in revuscalized and unrevuscalized ACS including unstable angina and 
myocardial infarction. As a results of trial, the use of clopidogrel has been incorporated into the 
American College of cardiology/American Hearth Association guidelines.1 
 
Figure 3.1. Antiplatelet thienopiryridines. 
 
3.2 Platelet activation 
In order to better understand the correlation between clopidogrel’s mechanism of action and the 
final cardioprotective role, is essential to think back over the ethiopatology of the coronary 
manifestation. The role of platelets in the pathophysiology of atherosclerosis and atherothrombosis 
that always evolves in artherial thrombosis is well-established; artherial thrombosis frequently 
causes acute and irreversible damage or infarction of target organs, most notably the heart and the 
brain, leading to death or permanent disability. Arterial thrombi are composed predominantly of 
plateles and relatively little fibrin or red cells and for this are called “white thrombi”. It has been 
established that antiplatelet agents, rather than anticoagulants should be the primary strategy for the 
treatment and prevention of arterial thrombosis. Actually, anticoagulants are effective in preventing 
acute myocardial infarction in patients with unstable angina or previous myocardial infarction and, 
to a lesser extent, in preventing stroke in patients with cerebrovascular disease.2   
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As shown in Figure 3.2, the monolayer of endotelian cells that normally lines the intima of the 
entire circulatory tree is a thromboresistant surface that secrets potent, locally-acting platelet 
inhibitory products. The two best characterized endothelium-derived platelet inhibitors are 
prostacyclin (PGI2) and nitric oxide (NO), which inactivate platelets by raising intraplatelet cyclic 
adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels, 
respectively. The physiological role of these autacoids is to preserve blood fluidity and, moreover, 
to relax smooth muscle of the vessel wall. 
 
Figure 3.2. Mechanism of platelet activation at a site of vascular injury. (A) Release of platelet inhibitory 
products of endotelial cells, including prostacyclin (PGI2) and nitric oxide (NO), maintains quiescent state of 
platelets traversing intact vessels. (B) Disruption of endothelium exposes thrombogenic subendothelial 
vessels wall costituents (eg, collagen); platelets adesion to this site is mediate by von Willebrand factor 
(vWf) binding to its platelet receptors localized in membrane glycoprotein (Gp)lb. (C) Other platelet 
activators (eg, thrombin, epinephrine) bind to their specific platelet receptors. (D) Platelets activated by these 
stimuli degranulate and undergo the release reaction, releasing ADP and thromboxane A2 (TXA2); ADP and 
TXA2 bind to their respective platelet receptors to further amplify the platelet activation process. (E) Platelet 
aggregation is mediated by fibrinogen or vWf binding to platelet membrane Gp IIb/IIIa, a functional 
heterodimeric receptor which is expressed on the surfaces of only activated platelets. 
When occurs a vascular injury, as shown in Figure 3.2B thromboresistant endothelium is disrupted 
and prothrombotic subendothelian vessel wall costituents (eg, collagen) are exposed to blood. 
Circulating platelets recognize this intimal breaks and undergo the process of “adhesion”, in which 
a carpet of platelets become anchored to the vessel wall. The ligand of adesion is von Willebran 
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factor (vWf), which binds to specific platelet receptors localized in membrane glycoprotein (Gp) 
Ib. 
A variety of other platelet stimuli (eg, collagen, thrombin, epinephrine, serotonin) can 
simultaneously bind to their specific platelet surface receptors (Figure 3.2C) and they function in 
concert to trigger a cascade of intracellular reactions that lead to the activation and subsequent 
aggregation of platelets. Fluids shear stress can also directly activate platelets. Activated platelets 
undergo the release reaction (Figure 3.2D), secreting preformed substances (eg, adenosine 
diphosphate (ADP) from their intracellular storage granules.3 Platelet activation also induces 
phospholipase A2 (PLA2)-mediated hydrolysis of free arachidonic acid (AA) from membrane 
phospholipid pools (Figure 3.3). Free AA is then rapidly metabolyzed by cyclooxygenase (COX) to 
the labile prostaglandin endoperoxides, PGG2 and PGH2 and then by thromboxane synthase (TxS) 
to thromboxane A2 (TXA2). Released ADP and PGH2/TXA2 bind to their respective platelet 
receptors to further amplify the platelet activation process. Platelet activation (and 
vasoconstriction) by TXA2 is antagonized in the presence of intact endothelium by platelet 
inhibitory and vasodilatory PGI2, which is produced in endotelial cells through prostacyclin  
synthase (PS) from either endothelium-derived or platelet-derived endoperoxides. 
 
Figure 3.3 Platelet (PLT)-endothelial cell (EC) interactions mediated by arachidonic acid (AA) metabolites. 
Activators of each cell type induce the phospholipase A2 (PLA2)-mediated hydrolysis of the AA from the 
membrane phospholipid (PL) pools (1) . Arachidonic acid is converted in each cell type by cyclooxygenase 
(COX) to prostaglandine endoperoxides, PGG2 and PGH2 (2). Endoperoxides are metabolized to 
thromboxane A2 (TXA2) by thromboxane synthase (TxS) in platelets and to PGI2 by prostacyclin synthase 
and (PS) in endothelial cells (3). TXA2 binds to platelet receptors to stimulate platelet activation (4) ; PGI2 
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binds to separate platelet receptors to inhibit platelet activation. Endothelial cells can also utilized platelet-
derived endoperoxides as substrates for  PS.      
Finally, activated and degranulated platelets attach to each other in the process of aggregation to 
form an occlusive thrombus at the site of vascular damage (Figure 3.2E). The ligand for platelet 
aggregation is fibrinogen (or vWf in higher shear stress regions of the circulation). The platelet 
receptor for these aggregating ligands is exposed only on the surfaces of activated platelets by the 
complexing of GpIIb and GpIIIa to form the GpIIb/IIIa complex. The binding of fibrinogen or vWf 
to their platel receptor GpIIb/GpIIIa receptor is mediated by the tripeptide amino acid sequence, 
arginine-glycine-aspartic acid (abbreviated “RGD”), a motif which is present on both of these 
adhesive molecules. 4 
3.3 Antiplatelet agents 
Each of the steps described above has been targeted in the development of antiplatelet agents. 
In order to maintain high level of platelet cAMP and cGMP, intravenous infusion of prostacyclin 
may have transient beneficial effects in coronary artery diseases but its systemic use is limited by 
its potent vasoactive effects and extreme lability. 
 
Figure 3.4. Compounds used in antiplatelet theraphy. 
Dipyridamole, (compound a in Figure 3.4), a coronaric  vasodilatator, has been suggested to act as 
an antiplatelet drug by several possible mechanisms. It directly stimulates prostacyclin synthesis, 
potentiates the platelet inhibitory action of prostacyclin, inhibits phosphodiesterase to raise platelet 
cyclic AMP levels and blocks the uptake of adenosine into vascular and blood cells, thereby 
causing accumulation of this platelet-inhibitory and vasodilatory compound in the thrombotic 
environment. Its side effects, include dose-related gastrointestinal symphtoms, headache, together 
with its variable absorption kinetics, does not support the use of dipyridamole as an antiplatelet 
agent. 
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Several antiplatelet strategies have been based on interruption of platelet TXA2 synthesis and/or 
action. Drugs can block platelet arachidonic acid (AA) mobilization, AA oxygenation by COX, 
thrombaxane synthase and TXA2 receptor. 
Evidences about reduced incidence of atherosclerotic in population eating marine lipids-rich diets, 
such as Greenland Eskimos, pointed out the antiplatelet activity of omega-3 fatty acid. Therefore, 
the major omega-3 fatty acid in fish oils is eicosapentaenoic acid (EPA)(compound b in Figure 
3.4). The antithrombotic alterations in platelet-vascular interaction attributed to fish oils are due to 
incorporation of EPA into cell-membrane phospholipids, leading to competition between EPA and 
AA as substrates of COX. The COX methabolism of AA in platelets produces the platelet-
activating and  vasoconstrictor TXA2, whereas the product of EPA metabolism is TXA3, 
biologically inert.  
The most extensively studied antiplatelet agent for stroke prevention certainly is Aspirin, 
(compound c in Figure 3.4),  acetyl salycic acid, that irreversibly inactivates COX by acetylating 
serine residues at position 529, leading to inhibition of platelet TXA2 synthesis. Moreover aspirin 
blocks the production of prostacycline, the major COX metabolite of AA in vascular endothelial 
cells. Therefore the half-life of aspirin is 20 minutes, its antiplatelet effect go on for 4-7 days, as the 
life time of the irreversible acetylated platelet. Aspirine is effective for primary and secondary 
prevention of myocardial infarction, stable and unstable angina, coronary arthery bybass graft 
patency, mechanical or high-risk tissue valves (when added to warfarin) and prevention of stroke or 
recurrent TIA. Aspirin is also possible effective in peripheral vascular disease and to prevent shunt 
thrombosis and spontaneous abortion in patients with lupus anticoagulant. 
Another important approach developed to achieve an antiplatelet effect is the use of compound able 
to interact and to inhibit platelet agonist-receptor. A theoretical limitation of inhibitors of individual 
platelet agonist-receptor interactions is their ability to block the initiation of only one of several 
pathways of platelet activation. Perhaps surprisingly, therefore, some of these agents have proven 
to be experimentally and clinically effective as antiplatel therapy. 
Of the platelet-derived agonists, trombaxane A2 receptor antagonist and ADP receptor blocker have 
received the most attention. ADP is present in high concentration in the dense granules within 
platelets and can initiate and reinforce aggregation after secretion of these granules. Ticlopidine 2, 
and its analog, clopidogrel 1, are thienopyridine derivatives that exert their antiplatelet action by 
inhibiting the binding of ADP to its platelet receptor and thereby inhibiting  ADP-induced platelet 
aggregation. 
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3.4 From ticlopidine to clopidogrel 
Ticlopidine 2 was discovered in 1972 through a screening tests performed in vivo while looking for 
anti-inflammatory compounds. The discovery of ticlopidine’s platelet antiaggregant properties led 
to its development as an antithrombotic drug some years later. In 1978 ticlopidine was introduced 
into the market in a very narrow therapeutic indication: prevention of thrombosis during 
extracorporeal circulation. Besides the wanted therapeutical effect, ticlopidine’s adverse effect 
profile include nausea, dyspepsia e diarrhea in more than 20% of patients; 1% of the treated 
patients was affected by neutropenia and thrombocytopenia.5 
Clopidogrel 1 is a second generation thienopyridine antiplatelet agents and was first filed in 1987. 
In its molecule, the presence of a methoxycarbonyl group on the benzylic position provides an 
increased pharmacological activity and better safety and tolerability profile compared with those 
seen with ticlopidine.6 
3.5 Mechanism of action and pharmacokinetics. 
Both ticlopidine 2 and clopidogrel 1 exhibit a platelet antiaggregant effect only “in vivo”, while “in 
vitro” they are inactive. In particular for clopidogrel, this effect occurs only after two hours after a 
single oral or intravenous administration. This behavior suggested that clopidogrel is, really, a 
prodrug that acts only after its metabolic activation. After its oral absumption, an amount of 
clopidogrel is rapidly converted to an inactive carboxylic acid metabolite after absorption from the 
gastrointestinal tract. Citocrome YP-mediated hepatic metabolism is required to produce the acting 
antiaggregating moiety, i.e. the acid 4a showed in the Figure 3.5.7 
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Figure 3.5. Metabolism of clopidogrel in vivo. 
Because of the requirement for in vivo activation the pharmacodynamic properties of the drug have 
been characterized in ex vivo studies in animals and humans. After metabolic activation, the 
pharmacological effect of clopidogrel are mediated by P2-purino-ceptors located on the surface of 
platelets. Different subtype of P2- purinoceptors are located on the surface of platelet’s membrane 
and involved in the mechanism of platelet aggregation, P2Y1 and P2Y12, that act in synergy to 
trigger platelet activation, being ineffective alone. The putative clopidogrel-sensitive purinoceptors 
is P2Y12 and is thought to be linked to adenylyl cyclase through an inhibitory G-protein. As 
mentioned above, ADP is a platelet activator that is relased from damaged endothelial cells, red 
blood cells, and activated platelets that induce platelet aggregation adhesion. The binding of the 
active metabolite of clopidogrel, the thiol derivative, to the P2Y12 purineceptor subtype, lead to 
inhibition of downregulation of adenylyl-cyclase through a protein Gi-dependent pathway and a 
resultant inhibition in the fall in intracellular cyclic adenosine monophosphate (AMP) level. 
Clopidogrel also inhibits other intracellular pathways  including phosphatidylinhositol triphosphate 
(PI3) kinase and RhoA/Rho-kinase downstream of P2Y12 activation. 
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Figure 3.6. Mechanism of action of different antiplatelet agents. Theinopyridines inhibits the stimulation of 
the adenosine diphosphate (ADP) receptor, a G-protein-coupled purinergic receptor (P2Y12). Aspirin 
(acetylsalicylic acid) inhibits cyclo-oxygenase (COX-1) and therefore thrombaxane A2 (TxA2) production 
with resultant decreased stimulation of the TxA2 receptor. Glycoprotein (Gp)IIb/IIIa inhibitors directly 
inhibits platelet aggregation at the receptor which thereby inhibits the final event in the pathway of platelet 
aggregation, the finding of fibrinogen by activating the (Gp)IIb/IIIa receptor. The boxes to the right of the 
drugs indicate potential mechanisms of limited drug effectiveness. 
Additionally, clopidogrel also has other important effects on several  proinflammatory events. It 
inhibits release of CD40 ligand from platelets and reduces the expression of P-selectine, which is a 
membrane glycoprotein that is stored in platelet granules  and promotes adhesion between platelets 
and leukocytes. Finally, clopidogrel inhibits the ADP-mediated effects of amplifier of other 
agonists of platelet aggregation including collagen and thrombin. 8 
The pharmacokinetics of the drug was studied by determining the fate of radiolabel after 
administration of [14C]-clopidogrel in healthy young male volunteers and showed that the inactive 
carboxylic acid is the major circulating methabolite that could be detected in the plasma less than 1 
hour after oral administration of clopidogrel while the inactive parent methylester, is below the 
limit of quantification (0.0025 mg/L) beyond 2 hours after administration of a repeating oral dose 
of 75 mg. The adsorption of clopidogrel dose occurres for the 50%  from the gastrointestinal tract. 
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The thieno-active methabolite of clopidogrel was isolated after exposure of clopidogrel or 2-oxo 
clopidogrel to human epatic mycrosomes; clopidogrel does not share any common metabolites 
which ticlopidine. Clopidogrel and its de-esterified metabolite are reversibly and highly (98 and 
94%, respectively) bound in an non saturable manner (at concentration ≤ 100 mg/L) to human 
plasma proteins in vitro. The half life of clopidogrel is 8 hours with excretion via urine and feces. 
Administration of clopidogrel with food or antiacids does not significantly alter the bioavailability 
of the drug and a low propensity to drug-drug interaction was found. 
3.6 Clinical applications 
Clopidogrel is one of the most widely prescribed drugs in the world, for the sodministration to 
patient that need antiplatelet theraphy and when drug-eluting stents for which dual antiplatelet 
theraphy may be needed for a number of years. 
Clopidogrel was US FDA approved in 1996 primarily based on data from the CAPRIE trial 
(Clopidogrel versus Aspirin in patients at Risk of Ischaemic Events). At that time, clopidogrel 
represented a new thienopyridine which was similar to ticlopidine, whose efficacy when used alone 
or with aspirin was widely demonstrated. However, its use was limited by potentially unfavorable 
adverse effects including diarrhea, nausea, vomiting, skin rush and neutropenia which did result in 
several fatalities. The CAPRIE trial enrolled 19 185 patients and compared the efficacy of 
clopidogrel 75 mg/day versus aspirin 325 mg/day in patients with atherosclerotic vascular disease: 
recent ischemic stroke,  recent myocardial infart, and symphtomatic peripheral arterial disease. 
Clopidogrel showed to be superior to Aspirin in all this deseases, for all the population treated. 
In their article about the  issue of the American Journal of Cardiovascular Drugs, Collins and 
Gurm review many of the clinical trials that have demonstrated the clinical efficacy of clopidogrel 
in patients with acute coronary syndromes, especially in myocardial infarction and unstable angina. 
Nowadays Clopidogrel in soministered in association with aspirin after placement of drug eluiting 
stent and for the treatment of patients with acute coronary syndromes.9   
Clopidogrel is being further evaluated in a range of atherothrombotic clinical settings such as the 
treatment of high-risk patients with recent transient ischemic attack or ischemic stroke.  
3.7 Aim of the work 
The structure of clopidogrel, as shown in the Figure 3.1, contains a stereocenter whose (S) -
configuration is important to preserve in order to obtain the desiderated pharmacological effect. In 
view of this, in a preparative approach is important to focus on the different methods we have to 
introduce this stereogenic carbon, that is nowadays object of studies and justifies the critical issue 
of cost. The most common methods to achieve the product enantiopurity are the fractional 
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crystallizations of the precursor (RS) 2-chlorophenylglycine 4 10, 11 or the final compound (RS) 1,  
with an optically pure acid, such as (1R)-camphor sulfonic acid or L(+) tartaric acid. The so-
obtained diastereomeric salts were then subjected to a series  tedious and time consuming fractional 
crystallizations to increase the enantiopurity of the recovered precipitate; then, the removal of the 
acidic component by a basic extraction, afforded often the desiderate stereoisomer with unsatisfied 
factory yields. 12, 13 
 
Scheme 3.1. One of reported pathways to obtain clopidogrel. 
The main objective of this work, was to obtain (S)- clopidogrel 1, in a fast, economic manner, that 
could afford the expensive thienopyridine with a very high enantiomeric excess, by the use of a 
biocatalyzed resolution. Analyzing the clopidogrel structure, two moiety can be easily recognized: 
the thiophen-ethanol and the 2-chloro phenyl-glycine; a nucleophylic substitution between tosilate 
3 and methylester 5 should, then, be a fast and easy way to obtain the clopidogrel skeleton being 
both the molecules easily prepared from commercially available, not expensive compounds. The 
obtained intermediate 6 could be then transformed into the final target by treatment with a 
formaldehyde source. (±) 
+
CO2CH3
NH2
Cl
S
HN
CO2CH3
Cl
1. Clopidogrel
S OH S OTs
3 5
6
(±)2-cl-phenilglycine 4
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Figure 3.7. Substrates of enzymatic resolution. 
Since in the course of an enzymatic resolution usually 50% of substrate has to be discarded, we 
decided to focalize our attention on the less precious precursor (±) 2-chloro-phenylglycine methyl 
ester 5, easily prepared from the commercially available 4, and on the key intermediate (±)-2-(2-
chlorophenyl)-2-[2-(thien-2-yl)ethylamino]-acetate 6, appropriately derivatized as showed in the 
Figure 3.7. In fact, both the compound are bifunctional molecules, providing two possible site of 
enzymatic attach: the methyl ester and the primary or secondary aminic group. Among the 
enzymes, were selected proteases, whose proteins and aminoacids are the natural substrates, 
esterase and chymotrypsin, for their ability to recognize ester moiety and  lipases because their 
versatility to adapt to a wide range of different functional groups. Beside the screening of the 
enzymatic reaction, including the selecting of substrate, and the setting of the biocatalysts in the 
best conditions for they activity,  the second critical aspect of the work will be the checking of the 
enantiopurity of all the intermediates. These because the presence of a benzylic proton at the α-
position makes aryl-glycines recemization prone.14 
 
3.8 Results and Discussion 
a) Enzymatic screening on derivatives of compound 6 
From the intermediate 6, we started the enzymatic screening, mainly because provided a new 
substrate to explore the behaviour of the different classes of enzymes. The first attempts were done 
directly on the intermediate 6, avoiding time consuming derivatization. 
The bi-functionality of the compound, allowed us to test both the hydrolysis of the methyl-ester 
moiety and the acylation of the secondary aminic function (Scheme 3.2). 
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Scheme 3.2. Enzymatic screening on intermediate 6. 
Entry Enzyme Solvent Time(h) Conversion (%)* 
a CAL B tert-butylmethylether, H2O 8 eq 25 0 
b CAL B THF, H2O 8 eq 48 0 
c CAL B tert-butylmethylether, 20% buffer pH 7.6 48 
0 
 
d α-Chymotripsin buffer phosphate pH 7.6 48 10 
e α-Chymotripsin buffer phosphate pH 7.6,  DMF 20% 120 Traces 
f α-Chymotripsin Acetonitrile, H2O 4 eq 48 0 
g CCL Toluene , H2O 4 eq 48 0 
h PFL THF, H2O 4 eq 48 0 
i PPL buffer pH 7.6 48 Traces 
l Papain buffer phosphate pH 7.6, DMF 20% 60 0 
m 
Protease from 
Bacillus 
licheniformis 
Acetonitrile, H2O, TEA 
(9:1:0.8) 60 0 
n CAL A Dioxane, butylamine, 1 eq. 70 0 
o CAL B Toluene, butylamine, 1 eq. 70 0 
p 
 CCL Hexane, butylamine, 1 eq. 70 0 
Table 3.1. Condition for methylester hydrolysis on substrate 6. 
*By tlc analysis  
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A wide range of enzymes are reported to hydrolyze an ester: first of all the lipases, for whom the 
triacylglycerols are the natural substrates and then the esterases, and α-chymotripsin and proteases 
endowed with esterase activity. Considering the low polarity of the substrate, all the reaction were 
carried on in a mixture of water, necessary to act as the nucleophilic compound that accept the acyl 
moiety, and a co-solvent.The choice of the cited cosolvents, arises from the previous results 
reported in literature; the use of only slightly alkaline medium is suggested in order to prevent the 
non-enzymatic ester hydrolysis.15 As described in Table 3.1 no one enzyme accepted the ester as 
substrate, with the exception of α-chymotripsin and PPL. The slowness of α-chymotripsin 
hydrolysis was in agreement with the reported resolution of (±) threo-methylphenidate, structurally 
similar to compound 6.16 Further attemps to increase the rate of reaction by solubilization of the 
starting material with a cosolvent failed. 
We also attempted to carry on the hydrolysis of the ester employing as nucleofile acceptor 
buthylamine, with lipases in the most suitable solvent for one of them, following the protocols 
reported by Gotor.17 No activity was detected by tlc and NMR analyses. (entry n-p, Table 3.1)  
The negative outcomes obtained working on the methyl-ester moiety, suggested us to select the 
acylation of the secondary aminic function as biocatalyzed reaction. This project was supported by 
a wide range of successful examples of resolution of secondary amines by acylation with lipases, in 
particular by lipase from Candida antarctica that seems to prefer hindered amine and amino 
esters.18 Our results are in agreement with these note knowledge: the acylation was obtained only 
with CAL A, but in a long time and without enantioselectivity (see Table 3.2).  
   Entry Enzyme Solvents Time (h) 
 
Conversion* (%) 
 
 
ee*% 
 
 
a CAL B 
Vinylacetate, 
tert-butylmethylethere 90  0 - 
b CAL B Vinylacetate, toluene 48  0 - 
c CAL B Trifluoro-ethylbutyrate DIPE 120 0 - 
d CAL B 
 
Trifluoro-ethylbutyrate 
tert-butylmethylether 
 
120 0 - 
e CAL B ACOEt 120 0 - 
f CAL A ACOEt 120 20  0 
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g CAL A Vinylacetate 120 30 0 
h CAL A Trifluoro-ethylbutyrate tert-butylmethylether 120 56 0 
i 
CAL A 
(supported on 
celite and 
saccharosium) 
Vinyl-butyrate 120 0 - 
Table 3.2. Condition for acylation on substrate 5. *By chiral Hplc analysis 
Thinking that these discouraging results on the intermediate 6, were probably imputable to the 
presence of two functional groups in the compound that could interact, we decide to protect the 
aminic function as acetyl amide and tert-butoxycarbonyl, respectively compounds 7 19 and 9, and to 
screen again some of the above mentioned hydrolases.  
Again no hydrolysis was observed. 
 
 Scheme 3.3  Enzymatic screening in hydrolytic conditions on compounds 7 and 9. 
Compound Enzyme Solvent Time (h) Conversion * (%) 
7 α-chimotrypsin buffer pH 7.6 48 0 
7 PPL buffer pH 7.6 48 0 
9 
Protease from Bacillus 
licheniformis 
buffer  pH 8, 
10%v/v acetonitrile 
120 0 
9 
Protease 
Carlsberg 
buffer pH 8, 
20% TBME 
120 0 
9 PLE 
buffer pH 8, 
20%  acetonitrile 
120 0 
9 PPL 
buffer pH 8, 
hexane 20% 
120 0 
Table 3.3. Condition of  hydrolysis on substrate 7 and 9. *By chiral Hplc analysis 
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As possible explanation for the results exposed till now, we proposed that the flexible structure of 
the intermediate 6 and of all its derivatives 7, 9 didn’t fit into the 2 hydrophobic pockets present in 
the active site of the hydrolases employed. 
As last approach, we carried on the hydrolysis of the butyric amide on the derivate 10 employing 
acylases from different microorganisms. 
 
Scheme 3.4. Enzyme-catalyzed hydrolysis on derivative 10 
 
Entry 
 
Enzyme Solvent Time (h) Conversion* (%) 
 
a Acylase from Aspergillus melleus 
 
buffer pH 7.5 
 
120 0 
 
b Acylase from 
Streptomyces toyocaensis buffer pH 7.5 120 0 
 
c Acylase I from 
porcine kidney 
 
buffer pH 7.5 
 
120 0 
Table 3.4.  Aminolysis on substrate 10. *By TLC analysis 
b) Enzymatic screening on derivatives of compound 5 
The study on derivatives 5 started, fist of all, examining the numerous publications dealing with the 
enzymatic resolution on amino acids, considering that their are important building blocks in the 
pharmaceutical field for the production of semisynthetic antibiotics, peptides and pesticides20. In 
particular, our analysis selected the works involving phenylglycine, the non proteogenic aminoacid 
sharing the most similarity with our substrate 4. Only a few cases of 2-chlorophenylglycines 
resolutions are described: for example the resolution of the tioester of the racemic 2-
chlorophenylglycine, protected on the aminic function as tert-butoxycarbonyl, by subtilisin 
Carlsberg 21 and the successful work, reported by Fadnavis et al, realyzed by employing 
immobilized penicillin G acylase.22 The value of this attempt of resolution, is underlined not only 
by the possibility to obtain an optically pure compound in a previous step of synthesis of 
clopidogrel, with a gain on the final yield, but also because the comparison of these results with 
those regarding  phenylglycine will be useful to better understand the influence of the chlorine 
ortho-substituent on the activity and selectivity of the enzymes. As in the case of compound 6, 
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again we started from 2-chlorophenylglycine methylesther  5, at first,in the same conditions tested 
above (Scheme 3.5). 
 
Scheme 3.5. Enzymatic screening on derivative 5. 
Differently from what observed for the compound 6, all the enzymes transformed the methyl ester 
into the free acid, even if with different rate and enantioselectivity. As described in the Table 3.5, 
all the reaction were done at room temperature, at first with only buffer phosphate, pH 7.5, and 
later in presence of 20% of co-solvent, always to increase the substrate solubility and hopefully the 
selectivity of the enzyme. As we expected, lipases were no enantioselective, probably for the well 
documented preference of organic medium: for this reason, following how reported for the same 
reaction on D,L-phenylglycine, the reaction was carried on also in the presence of proper 
concentration of the ionic liquid IL BMIM BF4, capable of dissolving a wide range of substrates, 
expecially those high polar and sparingly soluble in common organic ones. As evident from the 
result, this ionic cosolvent could boost the activity and the enantioselectivity of the lipase, probably 
for its interaction with charge group of the enzyme’s structure and making the enzyme more 
preferential for the preponderant enantiomer.23 The result was different when α-chymotripsin was 
used: in agreement with the results obtained for the compound 6, the enzyme afforded the best 
result with the only aqueous medium. Considering the global low degree of enantiopreference, a 
blance was done to verify that no chemical hydrolysis occurred. 
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Entry Enzyme Solvents Time (h) 
 
Conversion * (%) 
 
 
ee %*(S)-9 
 
a CAL B buffer pH 7.5, BMIM BF4 (20% v/v) 
12.5  60 ees = 30 
b CAL B buffer pH 7.5 12.5  44 eep = 11 
c α-chymotripsin buffer pH 7.5 4  42 ees = 67 
c α-chymotripsin buffer pH 7.5 CH3CN 20% 
12  10 eep =  0 
d α-chymotripsin buffer pH 7.5 EtOH 20% 6  13 eep = 60 
e α-chymotripsin buffer pH 7.5 MeOH 20% 4  22 eep = 50 
f α-chymotripsin buffer pH 7.5 BMIM BF4 20%  
4 17 eep = 12 
g α-chymotripsin buffer pH 7.5 BuOH 20% 27 46 eep = 16 
h α-chymotripsin buffer pH 7.5 propanol 20% 27  58 ees = 0 
i 
Protease from 
Bacillus 
licheniformis 
buffer  pH 7.5 12.5 88 ees = 27a 
l subtilisin buffer pH 7.5 12.5 81 ees = 23a 
m PPL buffer pH 7.5 12.5 77 ees = 24 
n CCL buffer pH 7.5 12.5  56 ees = 0 
o PFL buffer pH 7.5 12.5  66 ees = 17 
p Papain buffer pH 7.5 12.5 h 39 eep = 0 
Table 3.5. Enzymatic-hydrolysis on compound 5. 
*By chiral Hplc analysis. The enantiopreference in favour of the enantiomer (S) of the acid 4 was obtained by 
comparison with HPLC of enanantiomerically pure (S) 4 and (S) 5. 
a The (S) configuration belongs to unreacted ester 5.  
The HPLC analysis of hydrolysis on the compound 5, showed that the enantiopreference of the 
screened subtilisins, was opposite to the one of all the above cited lipases. More in detail, while the 
lipases showed the expected prefential hydrolysis of the S enantiomer of the racemic ester, even if 
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with a low selectivity, for both the two tested subtilisins the weak enantiopreference was directed 
against the R enantiomer, as reported in the Table 3.5. This outcome could be explained by the 
reported observation that subtilisin-protease have the catalytic site arranged as the mirror image of 
lipase’s catalytic site.24 
Going on with the reactions on compound 5, we screened the ability of lipases, CAL A, CAL B, 
CCL, to perform the ammoniolysis of the methyl ester using, as source of ammonia, ammonium 
carbamate (8 eq): this reactive replaces the role of ammonia that if used in excess could be 
detrimental for the enzyme. Again we followed the reported conditions for phenylglycine methyl 
ester.25, 26 As described in the Scheme 3.5, the ammoniolysis didn’t occur but was detected a 
chemical hydrolysis of the methyl ester that led to recover the free amino acid 4. 
In the Table 3.6, the conditions of N-acylation on substrate 5, using different acyl donor, from the 
most blande ethyl acetate to the activated trifluoroethyl butirrate, are collected. CAL A and CAL B 
were able to acylate the aminic function of the methylester 6 in organic medium, at room 
temperature, but, as reported for phenylglycine methylester with PPL and PFL, their action was no 
selective. 
 
Entry Enzyme Solvent Time (h) 
 
Conversion⃰ (%) 
 
 
ee⃰ % 
 
a CAL B ACOEt 120 35  
 
eep = 0 
 
b CAL B  Trifluoroethylbutyrate, DIPE 22   50  
 
eep = 0 
 
c CAL A Trifluoroethylbutyrate, DIPE 10  70 
 
ees = 0 
 
d CAL A ACOEt 78  20 
 
eep = 0 
 
e 
Subtilisin from 
Bacillus 
licheniformis 
Trifluoroethylbutyrate 
tert-BuOH 74  10 
 
eep = 0 
 
6 Subtilisin from 
Bacillus subtilis 
Trifluoroethylbutyrate 
tert-BuOH 74  30 
 
eep = 0 
Table 3.6. Condition of acylation on substrate 5.*By chiral Hplc analysis 
The same acylation realized with protease from bacillus subtilis and licheniformis, didn’t afforded 
better results on compound 5, while, the same reaction has permitted to obtain the correspondent 
natural amino acids phenylglycine with an ee of 65%.27 
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Further investigations on the resolution starting from the amidic functions were conduct on the 
acetyl- and trifluoroacetyl derivatives 13 and 14 respectively. The most suitable enzymes to operate 
the hydrolysis of these two amide are acylases from Aspergillus melleus, Streptomyces toyocaensis, 
and porcine kidney: the hydrolytic reaction were performed in aqueous solution at pH 7.5 , which is 
close to the maximum catalytic activity of aminoacylase I.28 In the medium was also added 1 mM 
of CoCl2, an additive that seems to enhance the rate of reaction29. All the acylases didn’t recognize 
the N-acetyl derivative 13 and, concerning the  derivative 14, the low hydrolysis of its N-
trifluoroacetyl amide, 10% after 24 h, as reported in the Table 3.7, was probably due to a 
spontaneous chemical hydrolysis, as confirmed by the assence of enantiopurity in the recovered 
free amino acid. Then, we can conclude that neither amides 13 and 14 were not substrate of the 
examined enzymes. 
 
Scheme 3.6. Aminolysis on derivatives 13 and 14 
Compound Enzyme Solvents Time (h) 
 
Conversion⃰  (%) 
 
eep⃰ % 
 13 Acylase from Aspergillus Melleus 
buffer pH 7.5 
CoCl2 
24  0  - 
 
13 
 
Acylase from 
Streptomyces toyocaensys 
buffer pH 7.5 
CoCl2 
24 0  - 
         13 Acylase I from PKA 
buffer pH 7.5 
CoCl2 
24 0  - 
14 Acylase from Aspergillus Melleus 
buffer pH 7.5 
CoCl2 
24 
 
10 
 
0 
 
14 
 
Acylase from 
Streptomyces toyocaensys 
buffer pH 7.5 
CoCl2 
24 
 
10 
 
0 
         14 Acylase I from PKA 
buffer pH 7.5 
CoCl2 
24 
 
10 
 
0 
Table 3.7. Conditions of  aminolysis on derivatives 13 and 14.*By chiral Hplc analysis 
These preliminary negative results prompted us to go back again on the hydrolysis of the ester 
moiety, tha gave the best results in term of activity of the enzymes but in order to enhance their 
stereoselectivity we decided to protect the aminic function as a tert-butoxycarbonyl (Boc) 
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derivative. The choice of this protective group was due to its easy cleavage and reported wide 
acceptability by hydrolytic enzyme. Since for the clopidogrel synthesis we needed the (S)-methyl 
ester 5 and not the (S)-acid, as first approach, we tried to use subtilisin as biocatalyst of the 
opposite reaction i.e. the esterification of the racemic acid 15: in fact, in this case, due to the 
enzyme (S)-enantiopreference, (S)-ester 16 should be obtained. Several examples of subtilisin-
catalyzed esterification of aminoacids30 or peptides31 are reported but in our case only the starting 
material was recovered in all the tested conditions. Also papain and α-chymotripsin were tested, 
using dichloromethane as organic medium and MeOH as alcohol donor. A low activity was 
detected, 20 % of methyl ester formed after 5 days but without any enantiopreference. Since these 
results could be due to the negative effects of methanol on the enzyme25 we tried to use a known 
more stable preparation of subtilisin, the cross-linked enzyme aggregation (CLEA) commercialised 
(Novozymes) with the Alcalase-CLEA® name 26-28 but also in this case no esterification of 15 to 16 
was observed.  
 
Scheme 3.7. Enzyme catalyzed esterification of derivative 15. 
However, the experimental advantages offered by the CLEA-subtilisin (e.g. the insoluble aggregate 
can be removed by simple paper filtration, avoiding tedious work-up of the obtained emulsions, 
when the free enzyme was used) prompted us to test this enzymatic preparation in hydrolytic 
conditions. 
 
Scheme 3.8. Enzyme-catalyzed hydrolysis on derivative 16. 
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Entry Enzyme Solvent Time (h) Conversion⃰  (%) ee⃰  % 
 
a CAL B buffer pH 7.5/TBME (2:1) 96 0 - 
 
b CCL 
buffer pH 7.5 
toluene 20% 96 0  
 
c CAL A 
buffer pH 7.5 
hexane 20% 120 10 eep = 0* 
d α chymotripsin buffer pH 7.5CH3CN 20% 96 0 - 
 
e 
Protease from 
Bacillus 
licheniformis 
buffer  pH 7.5/TBME (2:1) 65 40 
eep = 
97.6 
 
 
f 
Protease from 
Bacillus subtilis buffer pH 7.5/TBME (2:1) 65 40 
 
eep = 96 
 
 
g PPL 
buffer pH 7.5 
hexane 20% 120 10 eep = 54 
 
h PFL 
buffer pH 7.5 
THF 20% 12 66 ees = 17 
 
i Papaina 
buffer pH 7.5 
hexane 20% 120 0 - 
 
l PLE 
buffer pH 7.5 
CH3CN 20% 
120 10 eep = 0 
 
m Alcalase CLEA 
pH 8 buffer/CH3CN 
10/1 15 40 79 
 
n Alcalase CLEA 
pH 8 buffer/DMF 
10/1 16 40 65 
 
o Alcalase CLEA 
pH 8 buffer/THF 
10/1 14 40 98 
Table  3.8. Condition of hydrolysis on derivative 16. 
*By chiral Hplc analysis 
As showed in Table 3.8, among the tested lipases, only PPL showed a weak activity to hydrolyze 
the methylester 16 into the acid 15 while, surprisingly, CAL A, CAL B and CCL were no active: 
these results could be explained assuming that the bulk of the Boc compromise the access of the 
substrate in the active site of the enzyme. Also α-chymotripsin, which was the more promising 
enzyme in the case of unprotected methylester 5, did not transform at all the derivative 16. In 
agreement with how published for 2-chlorophenilglycine thioester and for several other amino 
acids, proteases succeeded to resolve the racemic 16, affording  the desidered acid (S)+ 15 in 40% 
of yield and an enantiomeric excess higher than 98%.    
 These satisfactory results were in agreement with the reported ones, by Arosio et al.,  in a detailed 
study of the proteases-catalyzed hydrolysis of a series of arylglycines thioesters.21 The 
ethylthioester, instead of a carboxyester, was chosen by the authors since suitable for a complete 
substrate deracemization through an in situ base-catalyzed continued racemization of R-isomer. 
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Use of bad smelling ethantiol was judged not suitable for large scale preparation purposes and, on 
the other hand, considering the low cost of (R,S)-2-chlorophenylglycin toward the final product 
value, the complete deracemization process was not so mandatory; in any case the  (R)-isomer 
could be  later racemized and recycled. The same reaction was also carried on with a known more 
stable preparation of subtilisin, the cross-linked enzyme aggregation (CLEA) commercialised 
(Novozymes) with the Alcalase-CLEA® name 32,33,34. However, the experimental advantages 
offered by the CLEA-subtilisin ( e.g. the insoluble aggregate can be removed by simple paper 
filtration, avoiding tedious work-up of the obtained emulsions, when the free enzyme was used) 
prompted us to test this enzymatic preparation in hydrolytic conditions. Among the examined 
organic solvents tetrahydrofuran afforded best results (>98% ee) while in acetonitrile and in 
dimethylformamide only 79% and 65% ee, respectively, were observed (Table 3.8, entries m-o). 
Use of cross-linked enzyme in THF/H2O shortened also reaction time, the desired 40% conversion 
to (S)-acid 15 being reached after 14 h, instead of 63 h required in the case of free subtilisin in 
TBME/H2O. The (S)-15 isomer was converted, by esterification  (methanol, DCC, DMAP in 
dichloromethane) and  removal of protecting group (TFA), into (S)-methyl ester 5 (90% yield), the 
suitable precursor for  the preparation of clopidogrel 1. 
 
c) Preparation of (S)-clopidogrel 1  
 The (S)-5 prepared by the CLEA enzymatic hydrolysis, we accomplished the preparation of the 
final compound following a reported pathway, explained in the Scheme 3.9. Chemo-enzymatically 
prepared (S)-5 was treated with tosylate 3 in acetonitrile in presence of sodium hydrogen carbonate 
to afford intermediate 6 (70%).13 The best results (50% yield) for the heterocyclic ring formation 
were obtained with paraformaldehyde,35 as formaldehyde source, formalin13 or 1,3-dioxolane 
affording lower yields and more complex final reaction mixture. The enantiopurity of the final 
clopidogrel (S)-1 was checked by HPLC analysis on a chiral column (see below). 
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Scheme 3.9. Final pathway followed for the preparation of  (S)+ 1. Reagents and conditions: (i) CH3OH, 
DCC, DMAP, CH2Cl2; (ii) TFA, CH2Cl2; (iii) 20% NH4OH; (iv) TsCl, (iPr)2O, Et3N; (v) NaHCO3, KI, 
CH3CN; (vi) paraformaldehyde, ClCH2CH2Cl, HCl in DMF. 
3.9 HPLC analyses 
In the case of N-unprotected 2-chlorophenylglycine methylester 4 the enzymatic reaction progress 
could be monitored,  contemporary to the  ee evaluation, using a chiral column.  
In the case of N-Boc derivatives 14 and 15 a chiral column screening showed some difficulties 
(very long retention times and broad peaks) in performing the two evaluations at the same time; we 
decided, then, to control the reaction progress by means of a C18 column, delaying the ee 
evaluation after the Boc group removal. In this way we could detect not only the stereochemical 
outcome of the biotransformation but also to verify if some racemization eventually occurred 
during the deprotection step. The known arylglycines tendency of racemization  suggested to check 
the ee, not only  of final product 1, but also of all intermediates. In fact, for example, when we tried 
to prepare (S)-4  as free base (necessary for the nucleofilic substitution on tosilate 3) from the 
trifluoroacetic salt obtained from Boc removal, use of 0.5M sodium hydrogen carbonate, caused the 
formation of a  10 % (R)-isomer. On the contrary, by treatment with 20% ammonium hydroxide no 
racemization was observed. Using chiral stationary phases optical purity of intermediate 5 and final 
product 1 were also determined. Chosen columns, mobile phases and retention times are collected 
in Table 3.9. 
 
80 
 
Compounda Column Mobile phaseb Rt(min)- 
(R)- (S) isomers 
4 Daicel Crownpack CR (+) 0.4 
cm X 15 cm 
10-2 M HClO4 2.71-5.02 
5 Daicel Crownpack CR (+) 0.4 
cm X 15 cm 
10-2 M HClO4 12.49-21.35 
15 Water spherisorb 5 µm OD 0.46 
cm X 25 cm 
H2O/CH3CN/HClO4 
1:1:0.1 
10.90 
(R) 16 Water spherisorb 5 µm OD 0.46 
cm X 25 cm 
H2O/CH3CN/HClO4 
1:1:0.1 
5.71 
6 Daicel Chiralpack IA 
 0.46 cm X 25 cm 
Hexane/AcOEt/Et3N 
95:5:0.1 
17.28-15.00 
1 Agilent Lichrocart 250-4 
Chiradex 5 µ 
CH3CN/CH3OH/0.01 M 
KH2PO4 15:5:80 
32.42-26.40 
Table 3.9. Hplc conditions 
aDetector wavelength was set at 220 nm for all compounds, with exception of  6  (250 nm); bFlow rate was of  
1ml/min, with exception of  9 (0.7 ml/min).                                                                                                                                                                                                                                                                          
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4. AMINOACYL-tRNA 
AMIDOTRANSFERASE INHIBITORS RELATED TO CHLORAMPHENICOL 
 
4.1 Introduction  
 
Biochemical investigations of the last few years selected the enzyme amidotransferase, involved in 
the translation process, as possible target for the development of new antibacterial compound.1 
In most organisms the translation of the genetic information into new proteins synthesis proceeds 
through a direct pathway involving 20 aminoacyl tRNA synthetases (aaRS) that produce the 
required set of 20 different aminoacyl tRNAs. As shown in the Figure 4.1, this process starts with 
the reaction of the aminoacid with ATP to form an enzyme-bound aminoacyl adenylate 
intermediate (aa-AMP) with displacement of pyrophosphate (PPi). In the second step, the 
aminoacyl group is transferred to a OH of the ribose at one end of the tRNA generating aminoacyl-
tRNA (aa-tRNA) and adenosine monophosphate (AMP). 2 
 
 
Figure 4.1: Direct pathway of tRNA aminoacylation: aaRS = aminoacyl-tRNA synthetase. 
 
Recent genomic studies revealed the absence of glutaminyl-tRNA synthetase (GlnRS) and/or 
asparaginyl-tRNA synthetase (AsnRS) in archaeabacteria, Gram-positive eubacteria and many 
Gram-negative eubacteria.3 The survival of microorganisms missing one or both of these essential 
enzymes implies an alternative pathway for the formation of Gln-tRNAGln  and Asn-tRNAAsn 
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(Figure 4.2). This indirect pathway involves the misacylation of tRNA of tRNAGln with Glu (or 
tRNAAsn with Asp) by a non discriminating aminoacyl tRNA synthetase (ND-aaRS) and the 
subsequent transamidation of the misacylated aa-tRNA by an amidotransferase (adT).  
Asp + tRNAAsn ND-AspRS Asp-tRNAAsn Asn-tRNAAsn
Glu + tRNAGln ND-GluRS Glu-tRNAGln Gln-tRNAGln
AdT
AdT
 
  
Figure 4.2: Indirect pathway for Asn-tRNAAsn and Gln-tRNAGln  biosynthesis: ND-AspRS = non 
discriminating aspartyl-tRNA synthetase; ND-GluRS = non discriminating glutamyl-tRNA synthetase; AdT 
= aminoacyl-tRNA amidotransferase. 
  
The proposed mechanism for the transamidation reaction catalysed by amidotransferase is a three 
step event (Figure 4.3). First, the hydrolysis of  the amino donor, glutamine, provide enzyme bound 
NH3 (glutaminase step) (Figure 4.3 a). The second step is the activation of the side-chain 
carboxylic group of the amino acid fixed on the tRNA (Glu-tRNAGln  or Asp-tRNAAsn) resulting 
from the reaction of this carboxyl group with ATP to form a mixed anhydride (kinase step) (Figure 
4.3 b). In this intermediate, the high-energy anhydride bond activates the carboxyl group. Finally 
the aminolysis of the activated amino acceptor by enzyme-bound NH3 (transamidase step) forms 
the final product (Gln-tRNAGln  or Asn-tRNAAsn ). The overall reaction is the simple conversion of 
the side chain carboxilyc acid (Glu or Asp) into an amide (Gln o Asn) while the amino acid is still 
attached to a tRNA ( pretranslational modification). 4 
a) 
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b) 
 
Figure 4.3: Reaction mechanism of aminoacyl-tRNA amidotransferase. For Asp-tRNAAsn  amidotransferase 
(AspAdT), n = 1, tRNAaa =tRNAAsn;  for Glu-tRNAGln  amidotransferase (GluAdT), n = 2, tRNAaa =tRNAGln. 
Two types of amidotransferases have been identified in nature: a trimeric one (GatCAB), 
present in most bacteria and some archea, can use both Glu-tRNAGln  and Asp-tRNAGln as 
substrates, whereas a dimeric GatDE, present only in archaea, uses only Glu-tRNAGln. 5 
Crystal structures of GatCAB and GatDE have been determined recently.6 
4.2 Characterization of GatCAB from the hyperthermophilic bacterium Aquifex aecolicus. 
Last year, Smith et al. reported the crystal structure of  GatCAB from the hyperthermophilic 
bacterium Aquifex aeolicus complexed with glutamine, asparagine, aspartate, ADP or ATP and 
unreact ATP with Mn2+ ions.6(d) As shown in the Figure 4.4 the enzyme is made by three units, 
colored differently in the stereo ribbon diagram, blue for the A subunit, green for the B and 
magenta for the C.  
The A. aeolicus A-subunit, which includes 478 amino acid residues, contains a conserved amidase 
signature sequence (62-192) that forms the enzymatic core composed of 11-stranded β-sheet 
surrounded by 12 α-helices. 
The B-subunit (478 amino acids) is composed of an N-terminal “cradle” domain (3-293), followed 
sequentially by a helical domain (294-412). The C-subunit (94 amino acid) wraps around the 
interface of the A and B subunits. The A-subunit of GatCAB functions to liberate ammonia from 
an amide donor and belongs to the amidase family of enzymes.7 Amidases are characterized by a 
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Gly/Ser-rich sequence motif, which folds to assemble a Ser-cisSer-Lys “catalytic scissor” (Ser171, 
cisSer147 and Lys72 in the A.aeolicus A-subunit).8 
 
Figure 4.4: Overall structure of the A. aeolicus GatCAB-Asn/ADP complex. 
Co-crystal with  Gln and Asn and kinetic data revealed that GatCAB is able to efficiently use both 
amino acids as amide donors (Kcat/ Kcat of 9.7 and 11.1 s-1 and mM-1, respectively). This subunit 
recognize both Gln and Asn in an identical manner using two invariant “anchor” side chain: an Arg 
for the substrate α-carboxyl group and a Asp for the α-amino group. The ability to form an acyl-
enzyme intermediate at the nucleophilic Ser171 depends on the distance of  Ser-cisSer-Lys 
catalytic scissor from the Arg-Asp anchor residues. 
The B-subunit is responsible of the ATP-dependent activation of substrate aa-tRNA (Glu-tRNAGln  
or Asp-tRNAAsn) that leads to the formation of a phosphoryl-aa-tRNA intermediate, then amidated 
with the ammonia liberated by the A-subunit. The hydrolysis product ADP binds the B-subunit 
active site: the adenine base fits into an hydrophobic pocket formed by Val8, Phe208 and Pro158 
with hydrogen bonds from N1 and N6 of the adenine to the conserved Ser199 side chain. The ADP 
α- and β- phosphates interact with bound water molecules. There are no bound metal ion associated 
with ADP. 
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Figure 4.5 (a): Synthetase activity site in the B-subunit: ADP/Mg2+ complex.  
Crystallization of the protein with the complex ATP/Mg2+ showed that  the γ-phosphate of ATP, 
together with the side chains of Glu12 and Glu213 and a molecule of water, coordinate the 
“transient” metal site of  Mg2+ that probably assists phosphoryl transfer (Figure 4.5 b). In the B-
subunit there is also a permanent metal site: here the metal is coordinated by His14, Glu127 and 
Glu153.(Figure 4.5 a) The permanent metal is too far from the nucleotide to participate directly in 
the phosphoryl-transfer reaction but mutation of residues in this area lead to inactive mutant 
enzymes suggesting a critical role for this site.  
Furthermore soaked with Asp, as a mimic of the aminoacyl end of  Asp-tRNAAsn, showed that one 
of the Asp carboxyl groups coordinate the metal ion in the permanent site and faces the ATP γ-
phosphate (Figure 4.5 b). 
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Figure 4.5(b): Synthetase activity site in the B-subunit: ATP/Mg2+ complex . 
 
The active sites of the A and B subunits are connected by a continuous  hydrophobic tunnel 35-Å 
long that allows the channelling of ammonia from A to B subunits. In the B-subunit, between the 
NH3 channel the C subunit there is a Zn2+ binding site with tetrahedral coordination by Cys25, 
Cys27, Cys40, Cys43. The presence of the Zn (Cys)4 site stabilises a B-subunit loop (residues 25-
40) that forms several hydrogen bonds with the C-subunit including a direct hydrogen bound from 
Ser68 in the C-subunit to the Cys27 Zn2+ ligand. In addition, residues Val42, Cys43 and Leu44 
form part of the wall of  the NH3 channel. Thus, Zn (Cys)4 is an important motif for maintenance of 
the channel and for the binding between the B- and C-subunits. 
4.3 Aim of the work  
The presence of a trimeric AdT in most bacteria, and the absence of either dimeric or trimeric AdT 
in the cytoplasm of eukariotes, identify GatCAB as a promising target for the development of new 
types of antiobiotics. The new AdT inhibitors will target protein biosynthesis in the above 
mentioned bacteria, without affecting it in mammalian cytoplasm or mitocondria.  
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Up to recently, only a few AdT inhibitors have been reported in part because of the absence of a 
convenient assay. So far, AdT inhibitors are essentially synthetic analogues of glutamine, ATP and 
aminoacyl-tRNA. In a mechanism-based approach, glutamyl-γ-boronate derivatives were evaluated 
as substrate-based (Gln) inhibitors acting as  serine inactivators in the AdT-glutaminase active site 
(Figure 4.6). 9  
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Figure 4.6: Glutamyl- γ-boronate derivatives and best values of activity against the glutaminase (GLA) and 
transferase (TRA) activities of Glu-AdT. 
 
In general, a serine inhibitor contains an electrophilic centre that is reactive toward an hydroxyl 
nucleofile and boronic-acid have been shown to be effective serine “traps” through the formation of 
a reversible serine-boronate-acetal.10 Some of these inhibitors, as shown in the Figure 4.6, provided 
potent inhibition in vitro and displayed also antibacterial activities for many AdT-dependent 
bacteria. In another study, ATP analogues have been useful to characterize the reaction coupling 
between glutaminase and kinase-transamidase active sites in AdT .11 However, as these analogues 
will likely to interfere with several other enzymatic processes within mammalian cells, they cannot 
be lead compounds for the design of novel antibiotics. 
In the laboratory where I worked during the third year of my PhD, the development of 
amidotransferases inhibitors is one of the research topics under investigation. In searching for 
inhibitors specific for AdT, at first, they focalized their attention on analogues of  3’ ends of  its aa-
tRNA substrates; 16 these are asparticin  and glutamycin (Figure 4.7 b), the second of which is a 
 
 
Compound 
R1 R2 IC50(µM) 
   GLA 
IC50(µM) 
    TRA 
a -OH - H 1.6 0.10 
a -OCH3 -H 1.3 0.05 
a -OCH3 -H 1.5 0.07 
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puromycine analogue that shows a weak inhibition of glutamyl-tRNAGlu  reductase, the first enzyme 
of the tRNA dependent tetrapyrrole biosynthesis pathway.  
N
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Figure 4.7: (a) Asp-tRNAAsn  when n = 1 and Glu-tRNAGln  when n = 2; (b) Aspartycin and Glutamycin 
analogues of Asp-tRNA and Glu-tRNA , respectively. 
 
Both compounds revealed to be competitive inhibitors of the transamidase activity of Helicobacter 
pylori GatCAB with respect to Asp-tRNAAsn  with Ki values of  134 µM for aspartycine and 105 
µM for glutamycine. This result is compatible with the fact that GatCAB has two natural 
aminoacyl-tRNA substrates whose nucleotide sequences differ significantly allowing  more 
interactions with the 3’- terminal features. 
Aspartycin, even if it presents the same aminoacid portion as  the natural Asp-tRNAAsn  is not a 
substrate for Adt, which indicates that its β-carboxyl group is not positionated in the active site 
exactly as for the natural substrate.  
More recently, going forward with this project to discover inhibitors of Helicobacter pylori 
GatCAB aminoacyl-tRNA amidotransferase, they reported a series of puromycin 1 (Figure 4.8) 
derivatives.12 In fact puromycin is an aminonucleoside antibiotic produced by Streptomyces 
alboniger that cause premature chain termination in the process of translation. Although its 
structure resembles the 3’-terminal of aminoacyl tRNA, puromycin is a very weak inibitor for Adt 
(ki = 4 mM). This is probably due to the amino acid chain, related to tyrosine, different from the 
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aspartic and glutamic side chain transformed by Adt. Starting from this consideration, they 
evaluated the inhibiton activity of a serie of compounds obtained by the replacement of the 
methoxyphenyl moiety by carboxylic acid derivatives. This substitution considerably enhances the 
ability to inhibit Adt and the compound 1 represented in the Figure 4.8, was found to have the most 
potent enzyme activity (Ki = 4 µM with respect to Asp-tRNAAsn) with the L-methionyl-sulfone 
moiety mimicking the transition state in the transamidation process. 
  
 
Figure 4.8: (1) Puromycin; (2) Most active AdT inhibitor related to the structure of puromycin. 
 
With this results in hand,  they decided to prepare a new serie of compounds, maintaining 
this promising L-methionyl-sulfone moiety binding to a simplified nucleoside. The 
antibiotic chloramphenicol 3 (Figure 4.9) inhibits protein synthesis by binding to the 
peptidyl transferase region of the ribosome, and overlaps the binding site of puromycin.13 
Moreover its nucleus of amino 1,3 propan-diol bounded to the p-nitrophenyl ring shows a 
similarity and a structural relationship with the sugar of puromycin. At first they assayed 
the activity of the pure chloramphenicol who is a very weak inhibitor of GatCAB (Ki  1.9 
mM). Replacement of the dichloroacetyl moiety of chloramphenicol 3 by L-methionyl-
sulfone considerably enhances the activity and compound 4 was identified as a very active 
inhibitor with a Ki value of 30 µM.  
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.  
Figure 4.9: Structural similarity between (1) Puromycin; (3) Chloramphenicol, (4) AdT inhibitor related to 
the structure of chloramphenicol. 
In order to complete this structure-activity relationship study, we wanted to evaluated the 
effect of the configurations at C-1 and C-2 stereogenic centers on the activity and to assay 
the activity of the diastereoisomers (1S, 2R)-5 and (1R, 2S)-6. 
 
Figure 4.10: Structure of the two threo diastereoisomers analogues of chloramphenicol. 
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As in the structures of the diastereoisomers 5 and 6 two moieties can be recognized,  (Figure 4.10), 
these compounds can be prepared by a coupling reaction between the commercially available L-
methionine-sulfone (represented in blue) and the aminic function present in the structure of  the 
two enantiomeric forms of  p-nitrophenylserinol (red portion of the structure), not commercially 
available. 
The goal of my research was to prepare these two enantiomers, with an high optical purity. 
In order to reach this objective following the fastest approach, I decided to start from the racemic 
mixture of  erythro-p-nitrophenylserine, the compound that share with the final products the most 
structural similarity, easily converted to the latter by a reduction at the carbonyl function (Scheme 
4.1). 
O2N
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Scheme 4.1: General  synthetic pathway to obtain the 2 enantiomers of p-nitrophenyl-serinol. R/ R’ = 
suitable protective groups to carry on the enzymatic reaction. 
In 1954, Moersch and co-workers reported the synthesis of (1R, 2S) erythro-p-nitrophenylserine, 
achieved with a long procedure and low yield.14  
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The well known enantioselectivity of enzymes could be useful to obtain these products with high 
optical purity and good yields overcoming the disadvantages of fractional crystallization and, 
moreover, could be interesting to explore the behaviour of enzymes towards these diasteroisomers. 
Indeed the β-hydroxy aminoacids are very attractive and versatile molecules, included in the 
structure of many bioactive compounds.15 L-Threonine is an essential amino acid, the threo-D-
phenyl serine is active against some microorganisms of Influenza A, some type of  E.Coli and some 
lactobacilles. The structure of threo-L-phenyl serine is included in the molecule of bradikynine, a 
nonapeptide endowed with vasodilatant action, and is essential for its terapeutic activity.  
Also the β-hydroxy aminoacids are chiral scaffold/building block very interesting for the 
preparation of  enzymatic inhibitors and β lactam antibiotics.16 
Due to their importance in the past, a lot of research groups accomplished the preparation of  threo 
and erythro phenylserine using enzymes. 
In 1953 Fones reported the resolution of  the four optical isomers of threo and erhytro phenyl-
serine through the asymmetric hydrolysis by carboxypeptidase of the N-trifluoroacetyl of the 
respective diastereoisomers.17 
In 1989 Chênevert et al. realized the enantioselective hydrolysis of the esters of both  threo and 
erythro p-nitrophenyl-serine N-acetyl derivatives and developed an efficient method for the 
preparation of the chloramphenicol. 18 
There are no studies on the optical resolution of the erythro enantiomers of p-nitrophenyl-serines 
with the free aminic group. 
 
4.4 Results and discussion 
The preparation of the racemic substrate 9 was realized following the procedure of Elphimoff-
Felkin that allows to obtain the only erythro isomer (Scheme 4.2). 19 
Methyl glycinate was condensed with 2 equivalent of p-nitrobenzaldeide to give the 
erythrobenzylidene 8.  
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Scheme4. 2: Synthetic pathway to obtain the (±) erythro p-nitrophenilserine methylester hydrochlorhyde 9. 
At the beginning of our work, in order to discover a new enzymatic approach for the 
resolution of erythro p-nitrophenyl-serine we tried to achieve this objective working on the 
β-hydroxy aminoacid ester 9 without any N-protection, in order to simplify the synthetic 
pathway (Scheme 4.3). Lipases and proteases have been widely used for the 
enantioselective hydrolysis of both natural and unnatural amino acid esters20: following the 
same procedure reported for florfenicol21 we screened several of them in hydrolytic 
conditions. As shown in the Table 4.1 below, using an aqueous medium, no enzyme 
exhibited any enantioselectivity even if, as is clearly visible by the times of reaction 
reported,  proteases were the most active.  
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Scheme 4.4:Enzymatic hydrolysis on derivative 9. 
Enzyme Conditions Time (h) Conversion* ee %** 
Protease from 
Aspergillus oryzae 
buffer pH 7.00, 
30°C 
3  40 ees = 0 
Protease from 
Subtilisin Carlsberg 
buffer pH 7.00, 
30°C 
5.5  40 ees = 0 
α Chymotrypsin 
buffer pH 7.00, 
30°C 
45 h 30 ees = 0 
Chymopapain 
buffer pH 7.00, 
30°C 
45 h 30 ees = 0 
Protease from 
Streptomyces griseus 
buffer pH 7.00, 
30°C 
48 h 30 ees = 0 
CAL B 
i-Pr2O 
H2O (5-10 eq), 30°C 
40 h - - 
CCL 
i-Pr2O 
H2O (5-10 eq), 30°C 
40 h - - 
CRL 
i-Pr2O 
H2O (5-10 eq), 30°C 
40 h - - 
Lipase from 
Burkholderia cepacia 
i-Pr2O 
H2O (5-10 eq), 30°C 
40 h - - 
 Table 1: Screening of hydrolytic condition on 3. *By TLC analysis;**By chiral HPLC analysis.  
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The probable reason of this low enantioselectivity is due to the non-enzymatic spontaneous 
hydrolysis as was confirmed by the blank. The same results were obtained with the ethyl-ester 
derivative. 
In order to overcome this problem, the aqueous solution was replaced by organic solvents, i-PrOH 
and toluene, in presence of only 5-10 equivalent of water acting as nucleofile but no hydrolysis 
occurred, probably because of the low solubility of the starting material in the medium of reaction. 
Later, following the protocol reported by Tasnàdi et al. 22 for the resolution of  β amino esters, with 
the objective to increase the solubility of the starting material in the organic solvent, known to be 
the best medium for lipases, I tested the same enzymes on the free base of  erythro p-nitrophenyl-
serine methyl ester 10. 
 
(±) erythro                                                (±) erythro 
Scheme 4.5: Enzymatic hydrolysis on derivative 10. 
As reported in the table 4.2, the amino ester 10 was substrate for CAL B, PLE and lipase 
from Pseudomona sp. but only CAL B showed some enantioselectivity. 
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          Enzyme Conditions Time(h) Conversion* ee %** 
CAL B 
i-Pr2O 
H2O (5-10 eq), 30°C 
48  ≥50 ees =67 
CCL 
i-Pr2O 
H2O (5-10 eq), 30°C 
94  - - 
CRL 
i-Pr2O 
H2O (5-10 eq), 30°C 
94  traces - 
Lipase from 
Burkholderia cepacia 
i-Pr2O 
H2O (5-10 eq), 30°C 
40  traces - 
PLE 
i-Pr2O 
H2O (5-10 eq), 30°C 
120  ≥50 ees = 0 
Protease from 
Streptomyces griseus 
i-Pr2O 
H2O (5-10 eq), 30°C 
48  - - 
Lipase from 
Pseudomonas Sp. 
i-Pr2O 
H2O (5-10 eq), 30°C 
120 ≥50 ees = 0 
PPL 
i-Pr2O 
H2O (5-10 eq), 30°C 
94  - - 
Table 4.2: Screening of hydrolytic condition on 10. *By TLC analysis;**By chiral HPLC analysis. 
Further investigations with CAL B in the usual preferred solvents didn’t afford better 
results (Table 4.3). 
Conditions Time Conversion* ee %* 
i-Pr2O 
H2O (1-7 eq*), 30°C 
7 days 50 ees=15 
Toluene 
H2O (1-7 eq), 30°C 
7 days 50 ees = 0 
Et2O 
H2O (1-7 eq), 30°C 
100 h 50 ees = 0 
Table 4.3: Screening of hydrolytic condition on 10 with CAL B lipase. *By TLC analysis;**By chiral HPLC 
analysis. 
Going on with the intention to obtain the resolution on the free amino ester, we 
investigated the well known ability of lipases and proteases to enantioselectively acylate 
the amino group on compound 10. 23 
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                                             (±) erythro                                            (±) erythro 
Scheme 4.6: Enzymatic acylation on derivative 10. 
As reported in the Table 4.4, the reactions were carried on using ethyl acetate as acyl donor and 
solvent: inspection of the results obtained in this reaction revealed that all the screened enzymes are 
ineffective catalysts. 
 
Enzyme Conditions Time(h) Conversion* ee %** 
CAL B AcOEt, 30°C 44 60 eep = 0 
Protease from  
Subtilisin Carlsberg 
AcOEt, 30°C 63 h 60 eep = 0 
CCL AcOEt, 30°C 65 h 60 eep = 0 
PPL AcOEt, 30°C 64 h 60 eep = 0 
Lipase from 
Burkholderia cepacia 
AcOEt, 30°C 63 h 60 eep = 0 
CRL AcOEt, 30°C 42 h 60 eep = 0 
Table 4.4: Screening of acylation with diffeents lipases and proteases on substrate 4. *By TLC 
analysis;**By chiral HPLC analysis. 
Continuing with this study and taking into account that the presence of the free amino group 
favourises the spontaneous chemical hydrolysis of the ester moiety, we decided to protect the 
amino function and to work on substrates more similar to the natural ones of the enzymes. 
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Following this approach, we focalized our attention on the hydrolysis of the methyl ester product 
by α chymotrypsin and protease from subtilisin Carlsberg, since their activity has already been 
stressed on erythro N-acetyl p-nitrophenyl-serine methyl-esters. 
In searching for new N-protective groups, more easy to hydrolyze than the acetyl amide, at first we 
proposed, as possible substrate the (±) erythro nitrobenzyl-iden-p-nitrophenylserinate methyl ester 
8, an intermediate of the synthesis of  final β-hydroxy amino acid. 24 
 
 Scheme 4.7: Enzymatic hydrolysis on derivative 8. 
In fact, the advantages of this substrate, are the lability of the N-protective group and their 
increased solubility in aqueous and aqueous-organic solvents. 
The real substrate is the free amino ester that was liberated from the Schiff bases by reaction with 
water and consequently the dissociation of the Schiff base is the rate-limiting process (Scheme 4.7). 
The reaction was carried out at room temperature in acetonitrile with 10 equivalents of water but 
after 10 days there was no detectable hydrolysis of the Schiff base; the possible explanation of the 
phenomenon might be the formation of the oxazolidine ring via the interaction of the C=N bond 
with the OH group of the side chain. 25   
This failure suggest us to test the usual amine protective groups and then we protected the (±) 
erythro p-nitrophenyl-serine methyl ester 9 as tert-butoxycarbonyl amide, one of  the most used for 
the resolution of  N-protected amino acids. 26 
Among the screened enzymes, both subtilisin Carlsberg and α-chymotripsyn recognized as 
substrate 11, as reported for the N-acetyl derivative. 
Differently, due to the low polarity of the tert-butoxycarbonyl moiety, the addition of a co-solvent 
was required and the best results were obtained with the mixture buffer pH 7.7/i-ProH (2:1) (Table 
4.5). Even with the co-solvent the reaction time was very long, compared with the one reported for 
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the N-acetyl derivative, and was not possible to achieve the desiderated conversion of 50%, 
necessary to recover both the acid and the unhydrolyzed ester with an high enantiomeric excess 
(Scheme 4.8). When the reaction was done on 2 g of racemic ester 11, the enzyme spent 3 weeks to 
hydrolyze the 40% of compound; at this time the reaction stopped and further additions of enzyme 
were not useful. Probably the hindrance of the tert-butoxycarbonyl group makes difficult the access 
of the ester moiety to the active site of the enzyme. 
 
Scheme 4.8: Enzymatic hydrolysis on derivative 11. 
Enzyme Conditions Time (h) Conversion* ee %* 
α Chymotripsin 
buffer pH 7.7, 
23°C 
50  < 5 - 
α Chymotripsin 
buffer pH 7.7/CH3CN 
(2:1), 23°C 
100  < 5 - 
α Chymotripsin 
buffer pH 7.7/tert-BuOH 
(2:1), 23°C 
100  < 5 - 
α Chymotripsin 
buffer pH 7.7/TBME 
(2:1), 23°C 
100  30 eep = 93 
α Chymotripsin 
buffer pH 7.7/THF 
(2:1), 23°C 
100  > 5 - 
α Chymotripsin 
buffer pH 7.7/ i-Pr2O  
(2:1), 23°C i-Pr2O 
    100  45 eep = >95 
CAL B 
buffer pH 7.7/THF 
(2:1), 23°C 
20  0 - 
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Lipase from 
Burkholderia cepacia  
Buffer pH 7.7/THF 
(2:1), 23°C 
20 h 0 - 
Protease from  
Aspergillus oryzae  
Buffer pH 7.7/THF 
(2:1), 23°C 
20 h 0 - 
Protease from  
Streptomyces griseus  
Buffer pH 7.7/ i-Pr2O  
(2:1), 23°C  
20 h 0 
- 
Protease from  
subtilisin Carlsberg 
Buffer pH 7.7 
 23°C 
70 h 25 eep = 73 
Protease from  
subtilisin Carlsberg 
Buffer pH 7.7/TBME 
(2:1), 23°C 
 26 h 7 - 
Table 4.5: Screening on hydrolysis of compound 11. *By chiral HPLC analysis. 
So, we decided to test, as N-protective group,  the trifluoro-acetyl amide, smaller in size and easy 
to hydrolyze under mild conditions. Unfortunately this derivative was not stable under the  reaction 
conditions and its spontaneous hydrolysis occurred in both the product and the starting material. 
 
With this results in hand, we decided to change approach and to investigate the possibility to 
achieve the resolution by the amino function. 
As mentioned above, good results were obtained with carboxypeptidase A on both threo and 
erythro N-trifluoroacetyl phenyl-serine while acylase I was found to be ineffective toward either N-
acetyl or N-chloroacetyl derivatives of  β-phenyl-serines. For this reason, we decided to perform 
the enzymatic deacylation of the N-amide not with the common acylases but to test another enzyme 
useful for the resolution of chiral amines: penicillin acylase from E.coli. 27 
As deeply described in the introduction, this enzyme (E.C. 3.5.1.11) selectively transfers the 
phenylacetyl-moiety to water and one of its largest application was the production of 6-
aminopenicillanic acid, the basic raw starting material for the industrial production of 
semisynthetic penicillins, from penicillin G. 28 The enzymatic activity of Pen G Acylase has been 
associated with the phenylacetyl moiety, even if the phenoxyacetyl derivatives are also accepted as 
substrates, and a wide variety of phenylacetyl derivatives of primary amines and alcohols has been 
selectively hydrolyzed. 29 The well known L-directed stereochemical preference in hydrolyzing N-
phenylacetylamino acids, makes this enzyme useful in the field of resolution of racemates and of 
configurational correlations30: Fadnavis et alt. reported the penicillin acylase catalyzed  resolution 
of  hydroxyleucine31 and in 1997, an Italian research group reported the resolution of a series of 
aminoacids, among them serine, the natural compound most similar to 9, by hydrolysis of the  L-N-
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acetylphenylderivative. 30 On the basis of these previous works it seems interesting to examine the 
potentiality of this enzyme towards this unnatural substrate; the presence of an additional chiral 
carbon atom poses the question about the stereoselectivity of the amidase. 
 
Scheme 4.9: Enzymatic resolution on derivative 12. 
Conditions Time (h) Conversion* ee %** 
Buffer pH 7.8, 25°C 5 > 50 14-ees = > 99  
Buffer pH 7.8, 25°C 3 < 50 13-eep = > 99  
Table 4.6: Screening on hydrolysis of compound 12. *By reverse phase HPLC; **By chiral HPLC 
We prepared the suitable N-phenylacetyl-derivative of  erythro p-nitrophenyl-serine 12 following a 
known method and  incubated it with the enzyme (80 U/ mmol substrate) in buffer phosphate at pH 
7.8; no cosolvent was required thanks to the good solubility of the substrate in the basic aqueous 
medium (Scheme 8). In preliminarys studies, we decided to analyzed the enantioselectivity of the 
enzyme being in the best conditions for the enantiomeric excess: with the help of reverse phase 
Hplc we stopped the reaction around 40% and 60% and checked the enantiopurity of the product 
and of the starting material, respectively. The ˃99 % enantiomeric excesses, evaluated by analysis 
with a chiral Hplc, reported in Table 4.6 , show that the hydrolytic activity of penicillin acylase 
toward the substrate 12 is very enantioselective. In fact with the aim to obtain both the two 
enantiomers 13 and 14 with high value of optical purity, by the same reaction, in further 
experiments, the hydrolysis was stopped around the 48-50% of conversion. 
The unreacted starting material 14, together with the phenyl-acetic acid, were separated from the 
free amino acid 13 by the usual work up and their enantiomeric excess was determined by a chiral 
hplc analysis. Both the compound 13 and 14 showed an enantiopurity superior to 95%. 
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The very high enantiomeric excess for both the product and the starting material, makes penicillin 
acylase the best enzyme to achieve the preparation of the precursors of the two amino alcohols 5 
and 6 analogues of chloramphenicol. 
In order to simplify the synthetic pathway and to avoid the delicate reduction of the free amino 
acid, we investigated also the ability of the enzyme to selectively acylate the free amino group of 
the erythro p-nitrophenyl-serine methylester 10 using methyl phenyl-acetate as acyl donor (Scheme 
4.10). As shown in the table 4.7, the reaction was carried on in the suitable conditions of pH and 
employing as medium different organic solvents, with a different polarity. We observed the 
formation of the amide in aqueous solution but the reaction was very slow and didn’t overcome the 
15-20% conversion: the reason of this is probably due, as seen previously, the formation of the free 
amino acid produced by the spontaneous hydrolysis of the methyl ester. 
 
Scheme 4.10: Enzymatic acylation on derivative 10.  
Conditions Time (h) Conversion* % ees(Unreact substrate)**
 eep(Product of 
acylation)** 
Buffer pH 6 a, 
20°C 
60 10-15 - 92 
THF 24 - - - 
CH2Cl2 48 - - - 
DIPE 48 traces - - 
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Toluene 69 25 76 - 
Hexane 48 40 70 45 
buffer pH 6/Toluene(1:1), 
20°C 60 h 10-15 92 - 
Toluene 40 h - - - 
iPrOH 24h - - - 
BuOH 24 h - - - 
Table 4.7: Screening on acylation of compound 10 with penicillium amidase. a Using penicillium acylase 
supported on Celite. *By reverse phase HPLC; **By chiral HPLC 
In the case of the organic solvents, the enzyme, as reported for phenylglycine methyl ester and p-
hydroxy-phenylglycine methyl ester32, was able to acylate the poorly soluble free amino group, 
present in the reaction medium mainly as a suspension , only in toluene or hexane, even if the 
enantioselectivity was not satisfacient. More polar solvents such as dichloromethane and 
tetrahydrofuran seemed to have a negative effect on the enzymatic activity, even if they solubilize 
the starting material. Since the penicillin acylase used for all the enzymatic reaction described in 
the Scheme 4.10 is a solution in buffer phosphate at pH 7.5, that is the best form only for the 
hydrolytic reaction, we repeated the reaction in the same conditions, using a sample of penicillin 
acylase supported on Celite, prepared according to the De Martin et al method.33 . No reaction 
occurred using toluene as solvent. No reaction wa also observed when the free amino acid (±) 13 
was submitted to the enzyme-catalyzed reaction.  
The penicillin acylase- catalyzed hydrolysis of (±)-erhytro-12 is, in conclusion, the best way to 
obtain enantiomerically pure (S, S)- and (R, R)- desired diasteroisomers, necessary as starting 
materials for our preparative purposes. 
The final preparative pathway is summarized in the scheme 4.11. 
Starting from two diastereoisomers of erythro p-nitrophenyl-serine methyl-ester hydrochloride 9, 
the racemic N-acetyl-derivate 12, substrate of the enzymatic reaction, was obtained in 81% yields 
by treatment with PhAcCl (1.1 eq) in presence of Et3N (1.5 eq) in THF. The product was purified 
by crystallization from Acetone/Et2O and after the treatment with aqueous K2CO3  afforded the 
desiderated acid, recovered after acidification of the aqueous layer (83%). 
The enzymatic reaction was carried on (±) 12, as previous described, at room temperature in buffer 
solution at pH 7.8, using a solution of penicillium acylase in the same buffer at pH 7.5. The 
progress of reaction was followed by a reverse phase Hplc (Zorbax C-8) eluted with the mixture of 
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H2O/CH3CN/TFA (80:20:0.1), with a flow rate of 0.8 ml/min  and it was stopped approximately 
near the 50% of conversion. The reaction mixture was then cooled and acidified and phenyl-acetic 
acid and the enantiomerically pure starting material 14 were recovered by an extraction with 
dichloromethane and separated by a chromatography on Silica gel employing as eluent the mixture 
Hexane/AcOEt 70:30 (46%). The pH of aqueous solution containing the L-free amino acid 13 was 
adjusted near its isoelectric point (pH 5.5); water was removed by evaporation at reduce pressure 
until crystals appeared (36%). The evaluation of the enantiomeric excess (≥ 98%) for both the 
product 13 and the remaining substrate 14 were determined by using a Chiral OD-H column 
(Daicel Chemical Industriee, LTD) eluted with hexane/i-PrOH/TFA (80:20:0.1), with a flow rate of 
0.7 ml. Peaks were detected at 210 and 254 nm. The Hplc analysis of the free amino acid 13 was 
done after its derivatization as N-acetyl derivative, in the mixture acetic acid/acetic anhydride. 
  
Scheme 4.11: Final synthetic pathway to obtain enantiomers 17 and 18. 
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In order to complete the preparation of the enantiomers of p-nitrophenylserinol a reaction of 
reduction was required. 
For the free amino acid 13, the methods reported in literature showed to be ineffective34 so it was 
reduced after its previous esterification employing the mild acidic conditions of the resin 
Amberlyst 15.35 The reaction was accomplished in EtOH after a 16 h reflux, due to the low 
solubility of the starting material in the solvent of reaction. To be sure that these conditions didn’t 
affect the enantiopurity of the compound, a little sample of the ester 15 was withdrawed and, after 
its conversion to the N-acetyl derivative, analyzed then with the chiral HPLC that confermed its 
purity (≥ 98%).  The so obtained ethyl-ester 15 was then transformed into the wanted amino 
alcohol 17 by treatment with CaCl2 and NaBH4 (60%).21 
In the case of the unreact substrate 14 the reduction was obtained with the complex BH3.SMe2 in 
THF (70% after purification by chromatography) to give the alcohol 16 and the subsequent 
hydrolysis of the phenylacetic amide in HCl 6N, at reflux, afforded the enantiomer 18. The high 
enantiopurity of the two amino alcohols 17 and 18 was confirmed by comparison with the values of 
optical rotation reported in literature36 and shows that, in agreement with the results reported on 
literature for analogues substrates, penicillin acylase hydrolized only the the (S)-enantiomer of the 
racemic substrate 12. 
 
Scheme 4.12: Coupling reactions between amino-alcohols 17 and 18 and n-Boc-L-methionine-sulfone. 
The conversion of the amino-alcohols 17 and 18 into the final amides 5 and 6 is explained in the 
Scheme 4.12. 
Commercially available N-Boc-methionine-sulfone was condensed with enantiomerically pure 
amines 5 and 6 under standard conditions using 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
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hydrochloride (EDC)/N-hydroxysuccinimide in DMF; treatment with 4 M HCl/dioxane resulted in 
cleavage of the N-tert-butoxycarbonyl group  provided the corresponding amides 5 and 6 (70%). 
4.5 Enzymatic assays 
The chemo-enzymatically obtained compounds 5 and 6 were evaluated for in vitro inhibitory 
activity against H. pylori GatCAB aminoacyl-tRNA amidotransferase.  
This investigation was done at the Département de Biochimie et de Microbiologie, PROTEO, 
Faculté des Sciences et de Génie, Université Laval in  Québec. 
The transamidases activity assays were done in presence of the natural substrates L-glutamine and 
Asp-tRNAAsn   
Differents concentrations of inhibitors were used: 0, 62.5, 125, 250, 500 and 1000 µM. 
  
 Figure 4.11: Graphics of the kinetic of inhibition for the compound 5 and 6 respectively. 
Competitive inhibition with respect to Asp-tRNAAsn was observed for both the two  
chloramphenicol derivatives. The value of Ki was calculated with the following equation: 
 
    )(1(0
KK
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v
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m
mi
IS
S


  and were 2.8 mM and 371 µM, respectively, for the diastereoisomers 
(1S,2R)-5 and (1R,2S)-6. 
Compared with the Ki of the derivative maintaining the same stereochemistry of chloramphenicol 
4,  5 and 6 are less active and, in particular, the loss in potency was more marked for  (1S,2R) 5  
than for the (1R,2S) 6 isomer. As explanation for these results, we can assume that (1R,2R) 
stereochemistry of chloramphenicol combined with the L-methionyl-sulfone moiety appeared to be 
optimal in this series. 
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Figure 4.12: Three new amidotransferase inhibitors related to the structure of  chloramphenicol . 
Compound 4 can be considered as a stable analog of the transition state in the last step of the 
transamidation process, where the carbonyl to be attacked by ammonia is replaced by a tetrahedral 
sulfur atom with a methyl group mimicking ammonia. It is noteworthy that 4 has an affinity for 
GatCAB comparable to the substrate Asp-tRNAAsn (Km  2 µM) considering its relative lower size. 
Chloramphenicol analogues 4 and 5 and 6 represent a new class of AdT inhibitors and may provide 
the basis for the design of other low-molecular weight inhibitors. 
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5.1. Materials and Methods 
 General for chapter 2 and 3. 
All the reagents and enzymes are purchased from Sigma-Aldrich. All reactions were 
monitored by TLC on silica gel 60 F254 precoated plates with a fluorescent indicator 
(Merck). For the detection of the products described in the first chapter was employed an 
ethanolic solution of phosphomolibdic acid (10%); for the compound of chapter two a 
ninydrin solution (0.3g in butanol, 100mL, and acetic acid, 3 mL) and heating at 110 °C.  
TLC eluant was prepared mixing water, butanol and acetic acid (5:4:1), and separating the 
organic phase, after vigorous stirring. Column chromatography were performed on silica 
gel 60 (0.063-0.200 mm) (Merck). 1H-NMR spectra were recorded on a Bruker-Avance 
500 MHz spectrometer. Optical rotations were determined on a Perkin-Elmer 241 
polarimeter in a 1 dm cell at 25 °C. HPLC analyses were performed with a Merck-Hitachi 
L-6200. Mass spectra were recorded on a Thermo Quest Finnigan LCQTM DECA ion trap 
mass spectrometer. Differential scanning calorimetry (DSC) was performed on a Perkin 
Elmer DSC-7 instrument. A detailed description of the commercial characteristics of the 
enzymes utilized is reported in the Table 5.1.1. 
Table 5.1.1 Main features of  enzymes employed for the experimental parts related to chapters 2-3-4.  
Name Abbrevation 
Commercial 
source 
U for mg of 
protein  
(U/mg) 
U of enzyme for 
mmol of 
substrate 
(U/mmol) 
Lipase immobilized from  
Candida antarctica A 
CAL A Fluka 3 100-600 
Lipase from Candida antarctica B 
CAL B 
Novozym 
435 
Fluka 2.5 50-400 
Lipase from Candida cilindracea CCL Fluka 5.18 90-400 
Lipase from Candida rugosa CRL Sigma 1.14 100 
Lipase from Burkholderia cepacia BKL Sigma 30 100 
Lipase from Pseudomonas 
fluorescens 
PFL fluka 42.5 200 
Lipase from hog pancreas PPL Fluka 23.9 300 
Hog liver esterase suspension in 
3.2 ammonium sulphate solution 
PLE Fluka 1273 100 
α-chymotripsin α-Chy Fluka 50 300 
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Papain - Sigma 1.2 300 
Protease from Bacillus subtilis - Biochemika 20 75 
Protease from Bacillus 
licheniformis (subtilisin Carlsberg) 
STC Fluka 10.7 75 
ALCALASE CLEA®          - Sigma 5 76 
Acylase from porcine kidney, 
Grade II 
PKA Sigma 500-1.500 5 
Acylase from Aspergyllus melleus CAL A Fluka 1.06 5 
Acylase from Streptomyces 
toyocaensis 
- Fluka 46 5 
Penicillin acylase from E. coli, 
buffer solution pH 7.5 
Pen G Fluka 
37; (56 mg 
enzyme/ml sol) 
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5.1.  Materials and methods chapter 2 
5.1.2  32-O-acetyl-ascomycin (3). 
 
 To a solution of ascomycin 1 (0.1 g; 0.126 mmol) in toluene (8 mL) vinyl acetate (0.473 g, 
5.5 mmoles) and CAL B, 0.240 g, were added. The reaction progress was monitored by 
TLC (hexane/acetone 65/35). After stirring at 40°C for 80 h the enzyme was filtered off  
and the recovered filtrate was concentrated under reduced pressure. The residue was 
crystallized from acetone/water (0.1 g; 94%).  
 
C45H71NO13: 834.05 g/mol; white solid. 
Differential Scanning Calorimetry (DSC) endothermic peak of fusion 134.25 °C;  
[α]D
20°C -74.2 (c 0.5 CHCl3);   
IR λmax  3484.245,  2935.287, 1735.331, 1649.741, 1450.039, 1372.278 cm-1;  
MS (ESI+) (m/z) 856.4 [M+Na]+. 
 
5.1.3  24,32-di-O-acetyl- ascomycin (4). 
 
 To a stirred solution of ascomycin 1 (1 g; 1.26mmol) in pyridine (12.5 mL), kept at 0°C, 
DMAP (0.680 g ) and acetic anhydride (0.570 g, 5.6 mmol) were added. After 1.5 h, under 
stirring at 0°C, the reaction mixture was diluted with water and extracted with ethyl acetate 
(3 x 25 mL); collected organic phases were washed with 0.5 N HCl (5 x 10 mL), dried over 
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Na2SO4 and evaporated at reduced pressure. The residue was crystallized from 
acetone/water  (0.985 g; 90%). A sample was purified for analytical purposes by silica gel 
column chromatography (hexane/acetone 8/2 as eluant).  
 
C47H73NO14: 876.08 g/mol; white solid. 
DSC endothermic peak of fusion 234.10 °C;  
[α]D
20°C -100.0 (c 0.5 CHCl3);  
IR λmax  3462.749, 2935.824, 1734.403, 1650.739, 1449.091, 1371.079 cm-1;  
MS (ESI+) (m/z) 898.4 [M+Na]+.  
 
5.1.4  24-O-acetyl-ascomycin (5). 
 
 To a solution of 24,32-di-O-acetyl-ascomycin 4 (0.5 g; 0.57 mmol) in TBME (25 mL) n-
octanol (4.5 eq;  0.371 g) and CAL B 1.1 g were added. The reaction progress was 
monitored by TLC (hexane/acetone 65/35). After stirring at 40°C for 100 h the enzyme 
was filtered off  and the recovered filtrate was concentrated under reduced pressure. The 
residue was crystallized from acetone/water (0.44 g; 93%). A sample was purified for 
analytical purposes by column chromatography on silica gel (hexane/acetone 7/3 as 
eluant).  
  
C45H71NO13: 834.05 g/mol; white solid. 
DSC endothermic peak of fusion  134.68 °C;  
 [α]D20°C -102.7 (c 0.5 CHCl3);  
IR λmax 3491.528, 2935.860, 1744.728, 1710.227, 1652.310, 1448.662, 1371.335  cm-1;  
MS (ESI+) (m/z) 856.4 [M+Na]+. 
 
5.1.5  24-O-acetyl-pimecrolimus (6).  
 
To a stirred suspension of polimer bound triphenyl phosphine (1.6 eq; 0.10 g) in anhydrous 
toluene (3 ml), under argon, 24-O-acetyl-ascomicin 4 (0.2 mmol; 0.167 g) dissolved in 2 
ml of toluene and anhydrous pyridine (0.54 ml) were added. The reaction was warmes at 
60 °C for 1 h and then, after cooling at room temperature, H2O (2 ml) was added. 
The organic phase was recovered by extraction and washed with NaCl sat.sol. (3 X 3 ml), 
dried over Na2SO4 and evaporated at reduced pressure. The residue was purified by silica 
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gel column chromatography (hexane/acetone 85/15 as eluant) to afford 6 (0.05 g; 40% 
yield). 
 
C45H70ClNO12: 852.49 g/mol; white solid. 
DSC endothermic peak of fusion 231.67 °C;  
[α]D
20°C -75.2 (c 0.5 CHCl3);  
1H-NMR (CDCl3)  selected data of major rotamer    (ppm) 2.06 (s, CH3CO), 4.50-4.60 
(m, H-2 and H-32), 5.22 (m, H-24).  
IR λmax   3464.941, 2934.360, 1738.993, 1650.366, 1450.424, 1371.557 cm-1;   
MS (ESI+) (m/z) 874.3 [M+Na]+. 
 
5.1.6  24-O-tertbutyldimethylsilyl, 32-O-acetyl-ascomycin (7). 
 
To a stirred solution of 32-O-acetyl-ascomycin 3 (0.1 g; 0.12 mmol) in CH2Cl2 (5 mL), 
kept at 0°C,  2,6 lutidine (15 eq; 0.2 ml) and TBDMSOTf (5 eq, 0.14 ml) were added. The 
reaction mixture was stirred at room temperature for 1 h, then cooled and quenched with 
NaHCO3 sat.sol. (5 ml). The organic phase was then recovered and washed with HCl 0.5 N 
(3 x 5 mL) and with NaCl (3 x 5 mL), dried over Na2SO4 and evaporated at reduced 
pressure. The residue was purified for analytical purposes by silica gel column 
chromatography (hexane/acetone 9/1 as eluant) to afford 7, 74%. 
 
C51H85NO13Si: 852.49 g/mol; white solid. 
DSC endothermic peak of fusion  236.43 °C; 
 [α]D20°C -81.4 (c 0.5 CHCl3);  
1H-NMR (CDCl3)  selected data of major rotamer δ (ppm) 0.05,(s, CH3Si),  0.06 (s, 
CH3Si), 0.89 (s, (CH3)3C), 2.10 (s, CH3CO), 4.08 (m, H-24), 4.71 (m, H-32).  
IR λmax 3462.948, 2934.450, 1739.236, 1649.937, 1450.323, 1371.477cm-1;  
MS (ESI+) (m/z) 970.5 [M+Na]+.  
 
5.1.7  24-O-tertbutyldimethylsilyl-ascomycin (8).  
 
Removal of 32-acetate was realized in the same conditions utilized for preparation of 24-
O-acetyl-ascomycin 5 from corresponding 24,32-diacetate 4. Chemical-physical data of 8 
are in agreement  with those reported in literature (Ref. 6). 
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5.1.8  Pimecrolimus (2). 
 
a) The chlorination of 24- O-tertbutyldimethylsiklyl-ascomycin 8 was performed following 
the procedure reported for 6, yield 70%. 
 
b) To a solution of compound 9 (1.23 g, 1.35 mmol) in dichloromethane/methanol (1/1, 11 
mL) PTSA was added (0.100 g, 0.53 mmol). The mixture was kept, under stirring, at 20-25 
°C for 72h, monitoring the reaction progress by TLC (hexane/acetone 8/2). A sodium 
dihydrogen carbonate (0.04 g) aqueous solution (6 mL) was added; the organic phase was 
washed with brine and water, dried over sodium sulphate. After  solvents evaporation at 
reduced pressure crude pimecrolimus, as a foam, was recovered. Silica gel column 
chromatography (hexane/acetone 8/2) afforded pure pimecrolimus  that was crystallized 
from ethyl acetate/ cyclohexane/ water (0.5 g, 46%).  
 
C43H68ClNO11: 810.45 g/mol; white solid. 
DSC endothermic peak of fusion  142.58 °C;  
[α]D
20°C -52.0 (c 0.5 CHCl3)  
IR λmax 3458.61, 2937.83, 1738.37, 1690.26 1634.72, 1445.60, 1445.63, 1382.72 cm-1; 
 MS (ESI+) (m/z) 832.5 [M+Na]+.  
 1H and 13C-NMR  data were in agreement with the reported ones (Ref.29).   
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5.2 Materials and Methods chapter 3 
5.2.1  2-(2-Thienyl)ethyl 1-p-tolylsulfonate (3) 
p-Toluenesulfonyl chloride (4.55 g, 23.87 mmoles) and triethylamine (3.36 mL, 24.1 
mmoles) were added to a solution of  2-(2-thienyl)-ethanol 7 (3 g, 23.4 mmoles) in 
diisopropylether (23 mL) kept under stirring at room temperature until starting material 
disappearance (50 h, TLC toluene/ethyl acetate 9/1, detection with a 5% phosphomolybdic 
acid ethanol solution). The organic phase was washed with water (15 mL), a 30% 
potassium carbonate aqueous solution (10 mL) and water (2 x 10 mL) and, then, dried over 
sodium sulphate, filtered and evaporated under reduced pressure to afford tosylate 3 (5.85 
g, 86%).  
 C9H10N2O5, 266.19 g/mol : yellow oil. 
1H-NMR (CDCl3) δ 2.47 (s, 3H, CH3Ar), 3.20 (t, 2H, CH2CH2O, J 7 Hz), 4.25, (t, 2H, 
CH2O, J 7 Hz), 6.82 (d, 1H, H-3’, J 3.4 Hz), 6.92 (m, 1H, H-4’), 7.16 (d, 1H, H-5’, J 5 Hz), 
7.34 (d, 2H, Ar, J 8 Hz), 7.78 (d, 2H, Ar, J 8 Hz).  
5.2.2  (R,S)-2-Chlorophenylglycine methylester  (5) 
To a solution of compound 4 (3 g, 10.5 mmoles) in dry dichloromethane (80 mL), 
anhydrous methanol (0.85 mL), DCC (2.38 g, 11.54 mmoles) and DMAP (0.12 g, 1.05 
mmoles) were sequentially added. The reaction mixture was kept under stirring at room 
temperature (2h). The ester formation was monitored by TLC. The white precipitate was 
removed by suction. The filtrate was washed with a sodium hydrogen carbonate solution at 
pH 8 (2 x 20mL), dried by treatment with sodium sulphate and evaporated at reduced 
pressure. The residue was purified by silica gel column chromatography (1/10) affording 
pure 6 (eluant hexane/ethyl acetate  98/2, 2.7 g, 86%).  
C9H10ClNO2, 199.63 g/mol : yellow oil. 
1H-NMR (CDCl3) δ 2.3 (m, 2H, NH2), 3.75 (s, 3H, CH3O), 5.06 (br s, 1H, CH), 7.25-7.33 
(m, 2H, Ar), 7.36-7.43 (m, 2H, Ar).  
13C NMR (125 MHz, CDCl3) δ 52.57, 55.95, 127.41, 128.65, 129.29, 129.96, 133.36, 
137.79, 173.63. 
 MS(ESI +) m/z 199.9 [M+H]+. 
119 
 
 
5.2.3 Methyl (±)-2-(2-chlorophenyl)-2-[2-(thien-2-yl)ethylamino]-acetate  (6) 
To a solution of  5 (2.2 g, 11.0 mmoles) in acetonitrile (11 mL) tosylate 3 (2.8 g, 9.9 
mmoles), sodium hydrogen carbonate (1.1 g, 13.2 mmoles) and potassium iodide (0.18g, 
1.1 mmoles) were added. The mixture was kept under stirring at reflux (14h). At this time 
an additional amount of potassium iodide (0.18g) was added and the reaction was 
continued for other 6 h, at reflux, monitoring the reaction progress by TLC (toluene/ethyl 
acetate 95/5, detection with 5% phosphomolybdic acid ethanol solution). Solvent was 
evaporated at reduced pressure and the residue was dissolved with ethyl acetate (30 mL); 
the organic phase was washed with water (10 mL) and a 15% sodium chloride aqueous 
solution (15 mL). After drying over sodium sulphate and filtration the solvent was 
removed under reduced pressure. Crude residue 6 was purified by silica gel column 
chromatography (1/10). Elution with hexane/ ethyl acetate 9/1 afforded pure 9 (2.38g, 
70%). 
C15H16ClNO2S, 309.81 g/mol : yellow oil. 
1H NMR (500 MHz, CDCl3) δ 2.21 (m, 1H, NH), 2.82 (m, 1H, CH-N), 2.96 (m, 1H, CH-
N), 3.07 (t, 2H, CH2-thienyl, J 7 Hz), 3.72 (s, 3H, CH3O),  4.98 (br s, 1H, CH-COOCH3), 
6.85 (d, 1H, H-3’, J 3.4 Hz), 6.94 (m, 1H, H-4’), 7.15 (d, 1H, H-5’, J 5 Hz), 7.23-7.32 (m, 
2H, Ar), 7.35-7.43 (m, 2H, Ar).  
13C NMR (120 MHz, CD3OD) δ 30.21, 48.70, 52.17, 61.32, 123.45, 124.90, 126.65, 
127.14, 128.54, 129.10, 129.84, 133.94, 135.78, 141.86, 172.27. 
MS (ESI+) m/z 310 (M+1 with 35Cl), 312 (M+1 with 37Cl).      
- General procedure for the enzyme-catalyzed acylation of (6) 
To a stirred solution of 6 (100 mg; 0.32 mmol), at room temperature, in the suitable solvent 
(5 ml), see (Table 3.1), the selected enzyme and acyl-donor were added (2 eq.). The 
reaction progress was monitored by TLC (Hexane/AcOEt 90:10). After stirring at room 
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temperature for the times reported in the table 2, the enzyme was filtered off and the 
recovered filtrate was evaporate under reduced pressure. The values of conversion and of 
enantiomeric excess were elaborated after analysis, of a sample of the reaction, with a 
chiral HPLC. 
The HPLC analysis was carried on a chiral Daicel Chiralpack IA 0.46 cm x 25 cm, using 
as mobile phase the mixture of hexane/THF/Et2NH (80:20:0.1) and a flow rate of 0.7 
ml/min. Detection wavelenght: 220 nm. 
RT: Methyl (±)-2-(2-chlorophenyl)-2-[2-(thien-2-yl)ethylamino]-acetate (6) : 6.95-7.70 min 
RT:N-Acetyl-Methyl (±)-2-(2-chlorophenyl)-2-[2-(thien-2-yl)ethylamino]-acetate (7)18-22 
min  
RT: N-butanoyl-Methyl (±)-2-(2-chlorophenyl)-2-[2-(thien-2-yl)ethylamino]-acetate (8) : 
11.18-12.67 min 
The identity of the products was confirmed by the comparison with the characterizations of  
the compounds obtained by chemical synthesis. 
-General procedure for the preparation of the substrates 7 and 8 
To a stirred solution of 6 (2 g; 6.4 mmol) in pyridine (10 ml) 5 eq of the suitable anhydride 
(acetyc anhydride for compound 7, butyric anhydride for compound 8) was added, cooling 
the solution with a bath of ice. The reaction was then stirred at room temperature for 1 
night. The reaction was diluted with water and extracted with ethyl acetate (3 x 25 mL); 
collected organic phases were washed with 0.5 N HCl (5 x 10 mL), dried over Na2SO4 and 
evaporated at reduced pressure. The residue was purified for analytical purposes by silica 
gel column chromatography (hexane/AcOEt 80/20 as eluant). Yields: 80-85 %. 
5.2.4 N-Acetyl-Methyl (±)-2-(2-chlorophenyl)-2-[2-(thien-2-yl)ethylamino]-acetate (7) 
 C17H18ClNO3S, 351.85 g/mol : yellow oil. 
1H NMR (500 MHz, CDCl3) δ 2.13 (s, 3H, CH3-CON),2.47 (m, 1H, CH-N), 2.87 (m, 1H, 
CH-N), 3.45 (m, 2H, CH2-thienyl), 3.76 (s, 3H, CH3O),  6.37 (br s, 1H, CH-COOCH3), 
6.59 (d, 1H, H-3’, J 2.9 Hz), 6.85 (dd, 1H, J1 = 3.4, J2 = 5.0, H-4’), 7.07 (d, 1H, H-5’, J 5.1 
Hz), 7.31-7.42 (m, 2H, Ar), 7.43-7.57 (m, 2H, Ar).  
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13C NMR (125 MHz, CDCl3) δ 21.35, 29.72, 48.75, 52.46, 59.14, 123.93, 125.33, 127.01, 
127.31, 130.05, 130.33, 130.54, 132.45, 135.51, 139.91, 170.56, 171.26. 
MS (ESI+) m/z 351.8 (M+1 with 35Cl). 
5.2.5-N-butanoyl-Methyl (±)-2-(2-chlorophenyl)-2-[2-(thien-2-yl)ethylamino]-acetate 
(8) 
C19H22ClNO3S, 379.90 g/mol : colourless oil. 
1H NMR (500 MHz, CDCl3) δ 0.98 (t, 3H, J = 7.4, CH3-(CH2)2CO), 1.74 (sestetto, 2H, J = 
7.4, CH2-CH3), 2.34 (m, 2H, CH2-CO), 2.48 (m, 1H, CH2-thienyl), 2.88 (m, 1H, CH2-
thienyl), 3.47, (t, 2H, J = 8, CH2-N) 3.79 (s, 3H, CH3O),  6.38 (br s, 1H, CH-COOCH3), 
6.60 (d, 1H, H-3’, J = 3.3 Hz), 6.88 (dd, 1H, H-4’, J1 = 3.4, J2 = 5.1 Hz), 7.10 (d, 1H, H-5’, 
J = 5.1 Hz), 7.30-7.44 (m, 3H, Ar), 7.44-7.55 (m, 2H, Ar).  
13C NMR (125 MHz, CDCl3) δ 13.95, 18.81, 30.08, 35.08, 48.08, 52.55, 59.40, 123.97, 
123.35, 127.10, 127.38, 130.17, 130.35, 130.64, 132.76, 135.70, 140.17, 170.85, 173.90. 
MS (ESI+) m/z 379.9 [M]. 
5.2.6  N-tert-butoxycarbonyl-Methyl(±)-2-(2-chlorophenyl)-2-[2-(thien-2 yl) 
ethylamino]-acetate (9) 
To a stirred solution of 6 (2 g; 6.4 mmol) in CH2Cl2 (15 ml) tert-butoxycarbonyl anhydride 
(5 eq; 7 g) and Et3N (5 eq; 4.46 ml) were added. The so obtained solution was stirred at 
room temperature for 1 night. The reaction was then diluted with water. The organic phase 
was recovered and washed with HCl 0.5 N (3 x 5 mL); dried over Na2SO4 and evaporated 
at reduced pressure. The residue was purified for analytical purposes by silica gel column 
chromatography (hexane/AcOEt 90/10 as eluant) to afford 2.5 g of 9. Yield 95%. 
 C20H24ClNO4S, 409.93 g/mol : colourless oil. 
1H NMR (500 MHz, CDCl3)  δ 1.48 (s, 9H, (CH3)3-O),2.80 (m, 2H, CH-thienyl), 3.04 (t, 
2H, J = 6.8, CH-N), 3.80 (s, 3H, CH3O),  6.85 (d, 1H, J = 2.7, CH-COOCH3), 6.92 (dd, 
1H, J1 = 3.5, J2 = 4.8, H-3’), 7.13 (d, 1H,  J = 5.0, H-4’), 7.24-7.32 (m, 3H, Ar), 7.32-7.43 
(m, 1H, Ar), 7.45-7.55 (m, 1H, Ar).  
13C NMR (125 MHz, CDCl3) δ 27.86, 28.50, 48.75, 52.42, 52.92, 74.11, 123.63, 125.25, 
126.65, 127.27, 129.44, 130.26, 131.16, 134.60, 135.65, 141.46, 167.39, 169.78. 
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MS (ESI+) m/z 409.8   
-General procedure for the enzymatic hydrolysis of (R,S)-2-Chlorophenylglycine 
methylester  5 
The substrate (R,S)-2-chlorophenylglycine methylester 5, (100 mg; 0.5 mmol) was 
dissolved in the selected medium (5 ml) and the catalyst was added (see table 5). The 
reaction was stirred at room temperature and periodically monitored by TLC analysis 
(eleuent:BuOH/AcOH 99:1 saturated of water; relevating agent: ninhydrine). At the times 
repoted in the Table 3.5, the reaction was stopped by filtering off the enzyme. The samples 
for HPLC analyses were prepared by extraction of an amount of reaction mixture, at pH 3, 
evaporation of solvents and dilution of the residue with methanol.  
The HPLC analysis was carried on a chiral Daicel Crownpack CR(+) 0.4 cm x 15 cm, 
using as mobile phase a solution of HClO4 10-2 M and a flow rate of 1 ml/min. Detection 
wavelenght: 220 nm. 
RT (R,S)-2-Chlorophenylglycine  4 : 3-5 min  
RT (R,S)-2-Chlorophenylglycine  methylester  5 : 18-33 min  
-Enzyme-catalyzed acylation of (R,S)-2-Chlorophenylglycine methylester (5)  
The screening of enzymes-catalyzed acylation on (R,S)-2-Chlorophenylglycine 
methylester 5 was carried on in the condition reported in Table 3.6 following the same 
procedure described for the substrate 6. The conversion and the enantiomeric excess of 
both the product and the unreact substrate were evaluated with the same column 
ChiralPack Daicel described above. 
mobile phase: Hexane/EtOH/Et2NH (93:7:0.1) 
flow rate: 0.7 ml/min, wavelength: 220 nm 
RT (R,S)-2-Chlorophenylglycine  methylester 5 : 17.8-21.3 min  
RT (R,S)N-acetyl-2-Chlorophenylglycine  methylester 11 : 26.9-30.4 min  
RT N-butirryl(R,S)-2-Chlorophenylglycine  methylester 12 : 18.3-21.9 min  
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The identity of the products was confirmed by the comparison with the characterizations of  
the compounds obtained by chemical synthesis. For the experimental procedures see the 
protocols reported for compound 7and 8. 
5.2.7 N-acetyl(R,S)-2-Chlorophenylglycine methylester (11) 
C11H12ClNO3, 241.67 g/mol : white solid. 
1H-NMR (CDCl3) δ 2.03 (s, 3H, CH3-CO), 3.75 (s, 3H, CH3O), 5.94 (d, 1H, J = 7.5,  CH-
NH), 6.23 (d, 1H, J = 6.5 , NH), 7.24-7.31 (m, 2H, Ar), 7.36-7.43 (m, 2H, Ar).  
13C NMR (125 MHz, CDCl3) δ 22.94, 53.02, 54.68, 127.34, 129.81, 130.18, 130.44, 
133.59, 134.82, 169.62, 170.95. 
MS(ESI +) m/z 241.9.  
5.2.8 N-butanoyl(R,S)-2-Chlorophenylglycine methylester (12) 
C13H16ClNO3, 269.72 g/mol : white solid. 
1H-NMR (CDCl3) δ 0.93 (s, 3H, J = ,7.3, CH3-CH2), 1.67 (m, 2H, CH2-CH3), 2.23 (m, 2H, 
CH2-CO), 3.74 (s, 3H, CH3O), 5.94 (d, 1H, J = 7.4 , CH-NH), 6.63 (d, 1H, J = 6.8, NH), 
7.24-7.31 (m, 2H, Ar), 7.36-7.43 (m, 2H, Ar).  
13C NMR (125 MHz, CDCl3) δ 13.68, 19.00, 38.25, 53.15, 57.70, 127.06, 127.76, 130.10, 
130.46, 133.65, 135.63, 171.05, 172.5. 
 MS(ESI +) 269.9 m/z .  
-The preparation for the substrates 13 and 14 was achieved following the procedure 
reported in ref.1 and 2 respectively. 
5.2.9 N-acetyl-(R,S)-2-Chlorophenylglycine (13) 
C10H10ClNO3, 227.54 g/mol : white solid. 
1H-NMR (CDCl3) δ 2.2 (s, 3H, CH3-CO), 5.75 (d, 1H, J = 4.5, CH-NH), 7.23-7.32 (m, 2H, 
Ar), 7.41 (dd, J1 = 1.7, J2 = 7.4, 1H,  Ar), 7.41 (dd, J1 = 1.7, J2 = 7.4, 1H, Ar), 8.3 (d, J = 
4.5 , NH). 
 13C NMR (125 MHz, CDCl3) δ 27.96, 55.11, 81.97, 127.09, 127.99, 129.04, 129.51, 
136.84, 156.95, 172.69. 
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 MS(ESI -) m/z 227.8. 
5.2.10 N-trifluoroacetyl-(R,S)-2-Chlorophenylglycine (14) 
C10H7ClF3NO3, 281.62 g/mol : white solid. 
1H-NMR (CD3OD) δ 6.00 (s, 1H, CH-NH), 7.31-7.41 (m, 2H, Ar), 7.43-7.52 (m, 2H Ar). 
 13C NMR (125 MHz, CD3OD) δ 53.38, 116.46, 126.48, 128.62, 128.94, 129.36, 132.47, 
133.47, 156.46, 169.65. 
 MS(ESI -) m/z 281.8.  
5.2.11 N-Boc-(R,S)-2-Chlorophenylglycine (15) 
To a suspension of 2-chlorophenylglycine 4 (10 g, 0.054 mol) in water (50 mL) 1,4-
dioxane (40 mL) and sodium hydroxide (2.37 g, 0.059 mol) were added. After addition of 
di-tert-butyl dicarbonate (12.4 mL, 0.054 mol) the mixture was kept under stirring at room 
temperature (18 h). The reaction progress was monitored in TLC. The mixture was 
concentrated at reduced pressure and 1M hydrochoric acid was added until pH 3. The  
precipitated product 15 (13.7 g, 89% yield) was recovered by suction. 
C13H16ClNO4 ; 285.08 g/mol: white solide 
 1H-NMR (CDCl3) δ 1.23 (s, 9H, CH3C), 5.75 (d, 1H, CH, J 4.5 Hz), 7.22-7.34 (m, 2H, 
Ar), 7.41 (d, 1H, Ar, J 6.5 Hz), 7.51 (d, 1H, Ar, J 6.9 Hz), 8.23 (d, 1H, NH, J 4.5 Hz).  
13C NMR (125 MHz, CDCl3) δ 28.02, 54.99, 82.00, 128.55, 128.84, 129.55, 130.11, 
134.08, 136.99, 154.13, 172.86. 
MS (ESI -) m/z 284 (M-1 with 35Cl), 286 (M-1 with 37Cl). 
5.2.12  N-Boc-(R,S)-2-Chlorophenylglycine methylester (16) 
To a solution of compound 15 (3 g, 10.5 mmoles) in dry dichloromethane (80 mL), 
anhydrous methanol (0.85 mL), DCC (2.38 g, 11.54 mmoles) and DMAP (0.12 g, 1.05 
mmoles) were sequentially added. The reaction mixture was kept under stirring at room 
temperature (2h). The ester formation was monitored by TLC. The white precipitate was 
removed by suction. The filtrate was washed with a sodium hydrogen carbonate solution at 
pH 8 (2 x 20mL), dried by treatment with sodium sulphate and evaporated at reduced 
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pressure. The residue was purified by silica gel column chromatography (1/10) affording 
pure 16 (eluant hexane/ethyl acetate  98/2, 2.7 g, 86%).  
C14H18ClNO4 ; 299.75 g/mol: white solide 
1H-NMR (CD3OD) δ 1.47 (s, 9H, CH3C), 3.74 (s, 3H, CH3O), 5.73 (br s, 1H, CH), 7.30-
7.38 (m, 2H, Ar), 7.43 (m, 1H, Ar), 7.50 (m, 1H, Ar ). 
13C NMR (125 MHz, CDCl3) δ 28.37, 52.96, 55.70, 80.30, 127.34, 129.70, 129.90, 130.20, 
133.70, 135.38, 154.95, 171.17. 
MS (ESI+ )m/z 321.9 [M+Na+]   
5.2.13 N-Boc-(S)-2-Chlorophenylglycine (15) 
 a. By subtilisin-catalyzed hydrolysis of (R,S)-(16) 
To a solution of  (R,S)-16 (1 g, 3.34 mmoles) in TBME (18 mL),  pH 7.5 buffer (0.1 M 
KH2PO4/ 0.1M NaOH 50 mL/ 40.9 mL) (36 mL) and protease from Bacillus licheniformis 
(24 mg, 255 U) were added. The reaction was kept under stirring, at 35 °C, and pH was 
maintained at pH 7.5 by addition of 0.5M sodium hydroxide. The reaction progress was 
monitored by HPLC (see Table 3). The samples for HPLC analysis were prepared as 
follows: an amount of aqueous and organic phase, 20 µl and  10 µl  respectively, was 
withdrawn and after collection, TBME was removed by means of a nitrogen stream. After 
addition of methanol, the mixture was filtered through a 0.45 µm GHP ACRODISC and 
the resultant solution was analyzed. At  40% conversion (65 h) the pH was brought at 8 
and the aqueous phase, after separation from the organic one, extracted with TBME (5 x 15 
mL). Extraction with TBME of aqueous phase at pH 3, drying with sodium sulphate, 
filtration and evaporation under reduced pressure afforded (S)-acid 15  (0.33 g. 35%).  
 [α]D +101 ( c 1, CH3OH). 
A sample was treated with TFA, as described below for compound 16, and analyzed by 
HPLC (Table 3.9) in order to determine the ee (>99%).   
 b. By Alcalase-CLEA®-catalyzed hydrolysis of (R,S)-(16) 
To a solution of  (R,S)-16 (1 g, 3.34 mmoles) in tetrahydrofuran (9 mL) water (90 mL) was 
added and the pH was adjusted to 8 with 2M sodium hydroxide. Alcalase-CLEA  (10 g,  
255 U) was added and the mixture was kept under stirring at 30 °C, maintaining the pH 8 
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by addition of 2N sodium hydroxide, monitoring the reaction progress by HPLC (see Table 
3). The samples for HPLC analyses were prepared by extraction of an amount of reaction 
mixture, at pH 3, evaporation of solvents and dilution of the residue with methanol. At  
40%  conversion (14 h) the reaction mixture was extracted with TBME (3 x 80 mL); the 
aqueous phase was filtered by suction to remove the enzyme and after acidification to pH 
3, extracted with TBME (4 x 60 mL). The organic phase was treated with sodium sulphate 
and, after filtration, evaporated under reduced pressure, affording (S)-acid 15 (0.32 g, 
34%). A sample, after removal of  protecting group to give the salt of compound 4, was 
analyzed by HPLC (See table 3.9) showing a 98% ee.   
 5.2.14 N-Boc-(S)-2-Chlorophenylglycine methylester (16) 
 Esterification of (S)-acid 15 (0.6 g, 2.10 mmoles) was performed following the procedure 
previously described for (R,S)-15. The crude (S)- methylester  16 (0.6 g, 95%) was used in 
the next step without any further purification. A sample was purified for analytical 
purposes. 
 [α]D + 119.3 ( c 1, CHCl3) lit3 +117.1 
5.2.15 (S)-2-Chlorophenylglycine methylester (5) 
To a solution of  (S)-16 (0.5 g, 1.67 mmoles) in dichloromethane (10 mL),  under stirring 
at room temperature, a solution of TFA (0.64 mL, 8.35 mmoles) in dichloromethane (10 
mL) was added dropwise. The reaction progress was monitored by TLC until 
disappearance of starting material (3 h). The solvent was removed at reduced pressure. To 
the residue (98% ee by HPLC) dissolved in water (10 mL), 20% ammonium hydroxide 
was added until pH 7. Extraction with dichloromethane (3 x 20 mL), followed by treatment 
with sodium sulphate, filtration and evaporation of the solvent afforded  title compound 5 
(0.315 g, 90% from (S)-5, 98% ee).  
[α]D + 123 ( c 1, CH3OH) lit4 +134. 
 1H-NMR (CDCl3) δ 2.3 (m, 2H, NH2), 3.75 (s, 3H, CH3O), 5.06 (br s, 1H, CH), 7.25-7.33 
(m, 2H, Ar), 7.36-7.43 (m, 2H, Ar).  
5.2.16  Methyl (S)-2-(2-chlorophenyl)-2-[2-(thien-2-yl)ethylamino]-acetate (6) 
The compound was prepared with the same procedure above for the racemic mixture. 
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ee 98% (by HPLC, see Table 3.9). 
 1H-NMR (CDCl3) δ 2.21 (m, 1H, NH), 2.82 (m, 1H, CH-N), 2.96 (m, 1H, CH-N), 3.07 (t, 
2H, CH2-thienyl, J 7 Hz), 3.72 (s, 3H, CH3O),  4.98 (br s, 1H, CH-COOCH3), 6.85 (d, 1H, 
H-3’, J 3.4 Hz), 6.94 (m, 1H, H-4’), 7.15 (d, 1H, H-5’, J 5 Hz), 7.23-7.32 (m, 2H, Ar), 
7.35-7.43 (m, 2H, Ar).  
MS (ESI+) m/z 310 (M+1 with 35Cl), 312 (M+1 with 37Cl).      
5.2.17 Clopidogrel 1 
 
To a solution of  6 (1 g, 3.23 mmoles) in 1,2-dichloroethane (20 mL) paraformaldehyde 
(0.11 g, 3.67 mmoles) was added; the mixture was kept under stirring, at reflux, removing 
water in azeotropic conditions for 4 h. After cooling at 30 °C, a solution (10 mL) of 
hydrochloric acid in dimethylformamide ( 4 g of HCl in 100mL of DMF) was added 
dropwise.  The mixture was heated at reflux (2 h) monitoring the reaction progress by TLC 
(toluene/ethyl acetate 95/5, detection with 5% phosphomolybdic acid ethanol solution). 
After cooling at room temperature, water (200 mL) was added and the pH was adjusted to 
7.5 by means a 30% aqueous potassium carbonate solution. Extraction with ethyl acetate 
(3x 100mL), followed by washing with water (100 mL), drying over sodium sulphate, 
filtration and removal of solvent at reduced pressure gave a residue (0.67 g) that was 
purified by silica gel column chromatography (1/10, hexane/ethyl acetate 98/2 as eluant) 
affording pure 1 (0.52 g,  50%). 
C16H16ClNO2S ; 321.82 g/mol: white solide 
 1H-NMR (CDCl3) δ 2.87-2.96 (m, 4H, H-6 and H-7), 3.68 (d, 1H, H-4, J 4Hz), 3.75 (s, 
3H, CH3O), 3.80 (d, 1H, H-4, J 4 Hz), 4.97 (br s, 1H, H-8), 6.68 (d, 1H, H-3, J 5 Hz), 7.08 
(d, 1H, H-2, J 5 Hz), 7.24-7.36 (m, 2H, H-12 and H-13), 7.44 (d, 1H, H-14, J 7.7 Hz), 7.74 
(d, 1H, H-11, J 7.7 Hz).  
MS (ESI+) m/z 322 (M+1 with 35Cl), 324 (M+1 with 37Cl).  
 [α]D + 45 ( c 1, CH3OH).  
Ee 98% (by HPLC).  
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For analytical purposes a sample was transformed into the corresponding  hydrogen 
sulphate: 
 [α]D + 54.8 ( c 1, CH3OH) lit31 +55   
DSC (5 °C/min) endotermic peak of fusion at 178.50 °C (∆H 75.769 J/g).     
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5.3. Materials and Methods chapter 4 
5.3.1. General 
Chemical reagents were purchased from Aldrich-Sigma Chemical Company. Flash column 
chromatography was carried out using 40-63 µM (230-400 mesh) silica gel. Optical rotations were 
measured using a JASCO DIP-360 digital polarimeter (c as g of compound per 100 mL). Infrared 
spectra were recorded on a Bomem MB-100 spectrometer. NMR spectra were recorded on a Varian 
Inova AS400 spectrometer (400 MHz). Mass spectra were obtained on an Agilent 6210 mass 
spectrometer. 
5.3.2. Glycine methyl ester (7) 
To a stirred solution of glycine methyl ester hydrochloride 1 (3.00 g, 23.9 mmol), cooled in a bath 
of  ice a cold solution of 1N NaOH (23.9 ml) was added. The aqueous phase was then extracted 
with CH2Cl2 (5 X 30 ml). The collected organic phases were dried with MgSO4 and the solvent 
evaporated under reduced pressure to yield 7 (0.805 g, 30%).  
C3H7NO2, 89 g/mol : yellow oil. 
IR(film): 3380-3320, 1735, 1600, 1200 
1H NMR (400 MHz, CDCl3) δ 1.47 (s, 2H, NH2), 3.48 (s, 2H, CH2), 3.77 (s, 3H, CH3). 
5.3.3 (±) – erythro-nitrobenzyl-idene- p- nitrophenylserinate methyl ester (8) 
To a stirred solution of freshly prepared glycine methyl ester  7 (0.56 g, 5.09 mmol), in MeOH (9 
ml), 4-nitrobenzaldehyde (1.54 g, 10.18mmol) was added. The so obtained yellow solution was 
warmed at 45-50 °C for 1 hour and then stirred at r.t. for 1 night. The next morning there was a 
suspension that was filtered under vacuum. The recovered cake was washed with MeOH (10 ml) 
and Et2O (5 ml) to yield 8 (1.10 g, 58%).  
C17H15N3O7, 373 g/mol : white solid. 
mp: 144-145 °C (lit.144 °C) 
IR(KBr): 3600-3140, 1720, 1643, 1600, 1515, 1435, 1380, 1342, 1230. 
1H NMR (400 MHz, DMSO) δ 3.73 (s, 3H, CH3), 4.36 ( d, J = 7.3 Hz, 1H), 5.32 ( d, 1H, CH3), 
6.31 ( d, J = 4.8 Hz, 0.38H, OH), 7.60 (d, J = 8.9 Hz, 2H),7.92 (d, J = 8.9 Hz, 2H), 8.15 (d, J = 8.6 
Hz, 2H), 8.27 (d, J = 8.9 Hz, 2H), 8.30 (s, 1H). 
13C NMR (100 MHz, DMSO) δ 52.1, 72.9, 78.5, 122.72, 123.83, 128.45, 129.16, 140.56, 146.66, 
148.77, 149.15, 163.36, 169.76. 
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 5.3.4. (±) – erythro- p- nitrophenylserine methyl ester N-hydrochloride (9) 
To a stirred suspension of  2 (0.50 g, 1.34 mmol), in MeOH (10 ml), HCl 12N (1.34 mmol) was 
added. After 10 minutes, the so obtained yellow solution was kept without stirring for one hour and 
then Et2O (10 ml) was added. The precipitation occurres in 2 hours; after filtration under vacuum 
the salt 3 was recovered as a white solid. (0.36 g, 97%).  
C10H13ClN2O5, 276.5 g/mol : white solid. 
mp: 178-183 °C (dec.) (lit.183 °C, dec.) 
IR(KBr): 3280, 1750, 1605, 1510, 1353, 1250. 
1H NMR (400 MHz, DMSO) δ 3.55 (s, 3H), 4.38 ( d, J = 2.4 Hz, 1H), 5.44 ( dd, J1 = 2.4 Hz, J2 = 
4.4 Hz, 1H), 6.81 ( d, J = 4.4 Hz, 0.63H, OH), 7.70 (d, J = 8.8 Hz, 2H),8.26 (d, J = 8.3 Hz, 2H), 
8.95 (s, 2H, NH3). 
13C NMR (100 MHz, DMSO) δ 13.72, 58.25, 61.38, 70.10, 122.99, 127.27, 146.71, 148.22, 166.21. 
5.3.5 (±) – erythro-N-tert-butoxycarbonyl p- nitrophenylserine methyl ester (11) 
To a stirred suspension of  9 (2 g, 7.62 mmol), in H2O (50 ml), NaOH 1N (7.62 ml, 7.62 mmol) and 
(Boc)2O (1.83 g, 8.38 mmol),  were added. The so obtained solution was refluxed for 1.5 hour and 
then stirred at r.t. for 1 night. The next morning there was a suspension that was filtered under 
vacuum. The recovered cake was crystallized from AcOEt/Hexane to yield 11 (2.10 g, 81%).  
C15H20N2O7, 340.3 g/mol : white solid. 
mp: 151-154 °C 
IR(KBr): 3425, 3361, 2986, 1720, 1689, 1521, 1350, 848, 716. 
1H NMR ( DMSO) δ 1.23 (s, 9H), 3.61 (s, 3H), 4.15 (t, J = 8.6 Hz, 1H), 4.87 ( d, J = 8.0 Hz, 1H), 
6.11 (sa, 1H), 7.29 (d, J = 9.2 Hz, 1H), 7.65 (d, J = 8.8 Hz, 2H), 8.19 (d, J = 8.8,  2H). 
13C NMR ( DMSO) δ 27.96, 51.74, 59.80, 71.68, 78.61, 123.00, 128.13, 146.83, 149.94, 154.85, 
171.07. 
HRMS (ESI) calculated for C15H20N2NaO7 [M+Na]+ 363.1163, found 363.1159. 
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5.3.6 (±) – erythro-N-phenylacetyl-p-nitrophenilserine (12) 
(a) To a chilled suspension of  3 (0.6 g, 2.17 mmol), in anhydrous THF (20 ml), Et3N (0.45 ml, 
3.25 mmol) and PhAcCl (0.31 ml, 2.39 mmol)  were added. The mixture of reaction was stirred at 
room temperature for one night, then the THF was evaporated under reduced pressure. The residue 
was dissolved in CH2Cl2, washed with NaHCO3 5% solution (3 x 10 ml) and HCl 1 N (3 x 10 ml) 
then anhidryfied with MgSO4 and evaporated under reduced pressure. Crystallization from 
Acetone/Hexane afforded 12-methylester (0.65 g, 83%).  
C18H18N2O6, 358.35 g/mol : white solid. 
mp: 130-132 °C  
IR(KBr): 3452, 3281, 1754, 1646, 1519, 1345, 1203, 728. 
1H NMR (CD3OD) δ 3.41 (s, 2H), 3.68 (s, 3H), 4.76 (d, J = 7.2 Hz, 1H), 5.01 (d, J = 7.2 Hz, 1H), 
7.06-7.09 (m, 2H), 7.15-7.19 (m, 3H), 7.50 (d, J = 8.8 Hz, 2H), 8.04 (d, J = 8.8, 2H). 
13C NMR (CD3OD ) δ 43.35, 52.66, 59.35, 74.24, 124.18, 127.89, 128.84, 129.43, 130.02, 136.36, 
148.80, 149.66, 171.71, 173.39. 
HRMS (ESI) calculated for C18H19N2O6 [M+H]+ 359.1238, found 359.1246. 
(b)To a solution of  12-methylester (0.63 g, 1.83 mmol), in MeOH (10 ml), K2CO3 aqueous 
solution was added (10 ml). After one night of stirring at room temperature MeOH was removed 
under reduce pressure and the aqueous residue was extracted with CH2Cl2 (2 x 5 ml). After the 
aqueous layer was chilled, acidified (pH 3) with HCl conc., and extracted with CH2Cl2 (3 x 10 ml). 
The collected organic phases were dried with MgSO4 and evaporated under reduced pressure. 
Cromatography on silica gel with AcOEt/Hexane 70:30 as eluent afforded 5 (0.51 g, 81%).  
C17H16N2O6, 344.32 g/mol : white solid. 
mp: 98-103 °C  
IR(KBr): 3465, 3282, 1712, 1524, 1350. 
1H NMR (CD3OD) δ 3.44 (s, 2H), 4.75 (d, J = 6.9 Hz, 1H), 5.05 (d, J = 6.9 Hz, 1H), 7.10 (m, 2H), 
7.16-7.23 (m, 3H), 7.51 (d, J = 8.8 Hz, 2H), 8.05 (d, J = 8.8, 2H). 
13C NMR (CD3OD ) δ 43.44, 59.33, 74.30, 124.11, 127.91, 128.89, 129.46, 130.10, 136.42, 148.78, 
149.75, 172.68, 173.50. 
HRMS (ESI) calculated for C17H17N2O6 [M+H]+  345.1086, found 345.1098. 
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5.3.7 Enzymatic resolution of (±) - erythro-N-phenylacetyl-p- nitrophenilserine (12) 
To a stirred solution of  12 (0.75 g, 2.18 mmol), in buffer phosphate at pH 7.8 (60 ml), adjusted 
with NaOH 0.5 N, penicillium G acylase buffer solution (0.07 ml, 145 U) was added.  The mixture 
was kept under stirring at 25 °C, monitoring the reaction progress by a reverse phase HPLC 
(Agilent Zorbax C8) using as eluent the mixture H2O/CH3CN/TFA (70:30:0.1). Flow rate 0.8 
ml/min, detection wavelenght 254 nm (rt = 4-8-12/product, phenylacetic acid, starting material). 
The samples for HPLC analyses were prepared by acidification (pH 3) of an amount of reaction 
mixture (0.2 ml)and diluition with the mixture H2O/CH3CN (70:30). After 4.30 h the reaction 
reached approximately the 48% of conversion. The reaction was then chilled, acidified (pH 3) with 
HCl 2N and extracted with CH2Cl2 (5 x 15 ml). The collected organic phases were dried with 
MgSO4 and evaporated under reduced pressure to afford the mixture of the (1R, 2R) erhytro-N-
phenylacetyl-p-nitrophernylserine 14 and phenylacetic-acid. The enantiomerically pure starting 
material 14 was purified from the phenylacetic-acid by chromatography on silica gel using as 
eluant the mixture AcOEt/Hexane 70:30 (0.35 g, 46%). The free amino acid 13 was  recovered by 
precipitation from the remaining aqueous solution, after adjusting the pH to 6.0 and concentration 
under reduced pressure (0.21 g, 36%). 
13: C9H10N2O5, 266.19 g/mol : white solid. 
mp: 155 °C (dec.) 
IR(KBr): 3524, 3452, 3231, 1608, 1518, 1349. 
1H NMR (DMSO) δ 3.44 (d, J = 6.0, 1H), 5.07 (d, J = 6.0 Hz, 1H), 7.66 (d, J = 8.8 Hz, 2H), 8.18 
(d, J = 8.8, 2H). 
HRMS (ESI) calculated for C9H11N2O5 [M+H]+  227.0668, found 227.0672. 
[α]d25 + 66.4 (c = 1, HCl 1N) 
A sample (15 mg, 0.04 mmol) was converted to the N-acetyl derivative in order to control the 
enantiopurity with a chiral HPLC. 
The reaction was carried on in the mixture of ACOH (2 ml) and  (AC)2O (1.5 eq). After two hours 
of strirring at room temperature the mixture was evaporated under reduced pressure; the residue 
was taken up in AcOEt (5 ml) and washed with H2O (5 x 3 ml). The organic phase was then dried 
with MgSO4 and evaporated under reduced pressure. 
With the same procedure a sample of the racemic mixture was prepared. 
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The HPLC analysis was carried on a chiral OD-H Daicel 0.46 cm x 25 cm, using as mobile phase 
the mixture of hexane/i-PrOH/TFA (80:20:0.1) and a flow rate of 0.7 ml/min. Detection 
wavelenght: 254 nm. 
RT (±) N-acetyl p-nitrophenyl serine : 14.73-17.66 
RT (+) N-acetyl p-nitrophenyl serine : 17.19 
14: C17H16N2O6, 344.32 g/mol : white solid. 
 [α]d25 - 26.5 (c = 1, MeOH) 
The HPLC analysis was carried on a chiral OD-H Daicel 0.46 cm x 25 cm, using as mobile phase 
the mixture of hexane/i-PrOH/TFA (80:20:0.1) and a flow rate of 0.7 ml/min. Detection 
wavelenght: 254 nm. 
RT (±) N-phenylacetyl p-nitrophenyl serine : 16.60 -19.04. 
RT (+) N-phenylacetyl p-nitrophenyl serine : 16.60. 
5.3.8 (+) erythro– p-nitrophenyl serinolo (17) 
 
 (a) The free amino acid  13 (0.15 g, 0.56 mmol), in EtOH (10 ml), was refluxed for one night with 
Amberlyst 15 (200 mg). Then the reaction was cooled and the resin was removed by filtration. A 
sample of the filtrate was dried under reduced pressure and derivatized as N-acetyl derivative to be 
analyzed with a chiral HPLC. The reaction was done in H2O with AcONa (4 eq) and Ac2O (1.5 eq). 
The reaction finished in 15 minutes, then the mixture was acidified (pH 3) with HCl 1 N and the 
product was extracted with AcOEt (3 x 2 ml). After dring on MgSO4 and removing the solvent 
under reduced pressure the (+) N-acetyl p-nitro-phenyl serine ethyl ester 15 was obtained. 
With the same procedure a sample of the racemic mixture was prepared. 
The HPLC analysis was carried on a chiral OD-H Daicel 0.46 cm x 25 cm, using as mobile phase 
the mixture of hexane/i-PrOH/TFA (80:20:0.1) and a flow rate of 0.5 ml/min. Detection 
wavelenght: 254 nm. 
RT (±) N-acetyl p-nitrophenyl serine ethyl ester 15 : 15.50 - 22.63. 
RT N-acetyl p-nitrophenyl serine ethyl ester 15 : 22.26. 
(b) The remaining filtrate was chilled and treated with anhydrous CaCl2 (0.086 g, 0.78 mmol) and 
NaBH4 (0.22 g, 2.97 mmol) and stirred at room temperature for one night under argon. The reaction 
is cooled and H2O (20 ml) and CH2Cl2 (40 ml) were added. The mixture was stirred vogorously for 
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1 hour. The insolubles are removed by filtration and the organic solvents were evaporated under 
reduced pressure. The aqueous phase was extracted with CH2Cl2 (5 x 10 ml) and the combined 
organic extracts were dried  on MgSO4 and the solvent was removed under reduced pressure. 
Compound  17 was purified by cromatography on silica gel with AcOEt/MeOH/NH4OH 50:20:1  
(0.05 g, 37%).  
C11H18N2O4, 242.27 g/mol : white solid. 
mp: 106-108 °C  
IR(KBr): . 3370, 3306, 2917, 1518, 1343, 1058, 1026  cm-1 
1H NMR (400 MHz, CD3OD) δ 3.06 (q, J = 5.8, 1H), 3.55 (d, J = 6, 2H), 4.78 (d, J = 5.8, 1H), 7.63 
(d, J = 8.6, 2H), 8.22 (d, J = 8.6, 2H).  
13C NMR (100 MHz, CD3OD) δ 57.79, 62.11, 73.85, 123.17, 127.68, 147.59, 149.99. 
HRMS (ESI) calculated for C9H12N2O4 [M+H]+ 213.0870, found 213.0878. 
[α]D25 + 3.0 (c 0.5, MeOH) 
5.3.9(-) -erythro-N-phenylacetyl-p- nitrophenylserinolo (16) 
To a stirred solution of 14 (0.28 g, 0.81 mmol) in anhydrous THF (50 ml) cooled with a bath of ice, 
a 2 M THF solution of BH3 (CH3)2S ( 0.6 ml, 1.2 mmol) was slowly added. The mixture was stirred 
at room temperature for one night. Then the reaction was chilled and MeOH (10 ml) was added. 
The solvents were evaporated and the resulting oil was chromatographyed on silica gel using as 
eluant the mixture of CH2Cl2/MeOH (98:2) to yield 16 (0.16 g, 59%). The unreact starting material 
14 was recovered with the mixture CH2Cl2/MeOH (99:1), (0.1 g, 36 %). 
C17H18N2O5, 330.34 g/mol : white solid. 
mp: 130-137 °C  
IR(KBr): 3542, 3407, 3291, 1657, 1524, 1355. 
1H NMR (400 MHz, CD3OD) δ 3.33 (d, J = 2.2, 2H), 3.70 (dd, J1 = 3.8, J2 = 11.3, 1H), 3.83 (dd, J1 
= 5.7, J2 = 11.2, 1H), 4.07-4.15 (m, 1H), 4.75 (d, J = 8.0, 1H), 7.00 (m, 2H), 7.11-7.16 (m, 3H), 
7.47 (d, J = 8.8 Hz, 2H), 7.99 (d, J = 8.8, 2H).  
13C NMR (100 MHz, CD3OD) δ 43.81, 57.55, 61.94, 73.53, 124.08, 127.74, 128.99, 129.32, 
129.95, 136.66, 148.56, 151.24, 173.53. 
HRMS (ESI) calculated for C17H19N2O5 [M+H]+ 331.1288, found 331.1294. 
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[α]D25 - 3.0 (c 1, MeOH) 
5.3.10 (-)-erythro-p-nitrophenyl-serinol (18) 
Compound 16 (0.12 g; 0.36 mmol) was refluxed for 1 h in  HCl 6N (6 ml). After cooling of 
solution, the solid was removed by filtration. Then the filtrate was evaporated and the so obtained 
residue was taken into H2O (5 ml) and made basic with NH4OH. The aqueous phase was extracted 
with AcOEt (5 X 3 ml), the extracts were dried over MgSO4 and evaporated under reduced 
pressure. The product  was chromatographied on SiO2 with AcOEt/MeOH/NH4OH (50:20:1) as 
eluant to give a yellow oil 18 (0.07 g, 80 %). Crystallization from CH2Cl2 was very slow. 
C11H18N2O4, 242.27 g/mol, yellow solid;  
mp 111-112°C (lit.112-113°C). 
 IR (KBr) 3371, 3307, 2913, 1515, 1347, 1056, 1025  cm-1. 
 1H NMR (400 MHz, CD3OD) δ 3.03 (q, J = 5.8, 1H), 3.49-3.62 (m, 2H), 4.76 (d, J = 5.9, 1H), 7.63 
(d, J = 8.6, 2H), 8.22 (d, J = 8.6, 2H). 
 13C NMR (100 MHz, CD3OD) δ 59.0, 63.7, 75.3, 124.3, 128.9, 148.8, 151.3. 
 HRMS (ESI) calculated for C9H12N2O4 [M+H]+ 213.087, found 213.0881. 
[α]D21 -2.5 (c 0.5, MeOH). 
-General procedure for preparation of amides (5 and 6) 
Amines 5 (25.0 mg, 103 µmol), N-Boc-L-methionine-sulfone (31.7 mg, 113 µmol), N-
hydroxysuccinimide (13 mg, 113 µmol) and EDC (23.6 mg, 123 µmol) were dissolved in 
anhydrous DMF (1.0 mL). The mixture was stirred at room temperature for 24 h. The solvent was 
coevaporated with toluene and the residue was purified by flash chromatography (7-8% 
MeOH/CH2Cl2) to yield compound 19 and 20 (70 %).  
5.3.11 (1S,2R)-1-(4-Nitrophenyl)-2-(Nα-Boc-L-methionyl-sulfone-amido)-1,3-propadiol 19.  
C19H29N3O9S; 475.51 g/mol; 
 yield 84%; white solid. 
 mp 171-173°C (dec);  
[α]D21 -18.4 (c 0.96, CH2Cl2/MeOH 1:1);  
IR (KBr) 3426, 3342, 2982, 1681, 1658, 1522, 1348, 1285, 1163, 1129, 1051 cm-1; 
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 1H NMR (400 MHz, CD3OD) δ 1.39 (s, 9H), 1.83-1.95 (m, 1H), 1.95-2.08 (m, 1H), 2.89 (s, 3H), 
3.03 (t, J = 7.8 Hz, 2H), 3.64 (dd, J = 10.9 and 2.8 Hz, 1H), 3.78 (dd, J = 10.8 and 6.4 Hz, 1H), 
4.00-4.14 (m, 2H), 4.80 (d, J = 7.5 Hz, 1H), 7.60 (d, J = 8.2 Hz, 2H), 8.24 (d, J = 8.2 Hz, 2H); 
 13C NMR (100 MHz, CD3OD) δ 25.1, 27.4, 39.3, 50.6, 53.3, 56.6, 60.3, 72.3, 79.8, 123.0, 127.8, 
147.5, 150.0, 156.4, 172.0;  
HRMS (ESI) calculated for C19H29N3O9SNa [M+Na]+ 498.1517, found 498.1530. 
5.3.12 (1R,2S)-1-(4-Nitrophenyl)-2-(Nα-Boc-L-methionyl-sulfone-amido)-1,3-propadiol 20. 
C19H29N3O9S; 475.51 g/mol; 
yield 72%; white solid 
mp 175-176°C (dec);  
[α]D21 -10.8 (c 1.7, MeOH );  
IR (KBr) 3424, 3357, 2978, 1681, 1660, 1523, 1350, 1294, 1166, 1131, 1053 cm-1;  
1H NMR (400 MHz, CD3OD) δ 1.43 (s, 9H), 1.64-1.74 (m, 1H), 1.80-1.88 (m, 1H), 2.87 (s, 3H), 
2.83-2.89 (m, 2H), 3.70 (dd, J = 11.2 and 3.7 Hz, 1H), 3.86 (dd, J = 11.3 and 5.5 Hz, 1H), 4.03 (dd, 
J = 8.5 and 5.1, 1H), 4.15-4.19 (m, 1H), 4.82 (d, J = 8.1 Hz, 1H), 7.63 (d, J = 8.6 Hz, 2H), 8.20 (d, J 
= 8.8 Hz, 2H);  
13C NMR (100 MHz, CD3OD) δ 26.5, 28.7, 40.6, 51.8, 54.4, 57.6, 61.9, 73.4, 81.1, 124.6, 129.3, 
149.0, 151.4, 157.7, 173.1; 
 HRMS (ESI) calculated for C19H29N3O9SNa [M+Na]+ 498.1517, found 498.1505. 
5.3.13 General procedure for the cleavage of the N-tert-butoxycarbonyl groups 
A solution of compound 19 (40 mg, 84.1 µmol) in 4 M HCl/dioxane (2.0 mL) was stirred 
at room temperature for 40 min. The solvent was coevaporated under reduced pressure 
with MeOH. The residue was dissolved in a minimum of EtOH (2.0 mL) and the product 
was precipitated by the addition of Et2O (20 mL). The product was collected by filtration 
and washed with Et2O to give 5 (28 mg, 81%).  
5.3.14 (1S,2R)-1-(4-Nitrophenyl)-2-(L-methionyl-sulfone-amido)-1,3-propadiol (5).  
C14H22ClN3O7S; 411.86 g/mol; 
yield 81%;white solid  
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mp 185-190°C (dec); 
 [α]D21 18.0 (c 0.58, MeOH); 
 IR (KBr) 3351, 2927, 1683, 1519, 1351, 1285, 1133 cm-1;  
1H NMR (400 MHz, CD3OD) δ 2.20-2.40 (m, 2H), 2.98 (s, 3H), 3.27 (t, J = 8.0 Hz, 2H), 
3.63-3.74 (m, 2H), 3.99 (t, J = 6.4 Hz, 1H), 4.15-4.22 (m, 1H), 4.88 (d, J = 6.4 Hz, 1H), 
7.64 (d, J = 8.4 Hz, 2H), 8.20 (d, J = 8.8 Hz, 2H);  
13C NMR (100 MHz, CD3OD) δ 24.6, 39.6, 49.1, 51.6, 57.3, 59.8, 72.4, 123.2, 127.5, 
147.6, 149.9, 167.6;  
HRMS (ESI) calculated for C14H22N3O7S [M+H]+ 376.1173, found 373.1186. 
5.3.15. (1R,2S)-1-(4-Nitrophenyl)-2-(L-methionyl-sulfone-amido)-1,3-propadiol (6).  
C14H22ClN3O7S; 411.86 g/mol; 
yield 75%;white solid 
 mp 165-170°C (dec);  
[α]D21 -1.8 (c 1, MeOH);  
IR (KBr) 3409, 2925, 1683, 1520, 1352, 1286, 1135 cm-1;  
1H NMR (400 MHz, CD3OD) δ 1.88-2.09 (m, 2H), 2.70-2.90 (m, 2H), 2.92 (s, 3H), 3.72-
3.86 (m, 2H), 3.90-3.99 (m, 1H), 4.23-4.33 (m, 1H), 4.84 (d, J = 8.0 Hz, 1H), 7.66 (d, J = 
8.5 Hz, 2H), 8.22 (d, J = 8.5 Hz, 2H);  
13C NMR (100 MHz, CD3OD) δ 25.2, 40.7, 50.2, 52.8, 57.5, 61.7, 73.1, 124.5, 129.2, 
148.9, 150.9, 168.4;  
HRMS (ESI) calculated for C14H22N3O7S [M+H]+ 376.1173, found 373.1185. 
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6. CONCLUSIONS 
Nowadays biocatalysis is a well-assessed methodology that has moved from the original 
status of academic curiosity to become a widely exploited technique for the preparation of 
products of biological interest. Many enzymes have been so thoroughly studied that their 
behavior in synthesis can be predicted reliably. 
The high level of chemo, regio and stereoselectivity of three of the most widespread, low 
cost and effective enzymes, that belong to different class of hydrolases, allowed us to 
achieve the preparations summarized in the schemes below. 
In the first project, the bacterial macrolactam ascomycin was converted into the high value 
immunosuppressive pimecrolimus through a regio and chemo-selective protection 
catalyzed by lipase from Candida antarctica B. Thanks to the mild conditions of this new 
chemoenzymatic approaches, only the desired products are obtained: the absence of 
rearrangements or degradations processes, very frequently observed in the case of sensitive 
molecules as ascomycin and related compounds, containing a large number of 
functionalities, afforded a gain on the final yield and on the cost of the process. In this 
work clearly emerges that enzymatic hydrolysis and transesterification reaction can be 
complementary processes for the regioselective acylation of secondary alcohol, because, 
the enzyme, keep its substrate selectivity unalterated in both the verses of the reaction 
(Scheme 6.1). 
 
 
 
Scheme 6.1. Synthetic pathway to prepare pimecrolimus from ascomycin.  
 
In the second project, a kinetic resolution of the non proteogenic 2-chloro phenylglycine 
methylester, with the aminic function protected as N-Boc 1, was obtained with an excellent 
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value of enantiomeric excess, by means of the  Alcalase-CLEA® affording the required (S)-
acid 2. As shown in the second chapter, by focusing on the modulation of enzyme 
selectivity by medium engineering, quite simple modification of the solvent composition 
can really have significant effects on the performance of the biocatalyst. The optically pure 
acid was then converted into  the (S)-2-chloro phenyl glycine methyl-ester, in turn used as 
chiral synthon in order to complete the preparation of the antiplatelet (S)-clopidogrel 4. 
The use of a chemoenzymatic approach allowed to overcome the tedious and time 
consuming fractional crystallizations, till now used with the aim to obtain the optically 
pure (S)-clopidogrel (Scheme 6.2). 
 
 
Scheme 6.2. Final pathway followed for the preparation of (S)+ 1. Reagents and conditions: (i) CH3OH, 
DCC, DMAP, CH2Cl2; (ii) TFA, CH2Cl2; (iii) 20% NH4OH; (iv) TsCl, (iPr)2O, Et3N; (v) NaHCO3, KI, 
CH3CN; (vi) paraformaldehyde, ClCH2CH2Cl, HCl in DMF. 
In the last project, penicillin acylase, was the best enzyme to realize the kinetic resolution 
of another non proteogenic amino acid, (±) erythro p-nitrophenylserine, important 
precursor of two diastereoisomers of chloramphenicol. The hydrolysis of the two amino 
acids, derivatized as N-phenylacetyl-aminoacids, the best substrates for the enzyme, was 
conducted in a very fast, and economic manner, using as medium of reaction a buffer 
phosphate weakly alkaline. The hydrolysis, stopped at the 50% of conversion, lead to 
recover the free L- amino acid 2 and the unreacted D-amide 3 both with a high value of ee. 
The so obtained (S) and (R) p-nitrophenylserines were later converted in the corresponding 
amino alcohol and N-acylated by reaction with L-sulfonilmethionine. This two compounds 
4 and 5 were tested as potential inhibitors for the enzyme amidotransferase, a new target 
for the development of new antibacterial compounds. The importance of this project 
overcomes the values of the constants of inhibition found for the two compounds, but 
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being inserted in a structure-activity study, underlines the importance of the configuration 
of chloramphenicol stereocenters for the interaction with the amidotransferase. 
 
 
 
Scheme 3. Synthetic pathway to prepare chloramphenicol derivatives 4 and 5. a) Amberlyst 15, EtOH, 
heat,16h; CaCl2/NaBH4,12h; b)L-methionine sulfone N-Boc, EDC, N-hydroxysuccinimide, DMF, 24h (c) 4 
M HCl / dioxane, 40 min; d) BH3(CH3)2S, THF, 12h; e) HCl 6N, CH3OH, heat, 2h. 
 
The use of hydrolytic enzymes afforded best results either for their regio- and 
chemoselectivity (see preparation of pimecrolimus) either in stereoselectivity (see 
resolution of 2-N-Boc-chlorophenyl glycine-methylester and erythro-p-nitrophenyl-serine). 
The obtained intermediates were easily converted into known and potential biologically 
active compounds. 
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